clopidogrel has been researched along with Cardiovascular Stroke in 1654 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (1.39) | 18.2507 |
| 2000's | 601 (36.34) | 29.6817 |
| 2010's | 883 (53.39) | 24.3611 |
| 2020's | 147 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Boersma, C; Claassens, DMF; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Morisco, C; Mosterd, A; Postma, MJ; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; van Dorst, PWM; Vos, GJA | 1 |
| Baumgartner, I; Berger, JS; Blomster, JI; Fowkes, FGR; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Mulder, H; Norgren, L; North, R; Patel, MR; Rockhold, FW | 1 |
| Dannenberg, L; Kelm, M; M'Pembele, R; Metzen, D; Petzold, T; Polzin, A; Zeus, T | 1 |
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Bressi, E; Capuano, M; Cavallari, I; Colaiori, I; Di Sciascio, G; Grigioni, F; Mangiacapra, F; Ricottini, E; Spoto, S; Sticchi, A; Ussia, GP; Viscusi, MM | 1 |
| Aslam, M; Butt, JH; Engstrøm, T; Fosbøl, EL; Grove, EL; Holmvang, L; Køber, L; Nabi, H; Sørensen, R; Tajchman, DH | 1 |
| Aronow, HD; Barbour, M; Belviso, N; Don, PK; Kogut, S; Lawal, OD; Wen, X; Wyss, R; Zhan, SY; Zhang, Y | 1 |
| Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD | 1 |
| Ahmad, H; Aronow, WS; Briasoulis, A; Gupta, R; Guthier, DG; Joshi, AM; Kluck, B; Malik, AH; Patel, NC; Popli, T; Vyas, AV | 1 |
| Chan, YH; Chang, CJ; Chang, SH; Kuo, CT; Liu, JR; See, LC; Tung, YC | 1 |
| Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV | 1 |
| Ahn, Y; Choi, DH; Gwon, HC; Hwang, JY; Jeong, MH; Ki, YJ; Kim, HK; Kim, HS; Kim, SS; Koh, YY; Park, KH; Rha, SW | 1 |
| Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Chang, H; Ghamraoui, AK; Maldonado, TS; Ricotta, JJ | 1 |
| Branny, M; Dusek, J; Hlinomaz, O; Hromadka, M; Jansky, P; Jarkovsky, J; Kala, P; Miklik, R; Motovska, Z; Mrozek, J; Rokyta, R; Simek, S; Svoboda, M; Tousek, F; Varvarovsky, I; Widimsky, P | 1 |
| Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A | 1 |
| Ahn, HS; Kim, BJ; Kim, DB; Kim, JS; Lee, D; Shin, SY | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Cho, MC; Choi, DJ; Gwon, HC; Hur, SH; Hwang, JY; Jeong, MH; Joo, SJ; Ki, YJ; Kim, CJ; Kim, DI; Kim, HK; Kim, HS; Kim, SS; Kook, HY; Oh, SK; Park, JS; Park, KH; Rha, SW; Seong, IW; Seung, KB; Yoon, JH | 1 |
| Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W | 1 |
| Ahmad, H; Bandyopadhyay, D; Chakraborty, S; Chaturvedi, A; Combs, WG; Gupta, R; Mahajan, P; Malik, AH; Mehta, SS; Patel, NC; Sreenivasan, J; Vyas, AV; Yandrapalli, S; Zaid, S | 1 |
| Biswas, M; Ibrahim, B; Khatun Kali, MS; Sukasem, C | 1 |
| De Luca, L; Ferraro, PM; Gabrielli, D; Grigioni, F; Mangiacapra, F; Mangiacapra, R; Melfi, R; Nusca, A; Paolucci, L; Ussia, GP; Viscusi, MM | 1 |
| Abu-Assi, E; Bianco, M; Bo, M; Breviario, S; Bruno, F; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; de Filippo, O; Elia, E; Iannaccone, M; Manai, R; Patti, G; Raposeiras-Roubin, S; Wańha, W | 1 |
| Bai, N; Ma, Y; Niu, Y; Shang, YS; Wang, ZL; Zhong, PY | 2 |
| Angiolillo, DJ; Capodanno, D; Farkouh, M; Goodman, SG; Kim, SW; Lennon, RJ; O'Cochlain, F; Pereira, NL; Rihal, CS; So, DY; Sweeney, J | 1 |
| Bergh, N; Myredal, A; Nivedahl, P; Petzold, M; Wallerstedt, SM; Wartenberg, C; Zarin, S | 1 |
| Abbott, JD; Aronow, H; Bavishi, C; Heinl, RE; Hyder, ON; Kadiyala, V; Kah, MO; Kennedy, KF; Lang, WR; Long, S; Mitsuyama, R; Ovide, G; Sharma, E; Wark, T; Williams, MU | 1 |
| Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA | 1 |
| Bach, RG | 1 |
| Abe, M; Ando, K; Domei, T; Furukawa, Y; Hibi, K; Ikari, Y; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Mori, H; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Natsuaki, M; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Sakamoto, H; Suwa, S; Suzuki, H; Tada, T; Tanabe, K; Tatsushima, S; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yamaji, K; Yamamoto, K | 1 |
| Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A | 1 |
| Azhar, AZ; Baibhav, B; Cheung, JW; Rao, M; Tan, BE; Thakkar, S; Wong, PY | 1 |
| Angiolillo, DJ; Beitelshees, AL; Cavallari, LH; David Anderson, R; Dempsey, AL; Franchi, F; Gong, Y; Gower, MN; Johnson, JA; Keeley, EC; Kerensky, RA; Kulick, N; Lee, CR; Malave, JG; McDonough, CW; Mulrenin, IR; Rossi, JS; Starostik, P; Stouffer, GA; Thomas, CD; Winget, M; Winterstein, AG | 1 |
| França, ACW; Macedo, LSDN; Magliano, CADS; Meirelles, I; Piccin Padilla, M; Santos, MDS | 1 |
| Aghaali, M; Hashemi Nazari, SS; Mozaffarian, S; Sistanizad, M; Taherpour, N | 1 |
| Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
| Andréka, P; Bársony, G; Ferenci, T; Jánosi, A; Szabóné Póth, A; Vajer, P | 1 |
| Dou, KF; Gao, R; Guan, C; Huang, Y; Qiao, S; Wang, HY; Wu, Y; Xie, L; Xu, B; Yang, W; Yang, Y; Zhang, R | 1 |
| Kamouchi, M; Kimura, K; Kitazono, T; Koyama, N; Matsumaru, Y; Matsuo, H; Nakamura, M; Tsutsumi, J; Umemura, K | 1 |
| Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB | 1 |
| Gersh, BJ; Holmes, DR; Kandlakunta, H; Kochar, A; Kuchkuntla, AR; Murad, MH; Patlolla, SH; Rab, ST; Vallabhajosyula, S; Wang, Z; West, CP; Zhao, DX | 1 |
| Abbott, JD; Farkouh, ME; Goodman, SG; Lennon, R; MacDougall, AM; Madan, M; McLaughlin, MA; Murthy, V; Pereira, NL; Rihal, C; Saw, J; So, DYF | 1 |
| Anastasiou, I; Hamilos, M; Kochiadakis, G; Lazopoulos, G; Pagonidis, K; Petousis, S; Skalidis, E; Vardas, P; Zacharis, E | 1 |
| Peng, F; Xu, B; Xuan, M; Yan, L; Yu, Z; Zhou, Y | 1 |
| Chen, S; Jiang, W; Wang, J | 1 |
| Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R | 1 |
| Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Sheu, JJ; Wang, CC; Wu, CH | 1 |
| Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ | 1 |
| Damasceno, NRT; Fonseca, FAH; Izar, MC; Lotfollahi, Z; Machado, LO; Mathias, AF; Mello, APQ; Neto, AMF; Oliveira, CLP | 1 |
| Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN | 1 |
| Batra, G; Becker, RC; Harrington, RA; Held, C; James, SK; Kempf, T; Lindbäck, J; Lopes, RD; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Swahn, E; Wallentin, L; Wollert, KC | 1 |
| Chen, M; Cheng, K; Ge, J; Huang, J; Lan, J; Li, G; Qian, J; Wang, X; Wang, Y; Wei, G; Wu, H; Xu, L; Zhang, C; Zhang, H; Zhao, X | 1 |
| Bae, JW; Han, JK; Hur, SH; Hwang, D; Kang, J; Kim, HS; Koo, BK; Lee, H; Lee, NH; Park, KW; Rha, SW; Shin, ES; Yang, HM | 1 |
| Ahn, Y; Chang, K; Choi, IJ; Choo, EH; Hwang, BH; Jeon, DS; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Lim, S; Moon, D; Park, MW; Seok Choi, Y; Yoo, KD | 1 |
| Kim, HH; Yoo, KJ; Youn, YN | 1 |
| Ando, K; Domei, T; Fujii, S; Hayashi, F; Isawa, T; Ishii, M; Kimura, T; Komiyama, K; Mori, H; Morimoto, T; Natsuaki, M; Nikaido, A; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Shigematsu, T; Suematsu, N; Suwa, S; Suzuki, H; Tada, T; Tatsushima, S; Watanabe, H; Watanabe, N; Yamaji, K; Yamamoto, K | 1 |
| Dangas, G; Dasgupta, S; Feng, Y; Giustino, G; Hooda, A; Khera, S; Kini, AS; Koshy, AN; Krishnamoorthy-Melarcode, P; Kumar, KR; Mehran, R; Sartori, S; Serrao, GW; Sharma, R; Sharma, SK; Snyder, C; Sweeny, J | 1 |
| Bae, JW; Bong, JM; Chun, KJ; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Kim, SY; Koo, BK; Lee, BK; Lee, KS; Lee, NH; Lim, HS; Lim, YH; Park, K; Park, KH; Park, KW; Rha, SW; Rhew, JY; Shin, WY; Yang, HM | 1 |
| Azzahhafi, J; Mani, N; Ten Berg, JM; van den Broek, WWA | 1 |
| Asada, K; Fukuyama, M; Hayashi, A; Higo, Y; Hira, D; Isono, T; Kodama, K; Kohyama, S; Morita, SY; Nakagawa, Y; Ozawa, T; Sakai, H; Sawayama, Y; Shioyama, W; Tomita, Y; Yagi, N; Yamamoto, T | 1 |
| Ahn, Y; An, M; Cho, K; Hong, Y; Jeong, MH; Kim, J; Kim, Y | 1 |
| Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J | 1 |
| Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S | 1 |
| Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T | 1 |
| Boyd, K; Brown, SA; Thomason, AR | 1 |
| Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A | 1 |
| An, L; Lei, M; Li, C; Li, Y; Sun, X; Wang, J; Xue, Z; Yang, Y; Zhao, Z | 1 |
| Manunga, J; Pai, A; Pedersen, C; Skeik, N; Stanberry, L; Sullivan, TM | 1 |
| He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L | 1 |
| Bajrić, M; Bećirović, E; Bećirović, M; Brkić, A; Ljuca, F; Ljuca, K; Ljuca, N | 1 |
| Alfredsson, J; Erlinge, D; James, S; Jernberg, T; Lindahl, B; Mohammad, MA; Omerovic, E; Szummer, K; Tjerkaski, J; Venetsanos, D | 1 |
| Je, NK; Lee, YJ | 1 |
| Goto, H; Kitahara, H; Kobayashi, Y; Matsumoto, T; Saito, Y; Sano, K; Sato, T; Suzuki, S; Wakabayashi, S; Yamashita, D | 1 |
| Chan, CC; Chan, YH; Chu, PH; Lee, KT; Tung, YC | 1 |
| Ge, P; Guo, Y; Li, Z; Xiao, J; Xie, L | 1 |
| Heidari Moghadam, R; Janjani, P; Mahmoudi, S; Nalini, M; Nasiri, S; Rouzbahani, M; Salehi, N; Shojaei, L; Siabani, S; Tadbiri, H | 1 |
| He, M; Xiang, Y; Xie, C | 1 |
| Baas, L; Gawaz, MP; Geisler, T; Gekeler, S; Harm, T; Kreisselmeier, KP; Müller, II; Müller, KAL; Prang, C; Rath, D; Schröder, S | 1 |
| Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ | 1 |
| Ahn, HS; Cha, KS; Choi, HH; Han, JK; Hur, SH; Hwang, D; Jo, SH; Kang, J; Kim, HS; Koo, BK; Lee, NH; Park, KW; Ryu, JK; Shin, ES; Suh, IW; Woo, SI; Yang, HM; Yang, S | 1 |
| Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Wang, CC; Wu, CH | 1 |
| Gawlik, Ł; Głuchowska, M; Krupińska, J; Nowak, K; Papros, K; Szeszko, A; Szeszko, Ł; Wróbel, G; Zieliński, PA | 1 |
| Liu, C; Ma, L | 1 |
| Brownlie, J; Cook, C; Dahl, L; Elbarouni, B; Fransoo, R; Katz, A; McGibbon, E; Nguyen, T; Prior, HJ; Sawatzky, JA; Schultz, A; Sinclaire, M; Throndson, K | 1 |
| Bernabò, P; Colivicchi, F; De Luca, L; Gabrielli, D; Granatelli, A; Gulizia, MM; Lardieri, G; Meessen, J; Piscione, F; Uguccioni, M | 1 |
| Cao, X; Li, JL; Liu, XJ; Xin, YG | 1 |
| Alexopoulos, D; Altman, RB; Aradi, D; Backman, JD; Bergmeijer, TO; Bliden, KP; Campo, G; Chang, K; Cleator, JH; Déry, JP; Dridi, NP; Fernandez-Cadenas, I; Fontana, P; Gawaz, M; Geisler, T; Gensini, GF; Giusti, B; Gong, L; Gurbel, PA; Hochholzer, W; Holmvang, L; Kim, EY; Kim, HS; Klein, TE; Kubo, M; Lee, MTM; Lewis, JP; Marcucci, R; Mitchell, BD; Montaner, J; Pakyz, RE; Reny, JL; Ritchie, MD; Roden, DM; Ryan, K; Schaeffeler, E; Schwab, M; Shin, JG; Shuldiner, AR; Siller-Matula, JM; Ten Berg, JM; Trenk, D; Valgimigli, M; Wen, MS; Whaley, RM; Winter, S | 1 |
| Al-Lawati, J; Al-Mulla, A; Al-Zakwani, I; Almahmeed, W; Alsheikh-Ali, AA; Rashed, W; Zubaid, M | 1 |
| Angiolillo, DJ; Capranzano, P | 2 |
| Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T | 1 |
| Bhatta, RS; Chhonker, YS; Dikshit, M; Kanuri, BN; Misra, A; Narain, VS; Negi, MPS; Pandey, CP | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Blanco, PF; Boccuzzi, G; Cequier, A; Correia, L; D'Amico, M; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Grossomarra, W; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Lopez-Cuenca, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Paz, RC; Peyracchia, M; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Saglietto, A; Taha, S; Usmiani, T; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS | 1 |
| Colombo, A; Marchese, A; Resta, F; Tito, A | 1 |
| Barbato, E; Bressi, E; Capuano, M; Cavallari, I; Colaiori, I; Di Sciascio, G; Mangiacapra, F; Ricottini, E; Spoto, S; Viscusi, MM | 1 |
| Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G | 1 |
| Budnik, M; Dignat-George, F; Eyileten, C; Filipiak, KJ; Gasecka, A; Harrison, P; Lacroix, R; Leroyer, A; Nieuwland, R; Opolski, G; Pluta, K; Postuła, M; Siljander, P; Siller-Matula, JM; van der Pol, E | 1 |
| Ahn, JH; Ahn, Y; Hong, YJ; Hur, SH; Hwang, JY; Jeong, MH; Kim, JH; Kim, MC; Oh, SK; Seong, IW; Sim, DS; Yoon, JH | 1 |
| Ben-Yehuda, O; Claessen, BE; Crowley, A; Faggioni, M; Farhan, S; Généreux, P; Kirtane, AJ; Maehara, A; Mastoris, I; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Atef, H; Atteia, HH; El-Sherbiny, M; Ibrahim, GA; Makary, S; Mohamed, AS; Mohammad, HMF; Zaitone, SA | 1 |
| Biros, MH; Coutts, SB; Cucchiara, B; Easton, JD; Elm, J; Johnston, SC; Ross, MA; Willey, JZ | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Angiolillo, DJ; Bergmeijer, TO; Capodanno, D; Danchin, N; Price, MJ; Sibbing, D; Simon, T; Ten Berg, JM | 1 |
| Chai, M; Liang, J; Liu, W; Liu, X; Xi, Z; Yu, Y; Zhao, Y; Zhou, Y | 1 |
| Antman, EM; Bergmark, BA; Bonaca, MP; Braunwald, E; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K | 1 |
| Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS | 1 |
| Ben-Dor, I; Chen, Y; Gajanana, D; Iantorno, M; Khalid, N; Khan, JM; Kolm, P; Musallam, A; Rogers, T; Satler, LF; Shlofmitz, E; Torguson, R; Waksman, R; Weintraub, WS; Zhang, C | 1 |
| Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A | 1 |
| Bergmeijer, T; de Vrey, E; den Hartog, F; Deneer, V; Gimbel, M; Heestermans, T; Hermanides, R; Hofma, S; Jukema, W; Kelder, J; Qaderdan, K; Ten Berg, J; Tjon Joe Gin, M; von Birgelen, C; Voskuil, M; Waalewijn, R; Willemsen, L | 1 |
| Feng, L; Gao, R; Li, M; Li, X; Wu, Y | 1 |
| Cannata, F; Cao, D; Chiarito, M; Condorelli, G; De Caterina, R; Ferrante, G; Godino, C; Panico, C; Regazzoli, D; Reimers, B; Sanz-Sánchez, J; Stefanini, GG; Sturla, M | 1 |
| Ahtarovski, KA; Engstrøm, T; Ghotbi, AA; Göransson, C; Høfsten, DE; Kelbæk, H; Kyhl, K; Køber, L; Lønborg, J; Nepper-Christensen, L; Sabbah, M; Sadjadieh, G; Schoos, MM | 1 |
| Atar, S; Bernaud, C; Fahrni, G; Frenoux, JM; Hmissi, A; Moccetti, T; Mueller, C; Schelfaut, D; Sinnaeve, P; Spirito, A; Ufer, M; Valgimigli, M | 1 |
| Chen, S; Qu, J; Rao, C; Zhang, D; Zhang, H; Zhao, Y; Zheng, Z | 1 |
| Bellemain-Appaix, A; Beygui, F; Boccara, F; Boueri, Z; Brunel, P; Caussin, C; Cayla, G; Christiaens, L; Collet, JP; Dillinger, JG; Ducrocq, G; Dumaine, R; El Kasty, M; Georges, JL; Guedeney, P; Hauguel-Moreau, M; Jourda, F; Labeque, JN; Laredo, M; Lattuca, B; Le Breton, H; Lhermusier, T; Montalescot, G; Motovska, Z; Pouillot, C; Range, G; Saint-Etienne, C; Silvain, J; Vicaut, E | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Che, JJ; Chen, KY; Liu, T; Rha, SW; Tao, HY; Wang, JR; Wang, P; Wang, WD; Wang, XW; Xu, LX; Xue, ZK; Zhang, YR | 1 |
| Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW | 1 |
| Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H | 1 |
| Asada, K; Fukuyama, M; Hira, D; Horie, M; Isono, T; Miyamoto, A; Nakagawa, Y; Ozawa, T; Sakai, H; Sawayama, Y; Terada, T; Tomita, Y; Yagi, N; Yamamoto, T | 1 |
| Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD | 1 |
| Chang, CJ; Chang, SH; Kuo, CT; Liu, JR; See, LC; Tung, YC | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Gregersen, I; Halvorsen, B; Himmelmann, A; James, SK; Johansen, HT; Kontny, F; Lakic, TG; Lindbäck, J; Lunde, NN; Michelsen, AE; Ryeng Skagen, K; Siegbahn, A; Skjelland, M; Solberg, R; Storey, RF; Ueland, T; Wallentin, L | 1 |
| Gao, R; Guo, T; Li, J; Li, Y; Qiao, S; Qiu, H; Tang, Y; Wang, Y; Xu, B; Yan, L; Yang, Y; Zheng, J | 1 |
| Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC | 1 |
| Lee, CH; Lee, NY; Li, YH; Lin, HW; Lin, SH | 1 |
| Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH | 1 |
| Cai, ZX; Dou, KF; Song, WH; Wang, HY; Yang, YJ; Yin, D | 1 |
| Li, FL; Liu, M; Ma, L | 1 |
| Jamali, HK; Khan, S; Kheiri, B; Osman, M; Saleem, M; Waqar, F | 1 |
| Ahmad, B; Alraies, MC; Biswas, S; Fichman, DL; Goldsweig, AM; Pacha, HM; Prasad, A; Sattar, Y; Ullah, W; Velagapudi, P; Zaher, N; Zghouzi, M | 1 |
| Chen, Y; Wang, B; Wang, W; Wei, S | 1 |
| Chen, WT; Chien, LN; Hsieh, YC; Hsu, CY; Huang, CY; Yeh, JS | 1 |
| Chelidze, K; Mamatsashvili, I; Sikharulidze, I | 1 |
| Auriel, E; Gronich, N; Lavi, I; Lejbkowicz, F; Pinchev, M; Rennert, G; Saliba, W; Zoabi, Y | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Hess, NR; Kilic, A; Sultan, I; Thoma, F; Wang, Y | 1 |
| Alfredsson, J; Desta, L; Erlinge, D; Hagström, E; Jernberg, T; Lindahl, B; Mellbin, L; Nilsson, J; Omerovic, E; Szummer, KE; Träff, E; Venetsanos, D; Zwackman, S | 1 |
| Asaumi, Y; Honda, S; Kimura, K; Kojima, S; Kosuge, M; Nishihira, K; Ogawa, H; Sakata, Y; Sumiyoshi, T; Suzuki, M; Takahashi, J; Takayama, M; Takegami, M; Yasuda, S | 2 |
| Ahn, JH; Cho, SW; Choi, JH; Choi, KH; Choi, SH; Gwon, HC; Hahn, JY; Jang, YH; Kim, DY; Lee, JM; Lee, SH; Park, KT; Park, TK; Song, YB; Yang, JH | 1 |
| Chan, MY; Chew, NWS; Dan, YY; Foo, LL; Ho, KY; Lee, CH; Lim, LG; Low, AF; Muthiah, MD; Richards, AM; Tan, HC; Xiao, J; Yip, JWL; Zheng, H | 1 |
| Fujita, H; Jinnouchi, H; Sakakura, K; Seguchi, M; Shibata, K; Taniguchi, Y; Tsukui, T; Wada, H; Yamamoto, K | 1 |
| Clemmensen, P; Desch, S; Dudek, D; Feistritzer, HJ; Freund, A; Fuernau, G; Geisler, T; Haller, P; Hausleiter, J; Huber, K; Kleeberger, J; Massberg, S; Montalescot, G; Neumer, A; Noc, M; Orban, M; Ouarrak, T; Schneider, S; Thiele, H; Zeymer, U | 1 |
| Becker, RC; Chan, MY; Grenier, JC; Hussin, JG; Jolicœur, EM; Lopes, RD; Lordkipanidzé, M; Mehanna, P; Neely, ML; Newby, LK; Ruiz, M; Samman, KN; Takla, E; Wang, TY | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solè, A; Bianco, M; Biolè, CA; Boccuzzi, G; Careggio, A; Cerrato, E; Correia, L; D'Ascenzo, F; De Ferrari, GM; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fujii, T; Gonzàlez Juanatey, JR; Henriques, JPS; Huczek, Z; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Luciano, A; Manzano-Fernàndez, S; Montagna, L; Morbiducci, U; Nie, SP; Nunez-Gil, I; Quadri, G; Quiros, A; Raposeiras-Roubin, S; Rognoni, A; Song, X; Spirito, A; Templin, C; Ugo, F; Varbella, F; Velicki, L; Wilton, SB | 1 |
| Lagergren, J; Maret-Ouda, J; Rosengren, A; Santoni, G; Xie, S | 1 |
| Bálint, A; Eitmann, S; Garami, A; Hanák, L; Hegyi, P; Komócsi, A; Márta, K; Rumbus, Z; Solymár, M; Szakács, Z | 1 |
| Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L | 1 |
| Dong, JY; Li, WN; Liu, HY; Ma, Q; Tian, XL; Zhang, HY | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Amann, M; Bömicke, T; Hochholzer, W; Neumann, FJ; Stratz, C; Valina, CM | 1 |
| Choe, YH; Choi, JH; Choi, SH; Chun, WJ; Gwon, HC; Hahn, JY; Kim, EK; Park, TK; Song, YB; Yang, JH | 1 |
| Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Peterson, ED; Schulte, PJ; Stone, GW; Wang, TY; Zettler, ME | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Van de Werf, F | 1 |
| Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW | 1 |
| Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC | 1 |
| Ahn, JM; Choi, HI; Kang, SH; Kang, SJ; Kim, YH; Lee, CW; Lee, PH; Lee, SW; Park, DW; Park, SJ; Park, SW | 1 |
| Chase, MR; Hanson, ME; Heithoff, K; Mavros, P; Patel, MD; Simpson, RJ; Wu, D | 1 |
| Choi, KN; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Park, YA; Seo, JS; Shin, HC; Yang, TH | 1 |
| Abnousi, F; Bhatt, DL; Deliargyris, EN; Desai, M; Ding, VY; Généreux, P; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Sundaram, V; White, HD; Yang, L; Yong, CM | 1 |
| Ariotti, S; Baldo, A; Franzone, A; Gargiulo, G; Moschovitis, A; Piccolo, R; Santucci, A; Tumscitz, C; Valgimigli, M; Windecker, S | 1 |
| Akasaka, T; Hirata, KI; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakamura, M; Osue, T; Otake, H; Saito, S; Shinke, T; Shite, J; Takahashi, H; Takaya, T; Terashita, D; Uzu, K | 1 |
| Ako, J; Ando, K; Anzai, H; Hamasaki, T; Iijima, R; Inoue, K; Ishiwata, S; Ito, Y; Kadotani, M; Kawaguchi, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Yasaka, Y; Yokoi, H; Zen, K | 1 |
| Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J | 1 |
| Antoniucci, D; Baldereschi, G; Bellandi, B; Carrabba, N; Cecchi, E; Giglioli, C; Marchionni, N; Marcucci, R; Migliorini, A; Parodi, G; Valente, S; Valenti, R | 1 |
| Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HK; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Jiang, M; You, JHS | 1 |
| Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Faggioni, M; Farhan, S; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Adriaenssens, T; Bernlochner, I; Byrne, RA; Colleran, R; Emmer, R; Fischer, M; Giacoppo, D; Han, Y; Harada, Y; Ibrahim, T; Jacobshagen, C; Kastrati, A; Kufner, S; Lahmann, AL; Laugwitz, KL; Lohaus, R; Maeng, M; Mayer, K; Mehilli, J; Michel, J; Morath, T; Neumann, FJ; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tölg, R; Wöhrle, J; Wolk, A; Zrenner, B | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Abizaid, A; Bhatt, DL; Colombo, A; Feres, F; Gilard, M; Hong, MK; Kim, HS; Morice, MC; Palmerini, T; Piccolo, R; Stone, GW; Valgimigli, M; Windecker, S | 1 |
| Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D | 1 |
| Grove, EL; Hvas, AM; Kristensen, SD; Larsen, ML; Pedersen, OH | 1 |
| Athanasiou, A; Spartalis, E; Spartalis, M; Tzatzaki, E | 1 |
| Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN | 1 |
| Adamson, PD; Anand, A; Dias, S; Lee, KK; McAllister, DA; Mills, NL; Newby, DE; Shah, AS; Welton, N | 1 |
| Alexopoulos, D; Davlouros, P; Despotopoulos, S; Xanthopoulou, I | 1 |
| Bhatt, DL; Deliargyris, EN; Eisen, A; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bauersachs, J; Schäfer, A | 1 |
| Chao, TH; Chen, JY; Cheng, CL; Kao Yang, YH; Lee, CH; Li, YH | 1 |
| Berger, JS; Bjerring Olesen, J; Gerds, TA; Gislason, GH; Hansen, ML; Lamberts, M; Langtved Pallisgaard, J; Nissen Bonde, A; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| He, B; Lin, H; Tobe, RG; Wu, B; Zhang, L | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Branny, M; Cervinka, P; Dusek, J; Hlinomaz, O; Hromadka, M; Jarkovsky, J; Kala, P; Knot, J; Kramarikova, P; Majtan, B; Miklik, R; Motovska, Z; Mrozek, J; Ostransky, J; Rokyta, R; Simek, S; Svoboda, M; Tousek, F; Varvarovsky, I; Widimsky, P | 1 |
| Byun, JK; Choi, BG; Choi, CU; Choi, SY; Kim, EJ; Kim, JB; Na, JO; Oh, DJ; Park, CG; Rha, SW; Seo, HS | 1 |
| Alexopoulos, D; Lekakis, J; Pappas, C; Sfantou, D | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Ahn, JM; Cho, JH; Choi, SW; Choi, YJ; Her, SH; Kang, SJ; Kim, HS; Kim, YH; Lee, CH; Lee, CW; Lee, JH; Lee, JY; Lee, PH; Lee, SW; Min, PK; Nam, CW; Park, DW; Park, GM; Park, SJ; Park, SW; Seo, JB; Shin, WY | 1 |
| Benavente, OR; Bhatt, DL; Connolly, SJ; Doros, G; Elmariah, S; Hsieh, WH; Liu, Y; Mauri, L; Steinhubl, SR; Yeh, RW; Yusuf, S | 1 |
| Boland, P; Bourke, M; Chan, V; Chong, AY; Dupuis, JY; Goubran, D; Hibbert, B; James, TE; Lordkipanidzé, M; Malhotra, N; Perrault, L; Rubens, F; Ruel, M; Russo, JJ; Singh, K; So, DY; Tanguay, JF; Tran, DT; Wells, GA | 1 |
| Ge, YL; Hu, S; Jiang, LX; Li, J; Li, X; Yu, Y; Zhang, LH; Zheng, X | 1 |
| Amann, M; Ferenc, M; Hochholzer, W; Löffelhardt, N; Merz, S; Neumann, FJ; Stratz, C; Valina, CM | 1 |
| Ajjan, RA; Bertilsson, M; Gabrysch, K; Himmelmann, A; James, SK; Siegbahn, A; Storey, RF; Sumaya, W; Wallentin, L | 1 |
| Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK | 1 |
| Hlinomaz, O; Máchal, J | 1 |
| Ardissino, D; Becker, RC; Cairns, R; Cannon, CP; Himmelmann, A; James, SK; Katus, HA; Mahaffey, KW; Storey, RF; Vignali, L; Wallentin, L | 1 |
| Généreux, P; Kirtane, AJ; Maehara, A; McAndrew, T; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Baele, P; Kahn, D; Lamberts, V; Liistro, G | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; De Luca, FA; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Saraiva, JFK; Tajer, C; Valeis, N; White, HD | 1 |
| Ahn, Y; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Han, JK; Hur, SH; Jeong, MH; Kang, HJ; Kang, J; Kim, HS; Kim, YJ; Koo, BK; Park, KW; Seong, IW; Seung, KB; Yang, HM | 1 |
| Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E | 1 |
| Bilker, WB; Brensinger, CM; Grosser, T; Hennessy, S; Kasner, SE; Leonard, CE; Li, X; Nam, YH | 1 |
| Onwordi, ENC; Parker, WA; Storey, RF | 1 |
| Carrero, JJ; Edfors, R; Evans, M; James, SK; Jernberg, T; Lagerqvist, B; Renlund, H; Sahlén, A; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Kou, N; Miao, Y; Qu, H; Shi, DZ; Wang, MM; Xue, M; Yang, B; Yang, L; Zang, MX | 1 |
| Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY | 1 |
| Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E | 1 |
| Jung, JM; Kim, SU; Kwon, DY; Park, JW; Park, MH | 1 |
| Andrássy, P; Aradi, D; Dézsi, CA; Jánosi, A; Kiss, RG; Komócsi, A; Kőszegi, Z; Kupó, P; Lupkovics, G; Merkely, B; Molnár, Z; Nagy, FT; Nagy, GG; Nagy, L; Noori, E; Ofner, P; Papp, E; Ruzsa, Z; Szűk, T | 1 |
| Bundhun, PK; Huang, F | 1 |
| Alexander, JH; Lopes, RD; Newby, LK; Newman, MF; Smith, PK; Wang, A; Wojdyla, D; Wu, A | 1 |
| Ahn, TH; Cha, KS; Chae, JK; Chae, SC; Cho, MC; Choi, DJ; Gwon, HC; Hur, SH; Hwang, JY; Jeong, MH; Joo, SJ; Kim, CJ; Kim, DI; Kim, HS; Oh, SK; Park, JS; Rha, SW; Seong, IW; Seung, KB; Sim, DS; Yoon, JH | 2 |
| Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY | 1 |
| Jiriaee, L; Jiriaee, Z; Rahmani, R; Shafiee, A; Zand Parsa, AF | 1 |
| An, GD; Han, JY; Kim, JM; Kim, KH; Kim, MH; Li, S; Lim, HH; Woo, KS | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG | 1 |
| Alfredsson, J; Gustafsson, KM; Janzon, M; Jonasson, L; Lindahl, TL; Logander, E; Nilsson, L; Swahn, E | 1 |
| Aradi, D; Baylacher, M; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Hausleiter, J; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Parma, R; Sibbing, D; Trenk, D | 1 |
| Huang, J; Liu, L; Tang, X; Zhang, X | 1 |
| Jørgensen, NR; Rath, CL; Wienecke, T | 1 |
| Abramson, BL; Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FGR; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Lopes, RD; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C; Rockhold, FW | 1 |
| Bai, J; Fu, Q; Gao, CZ; Liu, R; Ma, QQ; Wang, F; Wei, P; Wu, J; Yang, XJ | 1 |
| Antoniucci, D; Basili, S; Elmahdy, MF; Giusti, B; Gori, AM; Grifoni, E; Marcucci, R; Migliorini, A; Paniccia, R; Pratesi, C; Pulli, R; Valenti, R; Violi, F | 1 |
| Bellesini, M; Donadini, MP; Squizzato, A | 1 |
| Ahn, J; Ahn, JH; Carriere, KC; Cho, SW; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kim, J; Lee, JM; Lee, SH; Lee, SY; Park, K; Park, TK; Song, YB; Yang, JH | 1 |
| Badimon, L; Ben-Aicha, S; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Lambert, C; Mendieta, G; Pons-Lladó, G; Vilahur, G | 1 |
| Bortone, AS; Cecere, A; Ciccone, MM; D'Alessandro, P; Favale, S; Fumarola, F; Giordano, A; Guaricci, AI; Marchese, A; Pepe, M | 1 |
| Alfredsson, J; Erlinge, D; James, S; Jernberg, T; Omerovic, E; Persson, J; Ravn-Fischer, A; Svennblad, B; Tornvall, P; Ueda, P; Varenhorst, C | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH | 1 |
| Bermúdez, D; Galera, Á; Garcia Rinaldi, R; Quinones, J; Quinones, S; Rodriguez-Acosta, J | 1 |
| Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C | 1 |
| Hoppe, UC; Jung, C; Lauten, A; Lichtenauer, M; Navarese, EP; Wernly, B | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Gurbel, PA; Henry, TD; Kirtane, AJ; Mazzaferri, EL; McAndrew, T; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Desai, RJ; Gagne, JJ; Lewey, JJ; Patorno, E; Schneeweiss, S; Spoendlin, J | 1 |
| Abellán-Huerta, J; Jurado-Román, A; López-Lluva, MT; Lozano-Ruiz Poveda, F; Piqueras-Flores, J; Sánchez-Pérez, I | 1 |
| Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB | 1 |
| Bhattacharya, J; Chang, M; Kaltenbach, T; Limketkai, BN; Lin, J; Oliver, M; Soetikno, R; Yu, JX | 1 |
| Duconge, J; Gonzalez, S; Hernandez-Suarez, DF; Hua, S; Kaplan, RC; Melin, K; Moon, JY; Qi, Q; Zeng, D | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Mulder, H; Norgren, L; Olivier, CB; Patel, MR; Rockhold, FW | 1 |
| Graipe, A; Mooe, T; Söderström, L | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Anstrom, KJ; Bhandary, D; Cannon, CP; Choudhry, NK; Cohen, DJ; Fonarow, GC; Henry, TD; Kaltenbach, LA; Khan, ND; Peterson, ED; Wang, TY | 1 |
| Bolognese, L; Bovenzi, FM; Cacucci, M; Crimi, G; De Carlo, M; De Luca, G; De Servi, S; Elia, LR; Ferrario, M; Ferri, LA; Grosseto, D; Mandurino Mirizzi, A; Morici, N; Piatti, L; Piscione, F; Savonitto, S; Toso, A; Trimarco, B | 1 |
| Chiang, CH; Huang, WC; Hung, CC; Kuo, FY; Liang, HL; Lin, KC; Liu, CP; Mar, GY; Tang, PL; Wang, MT; Yang, JS | 1 |
| Alexiou, E; Geroulakos, G; Lazaris, AM; Poulou, A | 1 |
| Cheng, CI; Chung, WJ; Hsueh, SK; Lee, CH; Lin, CJ; Tsai, TH | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, DS; Kim, JS; Ko, YG; Lee, H; Oh, SK; Park, J; Shin, DH | 1 |
| Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Matsumoto, M; Minematsu, K; Nagao, T; Nagata, I; Nanto, S; Nishikawa, M; Ogawa, A; Tanahashi, N; Toyoda, K; Uchiyama, S; Yamagami, H | 1 |
| Henriksson, R; Mooe, T; Söderström, L; Ulvenstam, A | 1 |
| Katoh, N; Kawasaki-Nagano, M; Masuda, K; Nakae, M; Nakagawa, H; Tamagawa-Mineoka, R; Wakabayashi, Y | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Ahn, KT; Chae, SC; Cho, MC; Choi, SW; Choi, UL; Gwon, HC; Jeong, JO; Jeong, MH; Jin, SA; Kim, CJ; Kim, HS; Kim, JH; Kim, YJ; Lee, JH; Seong, IW; Seong, SW | 1 |
| Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S | 1 |
| Coons, JC; Huang, L; Iasella, CJ; Kreider, MS; Stevenson, JM | 1 |
| Fujimoto, Y; Fukushima, KI; Himi, T; Kitahara, H; Kobayashi, Y; Nakayama, T; Nameki, M; Shiba, T; Shikama, N; Tokimasa, S | 1 |
| Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D | 1 |
| Anisimova, VA; Divaeva, LN; Kucheryavenko, AF; Kuz'menko, TA; Morkovnik, AS; Sirotenko, VS; Spasov, AA | 1 |
| Björklund, F; Henriksson, R; Mooe, T | 1 |
| Chen, PC; Chen, ZW; Huang, JW; Lee, JK; Lin, LY; Lin, YH; Wu, CK; Wu, VC; Yang, YH | 1 |
| Hirayama, A; Isomura, N; Isshiki, T; Kato, M; Kimura, K; Nanasato, M; Nishikawa, H; Nishikawa, M; Nishimura, Y; Takayama, T; Takeda, Y; Tanigawa, T; Tsukahara, K; Yokoi, H | 1 |
| Åkerblom, A; Becker, RC; Cannon, CP; de Souza Brito, F; Himmelmann, A; James, SK; Katus, HA; Lopes, RD; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Goldberg, R; Gore, J; Hariri, E; Lessard, D; Rade, J | 1 |
| Ding, J; Xu, GM; Yuan, J | 1 |
| Dinh, AT; Luu, NM; Nguyen, TTH; Nguyen, VH | 1 |
| Bergmeijer, TO; Breet, NJ; Deneer, VHM; Godschalk, TC; Hackeng, CM; Janssen, PWA; Kelder, JC; Qaderdan, K; Ten Berg, JM; Vos, GA | 1 |
| Hao, Z; Xiang, L; Yang, C; Zheng, L | 1 |
| Aradi, D; Dézsi, CA; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; May, AE; Merkely, B; Mügge, A; Neumann, FJ; Rizas, KD; Ruzsa, Z; Sibbing, D; Trenk, D; Ungi, I; Zeiher, AM | 1 |
| Cai, JJ; Lu, Y; Sun, X; Wang, B; Wu, JR; Wu, QY; Xu, P; Yin, SH; Yuan, H; Zhou, ML | 1 |
| Cho, MS; Kim, S; Kim, YJ; Nam, GB; Park, DW; Park, JJ; Park, K; Yun, JE | 1 |
| Bruno, V; Egger, F; Farhan, S; Freynhofer, MK; Geppert, A; Huber, K; Hübl, W; Rohla, M; Tscharre, M; Weiss, TW; Willheim, M; Wojta, J | 1 |
| Almalla, M; Hennings, V; Hoffmann, R; Marx, N; Schröder, J | 1 |
| Di Luozzo, M; Di Roma, M; Lanzillo, C; Lioy, E; Maresca, L; Minati, M; Patrizi, R; Pendenza, G; Preziosi, P; Romagnoli, E; Romeo, F; Sciahbasi, A; Summaria, F | 1 |
| Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y | 1 |
| Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E | 1 |
| Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD | 1 |
| Bergmeijer, TO; Lichtveld, RA; Postma, S; Ten Berg, JM; Van't Hof, AW | 1 |
| Armstrong, PW; Arntz, HR; Bluhmki, E; Bogaerts, K; Carvalho, AC; Danays, T; Fresco, C; Gershlick, AH; Goldstein, P; Grajek, S; Halvorsen, S; Huber, K; Lambert, Y; Nanas, J; Ostojic, M; Regelin, A; Rosell Ortiz, F; Sulimov, V; Van de Werf, F; Vandenberghe, K; Welsh, RC; Wilcox, R | 1 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Brendel, K; Griesmacher, A; Mair, J; Pachinger, O; Weigel, G | 1 |
| Altarabsheh, SE; Boilson, BA; Deo, SV; Dunlay, SM; Erwin, PJ; Joyce, LD; Park, SJ; Shah, IK | 1 |
| Bauer, D; Berger, PB; Charnigo, RJ; Dunn, SP; Steinhubl, SR; Topol, EJ | 1 |
| Cannatà, A; Cavallari, I; D'Ambrosio, A; Di Sciascio, G; Dicuonzo, G; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V | 1 |
| Alexander, JH; Ferguson, TB; Gibson, CM; Hafley, GE; Harrington, RA; Lopes, RD; Mack, MJ; Mehta, RH; Peterson, ED; Smith, PK; Williams, JB | 1 |
| Chen, BD; Fu, ZY; Li, XM; Liu, F; Ma, X; Ma, YT; Xie, X; Yang, YN; Zheng, YY | 1 |
| Brown, A; Weinstock, BS; Young, JJ | 1 |
| Janus, M; Lesiak, M; Lukawski, K; Prech, M | 1 |
| Storey, RF | 1 |
| Angiolillo, DJ; Berdejo, J; Cequier, Á; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Homs, S; Marcano, AL; Romaguera, R; Roura, G; Sánchez-Elvira, G; Teruel, L | 1 |
| El Shamieh, S; Llerena, A; Monteiro, P; Peñas-Lledó, E; Shahabi, P; Siest, G; Silva Santos, L; Stathopoulou, MG; Thilly, N; Visvikis-Siest, S | 1 |
| Gao, YX; Li, L; Li, Y; Sun, TW; Yu, XZ; Yuan, YQ; Zhao, XY | 1 |
| Berglund, U; Janzon, M; Nilsson, L | 1 |
| de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S | 1 |
| Ageno, W; Donadini, MP | 1 |
| Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E | 1 |
| Christensen, CB; Gislason, GH; Hansen, ML; Kristensen, SL; Køber, L; Lamberts, M; Lip, GY; Mikkelsen, A; Olesen, JB; Schjerning Olsen, AM; Torp-Pedersen, C | 1 |
| Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M | 1 |
| Cano, P; Conesa, P; Consuegra-Sánchez, L; Dau, D; Jaulent, L; Picó, F; Torres-Moreno, D; Villegas, M | 1 |
| Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL | 1 |
| Cea Soriano, L; García Rodríguez, LA; Johansson, S | 1 |
| Liu, XH; Qu, Y; Shen, H; Xia, JG | 1 |
| Angioli, P; Bolognese, L; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Mandò, M; Porto, I | 1 |
| Kwak, YL; Shim, JK; Song, JW; Song, Y | 1 |
| Chang, K; Choi, YS; Chung, WS; Her, SH; Jeon, DS; Kim, CJ; Kim, DB; Kim, HS; Kim, HY; Kim, PJ; Koh, YS; Lee, JM; Park, CS; Park, HJ; Park, MW; Seo, SM; Seung, KB; Shin, DI; Shin, JG; Yoo, KD | 1 |
| Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F | 1 |
| Feldman, DN; Swaminathan, RV | 1 |
| Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD | 1 |
| Bednar, F; Kocka, V; Linkova, H; Sulzenko, J; Tousek, P; Widimsky, P | 1 |
| Dutton, P; Okunoye, GO | 1 |
| Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A | 1 |
| Ahn, T; Choi, H; Choi, IS; Han, SH; Kang, WC; Lee, K; Moon, CI; Oh, PC; Shin, EK; Suh, SY | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL | 1 |
| Chang, K; Choi, YS; Kim, EY; Kim, HS; Koh, YS; Oh, M; Park, CS; Park, MW; Seung, KB; Shin, JG; Shon, JH | 1 |
| Behera, V; Choudhary, G; Gaddam, S; Kim, J; Sharma, S; Wu, WC | 1 |
| Cha, KS; Chae, IH; Hwang, KK; Jeon, HK; Jeong, MH; Kang, HJ; Kang, SH; Kim, HS; Kim, S; Koo, BK; Kwon, HM; Lee, SY; Moon, KW; Oh, JH; Park, BE; Park, JJ; Park, KW; Park, TH; Rhew, JY; Shin, ES; Yang, HM; Yoon, JH | 1 |
| Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ | 1 |
| Changzhi, L; Dan, H; Jian, C; Mao, L; Suihua, H; Wei, W; Wenyi, T | 1 |
| Aryal Pandit, A; Aryal, MR; Hakim, FA; Jalota, L; Lee, HR; Mookadam, F; Pandit, A; Tleyjeh, IM | 1 |
| Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y | 1 |
| Limbruno, U; Musumeci, G | 1 |
| Casarosa, F; Colivicchi, F; Ebert, AG; Limbruno, U | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
| Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
| Biscaglia, S; Campo, G; Ferrari, R; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q | 1 |
| Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R | 1 |
| Bally, K; Buechel, RR; Buser, P; Martinaa, B; Tschudia, P; Zeller, A | 1 |
| Bal Dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Kchaou, I; Logeart, D; Magkoutis, N; Manzo Silberman, S; Sideris, G; Voicu, S | 1 |
| Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD | 1 |
| Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C | 1 |
| Abbate, R; Becatti, M; Fiorillo, C; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Pignatelli, P; Violi, F | 1 |
| DiNicolantonio, JJ; Fortmann, SD; Pokov, AN; Serebruany, VL | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Marchesini, J; Minarelli, M; Parrinello, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Metzger, NL; Momary, KM | 1 |
| Apró, A; Gulácsi-Bárdos, P; Hizoh, I; Horváth, Z; Kiss, RG; Kovács, A; Leé, S; Préda, I; Sztupinszki, Z; Tóth-Zsámboki, E; Vargová, K | 1 |
| Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L | 1 |
| Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC | 1 |
| Ay, C; Gremmel, T; Koppensteiner, R; Panzer, S | 1 |
| Chen, SL; Fan, HW; Lin, L; Lin, S; Tan, J; Xie, HG; Xu, HM; Zhang, J; Zhao, YY; Zou, JJ | 1 |
| Coxson, PG; Goldman, L; Gu, D; He, J; Heidenreich, PA; Liu, J; Moran, AE; Wang, M; Zhao, D | 1 |
| Balasubramaniam, K; Koshy, A; Noman, A; Zaman, AG | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Dawod, S; Rosenschein, U; Zaid, G | 1 |
| Inoue, Y; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Suzuki, S; Tanaka, A | 1 |
| Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD | 1 |
| Berti, S; De Caterina, A; Della Pina, F; Gianetti, J; Koni, E; Maffei, S; Marchi, F; Parri, MS | 1 |
| Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Lassen, JF; Lip, GY; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C | 1 |
| Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J | 1 |
| Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A | 1 |
| Garay-Sánchez, P; Limiñana, JM; Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra, P; Tugores, A | 1 |
| Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S | 1 |
| Bitar, A; Breall, JA; Desta, Z; Flockhart, DA; Jin, Y; Kreutz, RP; Nystrom, P; Owens, J; Sinha, A; Vatta, M; von der Lohe, E | 1 |
| de Waha, S; Desch, S; Eitel, I; Fuernau, G; Lurz, P; Schuler, G; Thiele, H | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Coons, JC; Harris, J; Schwier, N; Seybert, AL | 1 |
| Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J | 1 |
| Asanin, M; Brdar, N; Djuricic, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L | 1 |
| Adamson, P; Cruden, NL | 1 |
| Ho, PM; Magid, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S | 1 |
| Dalén, M; Holm, M; Tornvall, P; van der Linden, J | 1 |
| Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K | 1 |
| Braun, D; Gershlick, AH; Hauschke, D; Ibrahim, T; Kastrati, A; Laugwitz, KL; Mayer, K; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schulz, S; Schunkert, H; Tölg, R | 1 |
| Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, Y; Kim, HS; Lee, SH; Oh, JH; Seung, KB; Song, PS; Song, YB; Yang, JH | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Harskamp, RE; Ohman, EM | 1 |
| Boothroyd, DB; Chang, TI; Go, AS; Hlatky, MA; Kazi, DS; Leong, TK; Shilane, D; Solomon, MD | 1 |
| Gray, S; Keville, N; Murray, AM | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Taylor, J | 1 |
| Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD | 1 |
| Kim, EK; Kim, NY; Kwak, YL; Shim, JK; Song, JW | 1 |
| Biscaglia, S; Leonardi, S; Mehran, R; Parrinello, G; Rao, SV; Tebaldi, M; Valgimigli, M; Vranckx, P | 1 |
| Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW | 1 |
| Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Li, AY; Province, MA; Spertus, JA | 1 |
| Alexopoulos, D; Goudevenos, J; Xanthopoulou, I | 1 |
| Albert, F; Barbou, F; Belle, L; Berthier, R; Beygui, F; Brunel, P; Cazaux, P; Chassaing, S; Claudel, JP; Collet, JP; De Poli, F; Decomis, MP; Delarche, N; Dupouy, P; Köning, R; Montalescot, G; Rangé, G; Richard, P; Teiger, E; Thuaire, C; Yayehd, K | 1 |
| Kao Yang, YH; Lai, YS; Liu, PY; Yang, LT | 1 |
| Aboujaoude, R; Ayers, J; Hsi, DH; Mandell, R; Sanghvi, K | 1 |
| Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R | 1 |
| De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Cha, EY; Jeong, HE; Kim, EY; Kim, HS; Lee, SJ; Shin, JG; Song, YH | 1 |
| Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F | 1 |
| Carere, RG; Cruden, NL; Din, JN; Hilton, JD; Janssen, C; Klinke, WP; Robinson, SD; Siega, AD; Smith, R | 1 |
| Stone, GW | 2 |
| Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Joo, HC; Lee, S; Yi, G; Yoo, KJ; Youn, YN | 1 |
| Alexander, KP; Li, S; Magid, DJ; Peterson, ED; Roe, MT; Ting, HH; Wang, TY | 1 |
| Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y | 1 |
| Egbers, R; Helfrich, YR; Lowe, L; Tran, BA; Wang, F | 1 |
| Christiansen, CB; Gislason, G; Hansen, ML; Juul, N; Karasoy, D; Lamberts, M; Olesen, JB; Sorensen, R; Torp-Pedersen, C | 1 |
| Roe, MT; Sherwood, MW | 1 |
| Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
| Barbato, E; Boland, J; Chenu, P; Claeys, MJ; Cuisset, T; Dens, J; Gach, O; Legrand, V; Magne, J; Martinez, C; Vrolix, M; Wijns, W | 1 |
| Asselbergs, FW; Bergmeijer, TO; de Boer, A; Deneer, VH; Dewilde, WJ; Herrman, JP; Ishak, M; Janssen, PW; Kelder, JC; Postma, MJ; Qaderdan, K; Ruitenbeek, RS; Schipper, JC; Spanó, F; ten Berg, JM; van 't Hof, AW | 1 |
| Dambrink, JH; Gosselink, AT; Koopmans, PC; Ottervanger, JP; Postma, S; Suryapranata, H; ten Berg, JM; van 't Hof, AW | 1 |
| Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Spertus, JA; Wang, Q; Wang, Y | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J | 1 |
| Bach, RG; Cresci, S; Depta, JP; Lanfear, DE; Lenzini, PA; Spertus, JA; Wang, TY | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Armstrong, PW; Bakal, JA; Brown, EB; Fox, KA; Goodman, SG; Hochman, JS; Lokhnygina, Y; Ohman, EM; Roe, MT; Westerhout, CM; Zheng, Y | 1 |
| Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
| Agrawal, N; Parekh, P; Vasavada, A; Vinchurkar, M | 1 |
| Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y | 1 |
| Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X | 1 |
| Bøtker, HE; Chisholm, GE; Jensen, LO; Johansen, MB; Kaltoft, A; Kristensen, SD; Krusell, LR; Lassen, JF; Maeng, M; Schmidt, M; Sørensen, HT; Thayssen, P; Thim, T; Thuesen, L; Tilsted, HH | 1 |
| Androulakis, A; Dagres, N; Kalogeras, K; Kariori, M; Lavda, M; Moldovan, C; Mpei, E; Siasos, G; Stefanadis, C; Tousoulis, D; Vavuranakis, M; Vrachatis, D | 1 |
| Abbate, R; Cau, V; Chiostri, M; Gensini, GF; Giusti, B; Gori, AM; Lazzeri, C; Marcucci, R; Paniccia, R; Valente, S | 1 |
| Carter, RE; Ciolino, JD | 1 |
| Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C | 1 |
| Liang, Y; Wang, Z; Xu, LJ; Yan, J | 1 |
| Bhatt, DL; Byrd, JB; Grunwald, GK; Ho, PM; Maddox, TM; O'Donnell, CI; Rumsfeld, JS; Tsai, TT | 1 |
| Chen, PS; Cheng, CL; Lee, CH; Li, YH; Lin, SJ; Yang, YH | 1 |
| Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J | 1 |
| Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K | 2 |
| Andruszkiewicz, A; Fabiszak, T; Kasprzak, M; Koziński, M; Kubica, A; Kubica, J; Obońska, K; Paciorek, P; Pio Navarese, E; Siller-Matula, J; Swiątkiewicz, I; Sztuba, B | 1 |
| Chen, J; Gao, RL; Gao, Z; Ma, YL; Meng, XM; Song, L; Tang, XF; Wang, J; Wu, Y; Xu, B; Yao, Y; Yuan, JQ; Zhang, JH; Zhang, Y | 1 |
| Badimon, L; Cubedo, J; Juan-Babot, O; Martin-Yuste, V; Padró, T; Peña, E; Ramaiola, I; Sabate, M | 1 |
| Choi, BJ; Choi, SY; Choi, YW; Hwang, GS; Jin, XJ; Lee, YH; Lim, HS; Park, JS; Park, SJ; Seo, KW; Shin, JH; Shin, JS; Tahk, SJ; Yang, HM; Yoon, MH | 1 |
| Gislason, GH; Hansen, PR; Kristensen, KE; Markowitz, JS; Rasmussen, HB; Torp-Pedersen, C; Wang, X; Zhu, HJ | 1 |
| Franskavichene, LV; Golukhova, EZ; Serebruany, VL; Syvolap, VV | 1 |
| El-Hadidy, WF; Mannaa, HF; Mohamed, AR | 1 |
| Angiolillo, DJ; Barozzi, C; Bartorelli, A; Bianchi, R; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; De Rosa, R; De Servi, S; Della Riva, D; Généreux, P; Maffeo, D; Mariani, A; Mariani, M; Palmerini, T; Palmieri, C; Piscione, F; Podda, G; Reggiani, LB; Stone, GW; Taglieri, N; Tomasi, L; Toso, A | 1 |
| Aryal, MR; Badal, M; Fortuin, FD; Hakim, F; Karmacharya, P; Mahmood, M; Mainali, NR; Pandit, A; Pathak, R; Ukaigwe, A | 1 |
| Vengoechea, F | 1 |
| Chen, F; Lhermusier, T; Loh, JP; Magalhaes, MA; Minha, S; Pendyala, LK; Pichard, AD; Satler, LF; Torguson, R; Waksman, R | 1 |
| Blevins, A; El Accaoui, R; Karrowni, W; Vyas, A | 1 |
| Abdullah, AS; Ibrahim, H; Kiernan, TJ | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Adyaman, Ş; Altaş, Y; Altndağ, R; Altntaş, B; Baysal, E; Çetin, M; Kaya, İ; Sevuk, U; Yaylak, B | 1 |
| Aarøe, J; Abildgaard, U; Bligaard, N; Galløe, AM; Hansen, PR; Havndrup, O; Jeppesen, JL; Junker, A; Kelbæk, H; Kristensen, SL; Saunamäki, K; Thayssen, P; Thuesen, L | 1 |
| Anselmi, CV; Bacci, M; Mendolicchio, GL; Quagliuolo, V; Rota, LL; Roveda, M; Ruggeri, ZM; Zavalloni, D | 1 |
| Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S | 1 |
| Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD | 1 |
| Merli, GJ; Weitz, HH | 1 |
| Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY | 1 |
| Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
| Fabiszak, T; Grześk, G; Kasprzak, M; Koziński, M; Kubica, A; Kubica, J; Laskowska, E; Navarese, EP; Obońska, K; Świątkiewicz, I; Sztuba, B | 1 |
| Liang, Y; Ma, W; Wang, X; Wang, Y; Zhu, J | 1 |
| Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S | 1 |
| Abdel-Wahab, M; Adriaenssens, T; Angiolillo, DJ; Bernlochner, I; Byrne, RA; Desmet, W; Feuchtenberger, A; Fischer, M; Han, Y; Hengstenberg, C; Ibrahim, T; Jacobshagen, C; Janssen, PW; Kastrati, A; Kufner, S; Laugwitz, KL; Li, Y; Maeng, M; Mehilli, J; Morath, T; Mudra, H; Neumann, FJ; Rifatov, N; Schömig, A; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tiroch, K; Tölg, R; Valina, C; von Hodenberg, E; von Merzljak, B; Wöhrle, J; Zrenner, B | 1 |
| Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U | 1 |
| Lüscher, TF | 1 |
| Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW | 1 |
| Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A | 1 |
| Du, XJ; Feng, XH; Gao, W; Li, ZP; Wang, XY; Wang, YP; Yu, HY; Zhang, YY | 1 |
| Bultas, J | 1 |
| Alvarez-Contreras, L; Jørgensen, E; Kelbaek, H; Kocka, V; Martin-Yuste, V; Sabaté, M; Saunamäki, K | 1 |
| Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R | 1 |
| Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M | 1 |
| Ando, G; Calabro, P; Costa, F; Leonardi, S; Moscarella, E; Oreto, G; Valgimigli, M; Vranckx, P; Zijlstra, F | 1 |
| Bogaert, J; Doulaptsis, K; Nessler, J; Ntoumpanaki, M; Sadowski, M; Undas, A; Woznicka, O; Ząbczyk, M; Zalewski, J | 1 |
| Bourdakis, A; Charmpas, C; Christogiannis, Z; Dimoulis, N; Draganigos, A; Efthimiadis, I; Giannakoulas, G; Giatrakos, I; Giogiakas, V; Goudevenos, JA; Goumas, G; Hatziathanasiou, G; Kalantzi, KI; Kazakos, E; Kipouridis, N; Konstantinou, S; Nikolopoulos, D; Ntalas, IV; Panagiotakos, DB; Peltekis, L; Prokopakis, N; Sinteles, I; Stroumbis, CS; Terzoudi, K; Thoma, M; Tselepis, AD; Tsilias, K; Tsoumani, ME; Vakalis, JN; Vardakis, K; Vasilakopoulos, V; Vemmos, KN; Voukelatou, M; Xaraktsis, I | 1 |
| Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S | 1 |
| Amann, M; Bömicke, T; Hochholzer, W; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM | 1 |
| Gasior, M; Hawranek, M; Kaczmarski, J; Kuliczkowski, W; Laszowska, A; Polonski, L; Pres, D; Serebruany, VL; Szewczyk, M; Tajstra, M; Zeglen, S | 1 |
| Berard, L; Bonello, L; Collet, JP; Danchin, N; Dentan, G; Ennezat, PV; Ferrières, J; Leclercq, F; Meneveau, N; Motreff, P; Puymirat, E; Ravan, R; Schiele, F; Simon, T | 1 |
| Bernick, J; Dick, AJ; Froeschl, M; Glover, C; Gollob, MH; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; McPherson, R; Roberts, JD; So, DY; Tran, L; Wells, GA | 1 |
| Chen, K; Chu, H; Jia, M; Li, L; Li, Z | 1 |
| Farkouh, ME; Gandhi, S; Natarajan, MK; Schwalm, JD; Velianou, JL | 1 |
| Bainey, KR; Ferguson, C; Sharma, A | 1 |
| Ghobrial, J; Gibson, CM; Pinto, DS | 1 |
| Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M | 1 |
| Cressman, AM; Fernandes, KA; Gomes, T; Juurlink, DN; Macdonald, EM; Mamdani, MM; Paterson, JM | 1 |
| Langialonga, T; Maggi, A; Martimucci, M; Mele, M; Villella, A; Villella, M | 1 |
| Al-Hawwas, M; Azzalini, L; L'Allier, PL | 1 |
| Badimon, L; Bugiardini, R; Calmac, L; Cenko, E; Daullxhiu, I; Dorobantu, M; Kedev, S; Knežević, B; Koller, A; Manfrini, O; Miličić, D; Puddu, PE; Ricci, B; Trninic, D; Vasiljevic, Z | 1 |
| Biasco, L; Clemmensen, P; De Backer, O; Engstrøm, T; Helqvist, S; Holmvang, L; Jørgensen, E; Kelbaek, H; Olivecrona, G; Pedersen, F; Ratcovich, H; Saunamäki, K; Tilsted, HH | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Reid, C; Yudi, MB | 1 |
| Cherepanov, V; Kim, MH; Serebruany, VL; Tomek, A | 1 |
| Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y | 1 |
| Bauer-Mehren, A; Cooke, JP; Ghebremariam, YT; Iyer, SV; Leeper, NJ; LePendu, P; Marcus, J; Nead, KT; Shah, NH | 1 |
| Bao, H; Chen, Y; Fu, R; Liu, M; Luo, X; Wang, Y; Wang, Z; Yang, F | 1 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Liu, J; Liu, Y; Shang, Q; Shi, D; Wang, B; Zhang, L; Zhang, Q | 1 |
| Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW | 1 |
| Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Jang, WJ; Kim, BS; Kim, WS; Lee, SH; Lee, YT; Song, YB; Yang, JH | 1 |
| Cao, H; Wang, DG; Wei, YQ; Yang, H | 1 |
| Desai, NR; Hu, S; Jiang, L; Krumholz, HM; Li, J; Li, X; Masoudi, FA; Nuti, SV; Spertus, JA; Wang, Q; Wang, S; Zhang, L | 1 |
| Auer, R; Baumbach, A; Carballo, D; Engstrøm, T; Gencer, B; Heg, D; Jüni, P; Kelbæk, H; Klingenberg, R; Lüscher, TF; Mach, F; Matter, CM; Meier, B; Moschovitis, A; Ostojic, M; Räber, L; Rodondi, N; Roffi, M; Stefanini, GG; Tüller, D; von Birgelen, C; Windecker, S; Zanchin, T | 1 |
| Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Siddiqi, OK; Smoot, KJ; Temiyasathit, S; Young, M | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Hafley, G; Melloni, C; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Chong, AY; Qutub, MA; So, DY | 1 |
| Khatri, S; Pierce, T | 1 |
| Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Collet, JP; Costa, F; Kereiakes, DJ; Lee, CW; Lincoff, AM; Mauri, L; Montalescot, G; Park, SJ; Sabatine, MS; Udell, JA; Valgimigli, M | 1 |
| Bravo, PE; Di Carli, MF | 1 |
| Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P | 1 |
| Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X | 1 |
| Erne, P; Heg, D; Jüni, P; Pilgrim, T; Radovanovic, D; Tal, K; Windecker, S | 1 |
| Aradi, D; Balsam, P; Filipiak, KJ; Huczek, Z; Kochman, J; Kołtowski, Ł; Opolski, G; Sibbing, D; Tomaniak, M | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Assali, A; Greenberg, G; Kornowski, R; Lev, EI; Perl, L; Sasson, L; Vaknin-Assa, H; Weissler-Snir, A | 1 |
| Li-Sha, G; Peng, C; Yue-Chun, L | 1 |
| Arif, SA; D'Souza, J; Gil, M; Gim, S | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Cyr, DD; Fox, KA; Hochman, JS; Huber, K; McGuire, DK; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ | 1 |
| Anderson, RA; Freeman, PM; Hinz, C; James, PE; Kinnaird, TD; Moschonas, KE; O'Donnell, VB | 1 |
| Karjalainen, PP; Lepantalo, A; Mikkelsson, J; Paana, T | 1 |
| Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D | 1 |
| Ako, J; Morino, Y; Nakamura, M; Okuizumi, K; Usami, M | 1 |
| Koizumi, T; Nishimura, S | 1 |
| Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J | 1 |
| Dupouy, P; Labbe, R; Pernes, JM; Pongas, D; Rubimbura, V; Sotirov, I | 1 |
| Ahn, MS; Ahn, SG; Choi, E; Hung, OY; Kim, J; Kim, JY; Lee, JH; Lee, JW; Lee, SH; Samady, H; Yoo, BS; Yoo, SY; Yoon, J; Youn, YJ | 1 |
| Brilliant, MH; Burkley, B; Denny, JC; Gong, Y; Hoh, BL; Ingram, C; Johnson, JA; Kitchner, TE; Langaee, TY; Linneman, JG; McDonough, CW; Mocco, J; Mummareddy, N; Roden, DM; Royster, AJ; Shaffer, CM; Sheehan, TO; Stephens, ML; Waters, MF; Zuckerman, SL | 1 |
| Axelsson, C; Bremer, A; Claesson, A; Herlitz, J; Jimenez-Herrera, M; Karlsson, T; Ravn-Fischer, A; Strandmark, R | 1 |
| Braun, D; Braun, S; Hausleiter, J; Kastrati, A; Knipper, A; Massberg, S; Mehilli, J; Orban, M; Petzold, T; Schulz, S; Sibbing, D | 1 |
| Desch, S; Eitel, I; Empen, K; Ferenc, M; Fuernau, G; Hambrecht, R; Hausleiter, J; Hennersdorf, M; Limbourg, T; Neumann, FJ; Olbrich, HG; Orban, M; Pöss, J; Richardt, G; Schneider, S; Schuler, G; Thiele, H; Werdan, K; Zeymer, U | 1 |
| Apostolovic, SR; Jankovic, SM; Jevtovic-Stoimenov, T; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zivkovic, VS; Zvezdanovic, JB | 1 |
| Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K | 1 |
| Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M | 1 |
| Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY | 1 |
| Ahn, J; Carriere, KC; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Lee, SH; Park, TK; Song, YB; Yang, JH | 1 |
| Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Karanikas, S; Karvounis, H; Kontoprias, K; Koutsogiannis, N; Patsilinakos, S; Tsigkas, G; Xanthopoulou, I; Ziakas, A | 1 |
| Liu, W; Wu, S; Zhou, Y | 1 |
| Armstrong, PW; Bainey, KR; Carvalho, A; Fresco, C; Gershlick, AH; Goldstein, P; Halvorsen, S; Ostojic, M; Van de Werf, F; Westerhout, CM; Zheng, Y | 1 |
| Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O | 1 |
| Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L | 1 |
| Aisu, H; Hamada, M; Higashi, H; Hitsumoto, T; Ikeda, S; Inaba, S; Morofuji, T; Ohshima, K; Saito, M; Sumimoto, T; Takahashi, K | 1 |
| Dormuth, CR; Filion, KB; Platt, RW | 1 |
| Alamri, HS; Alkhudair, AA; AlMasood, AS; Almoghairi, AM; Sakr, HI | 1 |
| Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L | 1 |
| Parker, WA; Storey, RF | 1 |
| Li, Y; Li, Z; Miao, W; Su, G; Zhang, T | 1 |
| Beattie, WS; Carroll, J; Grewal, D; Harsha, P; Karkouti, K; Ragoonanan, T; Starzyk, Ł; Syed, S; Travis, G; Wąsowicz, M; Wijeysundera, DN | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S | 1 |
| Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY | 1 |
| Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Ariotti, S; Biscaglia, S; Campo, G; Costa, F; Esposito, G; Gargiulo, G; Leonardi, S; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M | 1 |
| Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ | 1 |
| Ruiz-Nodar, JM | 1 |
| Chen, J; Hu, XW; Li, CJ; Li, JM; Xu, K; Xu, L; Zhang, SH; Zhu, H | 1 |
| Bourdakis, A; Charmpas, C; Christogiannis, Z; Dimoulis, N; Draganigos, A; Efthimiadis, I; Giannakoulas, G; Giatrakos, I; Giogiakas, V; Goudevenos, JA; Goumas, G; Hatziathanasiou, G; Kalantzi, KI; Kazakos, E; Kipouridis, N; Konstantinou, S; Milionis, H; Nikolopoulos, D; Ntalas, IV; Panagiotakos, DB; Peltekis, L; Prokopakis, N; Sinteles, I; Stroumbis, C; Terzoudi, K; Thoma, M; Tselepis, AD; Tsilias, K; Tsoumani, ME; Vakalis, I; Vardakis, K; Vasilakopoulos, V; Vemmos, K; Voukelatou, M; Xaraktsis, I | 1 |
| Geske, JB; Mayr, M; Pereira, NL; Rihal, CS; Shah, SH | 1 |
| Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF | 1 |
| Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB | 1 |
| Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL | 1 |
| Chen, KY; Jiao, ZQ; Li, G; Liu, T; Xu, LX; Xu, Y; Zheng, XT | 1 |
| Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y | 1 |
| Bhatt, DL; Grunwald, GK; Ho, PM; Maddox, TM; O'Donnell, CI; Rumsfeld, JS; Tsai, TT; Vigen, R | 1 |
| Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A | 1 |
| Armstrong, PW; Boden, WE; Fox, KA; Hafley, G; Hagström, E; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Sidhu, MS; White, HD; Winters, KJ | 1 |
| Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C | 1 |
| Du, M; Ma, G; Shi, Y; Zhang, D | 1 |
| Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH | 1 |
| Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q | 1 |
| Dadjou, Y; Kojuri, J; Safavi, S | 1 |
| Cotton, JM; Cox, AR; Khan, N | 1 |
| Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY | 1 |
| Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ | 1 |
| Angiolillo, DJ; Barozzi, C; Bartorelli, A; Calabrò, P; Capodanno, D; Cattaneo, M; Crimi, G; De Carlo, M; De Servi, S; Della Riva, D; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Tomasi, L; Toso, A | 1 |
| Abaci, A | 1 |
| Tokgözoğlu, L | 1 |
| Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W | 1 |
| Fett, N | 1 |
| Brener, SJ; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Witzenbichler, B | 1 |
| Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Aonuma, K; Gosho, M; Hoshi, T; Nogami, A; Sato, A | 1 |
| Armstrong, PW; Bhatt, DL; Corbalán, R; Cyr, DD; Fox, KA; Jackson, LR; Lopes, RD; Lüscher, TF; Magnus Ohman, E; Martinez, F; Neely, ML; Piccini, JP; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Bhatt, DL; Cavender, MA; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Broderick, TM; Dalia, AA; Essandoh, MK; Flores, AS; George, BS; Kirtane, AJ; Otey, AJ; Rao, SV | 1 |
| Ariotti, S; Baldo, A; Esposito, G; Franzone, A; Gargiulo, G; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Valgimigli, M; Windecker, S | 1 |
| Cheng, W; Chi, L; Lin, J; Wang, C; Yi, X; Zhou, Q | 1 |
| Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Kim, JS; Ko, YG; Lee, SY; Palmerini, T; Shin, DH; Stone, GW; Valgimigli, M | 1 |
| Gao, RL; He, C; Liu, R; Ma, YL; Meng, XM; Song, L; Song, Y; Tang, XF; Wang, M; Xu, JJ; Yao, Y; Yuan, JQ; Zhang, JH | 1 |
| Dong, M; Li, L; Mu, N; Ren, F; Tan, J; Zhang, C; Zhang, X | 1 |
| Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Flaherty, JD; Gajjar, M; Ricciardi, MJ; Schimmel, DR; Yadlapati, A | 1 |
| Fatorova, I; Horacek, JM; Jakl, M; Pudil, R; Sevcik, R | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Fosbøl, EL; Ju, C; Messenger, JC; Peterson, ED; Waksman, R; Wang, TY; Zettler, ME | 1 |
| Badimon, L; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Pons-Lladó, G; Varela, L; Vilahur, G | 1 |
| Bovio, E; Nardi, P; Pellegrino, A; Russo, M; Ruvolo, G; Saitto, G; Scafuri, A | 1 |
| Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M | 1 |
| Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A | 1 |
| Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE | 1 |
| Cho, K; Do, JM; Dufour, AB; Faxon, DP; Gagnon, DR; Kinlay, S; Ly, S; Michael Gaziano, J; Ostrowski, S; Quach, L; Wimmer, NJ | 1 |
| Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Bagai, A; Brass, N; Cheema, AN; Dehghani, P; Dery, JP; Ducas, J; Fisher, HN; Fung, A; Goodman, SG; Kassam, SA; Kim, HH; Mehta, SR; Quraishi, AU; Schampaert, E; Wang, TY; Welsh, RC; Zhang, X; Zhu, YE | 1 |
| Alosh, M; Bretz, F; D'Agostino, RB; Huque, MF | 1 |
| Baber, U; Dangas, GD; Giustino, G; Guimarães, AH; Hemmrich, M; Mehran, R; Thomitzek, K; Tijssen, J; Valgimigli, M; van Es, GA; Volkl, AA; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Zazula, A | 1 |
| Bhatt, DL; Deliargyris, EN; Elkin, S; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Bykov, K; Choudhry, NK; Dong, YH; Donneyong, MM; Gagne, JJ; Schneeweiss, S | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD | 1 |
| Farkouh, ME; Fuster, V; Goodman, SG; Hamza, TH; Siami, FS; van Diepen, S; Verma, S | 1 |
| Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC | 1 |
| Johnston, SC; Ovbiagele, B; Wang, A; Wang, D; Wang, J; Wang, Y; Zhao, X | 1 |
| Abizaid, A; Angelini, GD; Bacchi Reggiani, L; Benedetto, U; Bhatt, DL; Biondi-Zoccai, G; Chieffo, A; Colombo, A; Della Riva, D; Feres, F; Généreux, P; Gilard, M; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Morice, MC; Palmerini, T; Park, KW; Pufulete, M; Sangiorgi, D; Stone, GW; Valgimigli, M; White, J | 1 |
| Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q | 1 |
| Chao, PW; Chen, HT; Chen, YT; Hsu, CY; Kuo, SC; Ou, SM; Shih, CJ | 1 |
| Baber, U; Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Ooi, SY; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K; Yu, J | 1 |
| Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW | 1 |
| Bae, JW; Hur, SH; Jeon, DW; Kim, BS; Kim, HS; Koo, BK; Lee, H; Lee, JH; Lee, NH; Lim, SW; Oh, SK; Park, KW; Park, TH; Rha, SW; Shin, ES | 1 |
| Chase, M; Davies, G; Du, M; Oguz, M | 1 |
| Ben-Yehuda, O; Brodie, BR; Gupta, R; Kirtane, AJ; Mehran, R; Metzger, DC; Ozan, MO; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Bhatt, DL; Colombo, A; Costa, F; Feres, F; Heg, D; Hong, MK; James, S; Kim, HS; Palmerini, T; Pilgrim, T; Räber, L; Steg, PG; Steyerberg, EW; Stone, GW; Valgimigli, M; van Klaveren, D; Wallentin, L; Windecker, S; Zanchin, T | 1 |
| Antman, EM; Hollander, JE; Pollack, CV | 1 |
| Aharonian, V; Brar, SK; Brar, SS; Hyett, R; Kim, J; Liu, IL; Mansukhani, P; Ree, M; Shen, AY; Zadegan, R | 1 |
| Choi, SH; Prasad, A; Tsimikas, S | 1 |
| Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Hamilos, M; Sarma, J; Sarno, G; Vanderheyden, M; Wijns, W; Wyffels, E | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 2 |
| Angiolillo, DJ; Campo, G; Colangelo, S; de Cesare, N; Ferrari, F; Ferrari, R; Furgieri, A; Hamon, M; Kubbajeh, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Battistone, S; Coons, JC | 1 |
| Jackson, J; Kolm, P; Mosse, F; Weintraub, WS; Zhang, Z; Zhao, L | 1 |
| Bøttcher, M; Hansen, HH; Jensen, LO; Johnsen, SP; Kaltoft, A; Krusell, LR; Lassen, JF; Maeng, M; Pedersen, L; Rasmussen, K; Sørensen, HT; Thayssen, P; Thuesen, L | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD | 1 |
| Bagatini, MD; Battisti, V; dos Santos, RB; Gasparetto, D; Gonçalves, JF; Martins, CC; Morsch, VM; Rosa, CS; Schetinger, MR; Spanevello, RM | 1 |
| Berger, PB; Blankenship, JC; Büttner, HJ; Byrne, RA; Dirschinger, J; Graf, I; Iijima, R; Kastrati, A; Khattab, AA; Mehilli, J; Minners, J; Neumann, FJ; Pache, J; Richardt, G; Schömig, A; Schulz, S; Seyfarth, M; Skelding, KA | 1 |
| Cohn, WE; Cooley, DA; de la Cruz, KI; Tsai, PI | 1 |
| Fefer, P; Hod, H; Matetzky, S; Savion, N; Shenkman, B; Varon, D | 1 |
| Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD | 1 |
| Alexander, D; Brown, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Ohman, EM; Ou, FS; Peterson, ED; Pollack, CV; Roe, MT | 1 |
| Tayyareci, Y | 1 |
| Hong, N; Kang, SM; Oh, J | 1 |
| Patel, RA; White, CJ | 1 |
| Bresnahan, JF; Gumina, RJ; Holmes, DR; Lennon, RJ; Prasad, A; Rihal, CS; Sandhu, GS; Singh, M; Yang, EH | 1 |
| Day, D; Pezalla, E; Pulliadath, I | 1 |
| Berger, PB; Braun, S; Byrne, RA; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Schömig, A | 1 |
| Bosevski, M; Kalpak, O; Maksimovic, J; Pejkov, H; Peovska, I | 1 |
| Erdmann, E; Flesch, M; Krausgrill, B | 1 |
| Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S | 1 |
| Abildstrom, SZ; Fosbøl, EL; Gislason, GH; Køber, L; Madsen, JK; Rasmussen, S; Sørensen, R; Torp-Pedersen, C | 1 |
| Asakura, Y; Ehara, M; Katoh, O; Kimura, M; Kinoshita, Y; Matsubara, T; Nasu, K; Suzuki, T; Tanaka, N; Terashima, M; Tsuchikane, E | 1 |
| Archvadze, A; Gogorishvili, I; Kipiani, V; Kipshidze, N | 1 |
| Giannitsis, E; Ivandic, BT; Katus, HA; Keck, F; Kurz, K; Lehrke, S; Staritz, P | 1 |
| Damman, K; de Smet, BJ; Hillege, HL; Svilaas, T; Tijssen, JG; Vlaar, PJ; Zijlstra, F | 1 |
| Ajani, AE; Al-Fiadh, A; Andrianopoulos, N; Black, A; Brennan, AL; Clark, DJ; Duffy, SJ; Gurvitch, R; Lefkovits, J; Lew, R; New, G; Reid, CM; Shaw, JA; Yan, BP | 1 |
| Aradi, D; Komócsi, A; Vorobcsuk, A | 1 |
| Giugliano, RP; Thomas, D | 2 |
| Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Alexander, D; Gibler, WB; Mann, N; Ohman, EM; Ou, FS; Peterson, ED; Roe, MT | 1 |
| Satler, LF | 2 |
| Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M | 1 |
| Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Bielis, L; Grabczewska, Z; Koziński, M; Kubica, J; Rość, D; Sukiennik, A; Swiatkiewicz, I; Wiśniewska-Szmyt, J; Ziołkowski, M | 1 |
| Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V | 1 |
| Heintzen, MP | 1 |
| Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG | 1 |
| Bakhai, A; Brennan, A; Holmes, MW; Karnon, J; Williams, R | 1 |
| Becquemont, L; Danchin, N; Drouet, E; Ferrières, J; Mary-Krause, M; Méneveau, N; Quteineh, L; Simon, T; Steg, PG; Verstuyft, C | 1 |
| Bensimon, G; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Esteve, JB; Funck-Brentano, C; Hulot, JS; Montalescot, G; Payot, L; Pena, A; Silvain, J; Villard, E | 1 |
| Freedman, JE; Hylek, EM | 1 |
| Yiadom, MY | 1 |
| Austin, PC; Gomes, T; Henry, DA; Juurlink, DN; Ko, DT; Kopp, A; Mamdani, MM; Szmitko, PE; Tu, JV | 1 |
| Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R | 1 |
| Ottervanger, JP; Remijn, JA; Slingerland, RJ; Smit, JJ; van 't Hof, AW; van Oeveren, W; Zijlstra, F | 1 |
| Milani, RV | 1 |
| Bildirici, U; Celikyurt, U; Ural, E | 1 |
| Antonino, MJ; Bassi, AK; Bliden, KP; DiChiara, J; Gesheff, TB; Gurbel, PA; Hennebry, TA; Herzog, WR; Mahla, E; Saucedo, JF; Singla, A; Suarez, TA; Tantry, US | 1 |
| Faxon, DP; Freedman, JE | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD | 1 |
| Kereiakes, DJ | 2 |
| Kammer, RT | 1 |
| Bonello, L; Kaneshige, K; Kent, KM; Lindsay, J; Okabe, T; Pichard, AD; Pinto Slottow, TL; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R; Xue, Z | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Saracini, C; Sestini, I | 1 |
| Fukuuchi, Y; Uchiyama, S; Yamaguchi, T | 1 |
| Ammon, SE; Armstrong, PW; Cleland, JG; Collins, JF; Ezekowitz, M; Jafri, SM; Krol, WF; Massie, BM; O'Connor, CM; Schulman, KA; Teo, K; Warren, SR | 1 |
| Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW | 1 |
| Korenstein, D; McGinn, T; Stulman, J | 1 |
| Dirschinger, J; Dotzer, F; Früngel, S; Huber, K; Kastrati, A; Martinoff, S; Mehilli, J; Moshage, W; Nekolla, SG; Pache, J; Schömig, A; Schulz, S; Schwaiger, M; Seyfarth, M | 1 |
| Sabatine, MS | 2 |
| Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S | 1 |
| Becker, D; Beres, BJ; Fülöp, G; Kerecsen, G; Kiss, RG; Merkely, B; Preda, I; Spaulding, C; Szabó, G; Tóth-Zsamboki, E; Vargova, K | 1 |
| Li, Z; Liu, R; Miao, J | 1 |
| Bhattacharyya, S; Rakhit, R | 1 |
| Ramaraj, R | 1 |
| Cannon, CP; Desai, NR; Jiang, S; Mega, JL; Sabatine, MS | 1 |
| Akbulut, M; Altas, Y; Baydas, A; Bilen, MN; Kutlu, M; Ozbay, Y; Polat, V | 1 |
| Chua, D; Ignaszewski, A | 1 |
| Airoldi, F; Aranzulla, TC; Carlino, M; Castelli, A; Chieffo, A; Colombo, A; Cosgrave, J; Godino, C; Latib, A; Magni, V; Michev, I; Montorfano, M; Rogacka, R; Romagnoli, E; Sangiorgi, GM | 1 |
| Antoniades, C; Briasoulis, A; Dhamrait, SS; Stefanadis, C; Tousoulis, D | 1 |
| Gersh, BJ; Gulati, R | 1 |
| Gleason, PP; Kjesbo, NK; Schafer, JA | 1 |
| Bruskina, O; Byrne, RA; Dirschinger, J; Iijima, R; Kastrati, A; Laugwitz, KL; Massberg, S; Mehilli, J; Pache, J; Schömig, A; Schulz, S; Seyfarth, M | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP | 1 |
| Angiolillo, DJ; Brugaletta, S; Campos, B; Cola, C; Martín Yuste, V; Sabaté, M | 1 |
| Dasgupta, A; Mukherjee, D | 1 |
| Budziaszek, Ł; Czaniecka, M; Gajos, G; Kleczkoska, A; Podolec, J; Zmudka', K | 1 |
| Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD | 1 |
| Price, MJ | 1 |
| Bass, TA | 1 |
| Poullis, AP; Sadler, GJ | 1 |
| Gurbel, PA; Kereiakes, DJ | 1 |
| Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC | 1 |
| Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH | 1 |
| Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G | 1 |
| Kapoor, JR | 2 |
| Motovska, Z; Widimsky, P | 1 |
| Floyd, J; Wolfe, S | 1 |
| Gladding, P; Webster, MW | 1 |
| Shil, AB; Strohm, MP | 1 |
| Fernández-Fernández, FJ; Pía, G; Sesma, P | 1 |
| Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J | 1 |
| Makarov, LM; Serebruany, VL | 1 |
| Björnberg, A; Odén, A; Welin, L; Wilhelmsen, L | 1 |
| Allen, MJ; McLean-Veysey, P | 1 |
| Friesen, MH | 1 |
| Serebruany, VL | 8 |
| Harrington, RA; Sellers, MB; Tricoci, P | 1 |
| Campo, G; Carletti, R; Carrescia, C; Ferrari, R; Valgimigli, M | 1 |
| Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P | 1 |
| Ahn, YK; Bae, JH; Chae, IH; Chae, JK; Chen, KY; Cho, MC; Choi, DH; Chung, WS; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Jin, Z; Kim, CJ; Kim, EJ; Kim, YJ; Li, YJ; Minami, Y; Oh, DJ; Park, CG; Park, SJ; Poddar, KL; Rha, SW; Seo, HS; Seong, IW; Seung, KB; Wang, L; Yoon, JH | 1 |
| Campbell-Scherer, DL; Green, LA | 1 |
| Mathew, ST; Owora, A; Patel, JH; Stoner, JA; Thadani, U | 1 |
| Boura, J; Harjai, KJ; Orshaw, P; Shenoy, C | 1 |
| Petersen, KU | 1 |
| Bruskina, O; Byrne, RA; Ellert, J; Goedel, J; Kastrati, A; Massberg, S; Mehilli, J; Schömig, A; Schulz, S; Schuster, T; Ulm, K | 1 |
| Alessi, L; Barozzi, C; Bassi, M; Branzi, A; De Servi, S; Lauria, G; Marzocchi, A; Ortolani, P; Palmerini, T; Reggiani, LB; Sangiorgi, D; Tomasi, L | 1 |
| Brunner-La Rocca, H; Kaiser, CA; Leibundgut, G; Nietlispach, F; Pfisterer, ME; Pittl, U | 1 |
| Berenson, K; Casciano, R; Corbelli, J; Lamerato, L; Makenbaeva, D; Mozaffari, E; Stern, L; Wiederkehr, D | 1 |
| Casciano, R; Corbelli, J; Makenbaeva, D; Mozaffari, E; Ogbonnaya, A; Wiederkehr, D | 1 |
| Bhindi, R; Kumar, S; Ryding, A | 1 |
| Akdemir, R; Karakurt, O | 1 |
| Fernandez-Pereira, C; Llaurado, C; Mieres, J; Perez, G; Risau, G; Rodriguez, AE; Rodriguez-Granillo, AM; Rubilar, B | 1 |
| Lovric, D; Milicic, D; Skoric, B | 1 |
| Appelbaum, E; Cannon, CP; Gibson, CM; Lord, EE; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Behar, S; Beinart, R; Boyko, V; Fefer, P; Hammerman, H; Hod, H; Matetzky, S; Segev, A | 1 |
| Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD | 1 |
| De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
| Arimura, T; Kawamura, A; Mitsutake, R; Miura, S; Nishikawa, H; Saku, K | 1 |
| Dauerman, HL | 1 |
| Berger, JS | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Levi, E; Shimony, A; Zahger, D | 1 |
| Bansal, D; Gupta, E; Olden, K; Sotos, J | 1 |
| Akkaya, E; Ayhan, E; Bozbay, M; Ergelen, M; Orhan, AL; Osmonov, D; Sayar, N; Soylu, O; Turer, A; Uyarel, H; Yekeler, I; Yildirim, E | 1 |
| Cahoon, WD; Ensor, CR | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; Larochellière, RD; Larose, E; Nguyen, CM; Noel, B; Poirier, P; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Chakrabarti, D; Saikia, PK | 1 |
| Bertrand, ME; Cox, DA; Dangas, GD; Fahy, M; Feit, F; Kirtane, AJ; Lansky, AJ; Lincoff, AM; Manoukian, SV; McLaurin, B; Mehran, R; Moses, JW; Nikolsky, E; Ohman, EM; Stone, GW; White, HD | 1 |
| Chua, D; Legal, M; Shalansky, SJ | 1 |
| Bartra, J; Muñoz-Cano, R; Picado, C; Sanchez-Lopez, J; Valero, A | 1 |
| Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B | 1 |
| Parikh, SA; Simon, DI | 1 |
| Bauer, T; Gitt, AK; Juenger, C; Koeth, O; Senges, J; Zahn, R; Zeymer, U | 1 |
| Hankey, GJ; Mason, G; Maurice, JB; Sudlow, CL; Wedderburn, CJ | 1 |
| Liang, B; Mei, Q; Wang, Z | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; De Larochellière, R; Gleeton, O; Larose, E; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Gurbel, PA; Tantry, US | 2 |
| Menon, V; Raymond, C | 1 |
| Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC | 1 |
| Hulikova, K; Jirmar, R; Motovska, Z; Osmancik, P; Peroutka, Z; Pompachova, A; Widimsky, P | 1 |
| Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD | 1 |
| Chu, KM; Kan, LP; Lin, GM | 1 |
| Kent, DM; Trikalinos, TA | 1 |
| Kremneva, LV; Shalaev, SV | 1 |
| Gilchrist, IC | 1 |
| Hsu, PC; Sheng-Wen Wang, S; Tsai, SS; Wu, DC; Yang, CY | 1 |
| Danenberg, HD; Lotan, C; Marincheva, G; Nassar, H; Varshitzki, B | 1 |
| Aplin, R; Erickson, B; Gartner, M; Lovitz, C; Mahowald, J; Martin, P; Pelzel, J; Robinson, D; Schmidt, W; Tiede, D; Wendt, D; Xu, H | 1 |
| Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C | 1 |
| Atar, D; Serebruany, VL | 1 |
| Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S | 1 |
| Herszényi, L; Juhász, M; Tulassay, Z | 1 |
| Bhatt, DL; Chhatriwalla, AK | 1 |
| Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA | 1 |
| Bilodeau, ML; Simon, DI | 1 |
| Berger, PB; Brennan, DM; Charnigo, R; Dosh, K; Marso, S; Steinhubl, S; Topol, EJ; van Lente, F | 1 |
| Aberg, C; Bojestig, M; Carlhed, R; Garmo, H; Lindahl, B; Peterson, A | 1 |
| Cattaneo, M | 2 |
| Janion, M; Polewczyk, A; Sielski, J; Wałek, P | 1 |
| Istad, R; Ringdal, MA; Tangen, G; Tølløfsrud, S; Øvrum, E; Øystese, R | 1 |
| de Charro, F; Heeg, B; Thurston, SJ; van Hout, B | 1 |
| Han, CL; Lin, GM | 2 |
| Badimon, JJ; Burg, MM; Chaplin, W; Davidson, KW; Fuster, V; Paz-Yepes, M; Shimbo, D; Vilahur, G; Zafar, MU | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Harkness, JR; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Wiviott, SD | 1 |
| Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC | 1 |
| Ghaffari, S; Pourafkari, L | 1 |
| Abildgaard, U; Abildstrom, SZ; Folke, F; Fosbøl, EL; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Madsen, JK; Poulsen, HE; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Webster, MW | 1 |
| Campo, G; Cangiano, E; Cavazza, C; Ferrari, R; Fileti, L; Frangione, A; Luccarelli, S; Valgimigli, M | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kwak, CH; Lee, SW; Park, SW; Park, Y | 1 |
| Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Jensen, JS; Jørgensen, E; Kelbaek, H; Lønborg, J; Saunamäki, K; Treiman, M; Vejlstrup, N | 1 |
| Hayashi, F; Iijima, R; Nakamura, M; Sugi, K | 1 |
| Akhter, M; Baber, U; Kini, A; Kothari, S; Sharma, SK | 1 |
| Serebruany, V | 2 |
| Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W | 1 |
| Ben-Dor, I; Pichard, AD; Waksman, R | 1 |
| Bidet, A; Coste, P; Jais, C; Jakubowski, J; Nurden, A; Nurden, P; Puymirat, E | 1 |
| Kloppenburg, G | 1 |
| Adamopoulou, EN; Argyrakis, SK; Fakiolas, CN; Foussas, SG; Georgilas, AT; Kontos, CF; Patsourakos, NG; Tsiaousis, GZ; Vogiatzidis, K; Zairis, MN | 1 |
| Hong, MK; Kim, JJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC | 1 |
| Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD | 1 |
| Croce, K | 1 |
| Avorn, J; Rassen, JA; Schneeweiss, S | 1 |
| Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C | 1 |
| Bal, ET; Bouman, HJ; Breet, NJ; Deneer, VH; Hackeng, CM; Harmsze, AM; Kelder, JC; Rensing, BJ; Ruven, HJ; Suttorp, MJ; ten Berg, JM; van der Heyden, JA; van Werkum, JW | 1 |
| Andersen, NH; Bøtker, HE; Bøttcher, M; Christiansen, EH; Hansen, TM; Kaltoft, AK; Kharbanda, R; Kristensen, SD; Krusell, LR; Lassen, JF; Munk, K; Nielsen, SS; Nielsen, TT; Redington, AN; Rehling, M; Schmidt, MR; Sørensen, HT; Terkelsen, CJ; Thuesen, L; Trautner, S | 1 |
| Bosmans, JM; Claeys, MJ; Haine, S; Kluppels, K; Miljoen, H; Moerenhout, CM; Van der Planken, M; Vertessen, F; Vrints, CJ | 1 |
| Anstrom, KJ; Barron, JJ; Califf, RM; Curtis, LH; Cziraky, MJ; Eisenstein, EL; Hammill, BG; Krucoff, MW; Petersen, JL; Schulman, KA; Wahl, PM | 1 |
| Cannon, CP; Cohen, DJ; Gibler, KB; Huskamp, HA; Murphy, SA; Sabatine, MS | 1 |
| Balbi, M; Barsotti, A; Bezante, GP; Brunelli, C; Fedele, M | 1 |
| Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC | 1 |
| Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E | 1 |
| Ruparelia, N; Spyrou, N | 1 |
| Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W | 1 |
| Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY | 1 |
| Rotheray, K | 1 |
| Abildstrøm, SZ; Bonde, L; Bretler, DM; Fosbøl, EL; Gislason, GH; Hansen, PR; Kober, L; Olesen, J; Schramm, TK; Sorensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Cimino, E; Conca, P; Coppola, A; De Simone, C; Di Capua, M; Di Minno, G; Guida, A; Morisco, C; Tufano, A | 1 |
| Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY | 1 |
| Colonna, G; Di Sciascio, G; Mangiacapra, F; Montinaro, A; Pasceri, V; Patti, G | 1 |
| Guo, KW; Tan, JW | 1 |
| Bartus, S; Bryniarski, L; Dobrowolski, W; Dubiel, JS; Dudek, D; Dziewierz, A; Giszterowicz, D; Janus, B; Legutko, J; Ochala, A; Rakowski, T; Wieja, P; Zalewski, J; Zmudka, K | 1 |
| Boulanger, J; Doutrelan, L; Elmkies, F; Luycx-Bore, A; Malaquin, D; Meimoun, P; Tribouilloy, C; Zemir, H | 1 |
| Coolong, A; Kereiakes, DJ; Mauri, L; Naidu, SS; Popma, JJ; Turco, MA | 1 |
| Afshari, A; Johansen, M; Kristensen, BB | 1 |
| Carroll, NM; DeFor, TA; Go, AS; Ho, PM; Jackevicius, C; Maddox, TM; Magid, DJ; Margolis, KL; Powers, JD; Rumsfeld, JS; Tsai, TT | 1 |
| Brzeziński, M; Dubiel, JS; Dudek, D; Dziewierz, A; Mielecki, W; Rakowski, T; Siudak, Z; Zdzienicka, J | 1 |
| Dziri, C; Guesmi, F; Houissa, M; Khemiri, K; Landolsi, M; Ounalli, K; Saidi, Y; Trabelsi, S | 1 |
| Addiego, JE; Harada, AS; Le, L; Ramsey, S; Solow, BK; Stockl, KM; Zakharyan, A | 1 |
| Abidi, M; Boiangiu, C; Cohen, M | 1 |
| Schwartz, RS | 1 |
| Carroll, NM; Go, AS; Ho, PM; Maddox, TM; Magid, DJ; Margolis, K; Powers, JD; Rumsfeld, JS; Shetterly, SM; Tsai, TT; Xu, S | 1 |
| Neumann, FJ | 1 |
| Cho, JH; Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Koh, JS; Kwak, CH; Park, Y | 1 |
| Decker, C; Foody, JM; Garavalia, B; Garavalia, L; Ho, PM; Kruse, H; Spertus, JA | 1 |
| Horowitz, JD; McKinnon, RA; Sorich, MJ; Vitry, A; Ward, MB | 1 |
| Cannon, CP | 5 |
| Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C | 1 |
| Igonin, VA; Ivanov, VA; Krashutskiĭ, VV; Shames, AB; Terekhin, SA | 1 |
| Zeymer, U | 1 |
| Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Gerszten, RE; Gibson, CM; Jiang, S; Morrow, DA; Rifai, N; Sabatine, MS; Scirica, BM; Sherwood, MW | 1 |
| Heeg, BM; Herlitz, J; Logman, JF; van Hout, BA | 1 |
| Birkmeier, KA; Dirschinger, J; Dotzer, F; Huber, K; Kastrati, A; Mehilli, J; Moshage, W; Ndrepepa, G; Schömig, A; Schulz, S; Seyfarth, M | 1 |
| Armstrong, PW; Bluhmki, E; Danays, T; Gershlick, A; Goldstein, P; Van de Werf, F; Wilcox, R | 1 |
| Armstrong, PW; Brown, E; Chin, CT; Fox, KA; Lokhnygina, Y; Marshall, DA; Ohman, EM; Petitjean, H; Prabhakaran, D; Roe, MT; White, HD | 1 |
| Burke, MN; Duval, S; Henry, TD; Larson, DM; Lips, DL; Sharkey, SS; Solie, C; Steinhubl, S; Tschautscher, C | 1 |
| Bonassin, F; Schneemann, M; Wyss, C | 1 |
| Belle, L; Bonnefoy, E; Capel, O; Debaty, G; Dubien, PY; El Khoury, C; Mercier, C; Perret, T; Savary, D; Serre, P | 1 |
| Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II | 1 |
| Galiavich, AS; Makhiianova, ÉI | 1 |
| Byrne, RA; Ellert, J; Kastrati, A; Mehilli, J; Sarafoff, N; Schömig, A; Schulz, S; Sibbing, D; Sonntag, U | 1 |
| Okura, H | 1 |
| Colonna, G; Di Sciascio, G; Gatto, L; Montinaro, A; Pasceri, V; Patti, G | 1 |
| Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X | 1 |
| Bae, JP; Dean, BB; Emons, MF; Fiske, S; Meadows, E; Xiong, Y; Yu, HT | 1 |
| Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Muller, O; Patti, G; Peace, A; Ricottini, E; Vizzi, V | 1 |
| Gitt, A; Senges, J; Zahn, R; Zeymer, U | 1 |
| Adamczak, M; Boulesteix, AL; Eifert, S; Kilian, E; Lamm, P; Mair, H; Reichart, B | 1 |
| Bae, JH; Bae, JW; Chae, IH; Cho, MC; Choi, DJ; Kang, HJ; Kim, HS; Koo, BK; Kwon, TG; Lee, HY; Lee, SP; Park, KW; Rha, SW; Suh, JW | 1 |
| Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM | 1 |
| Bryant, AS; Cerfolio, RJ; Minnich, DJ | 1 |
| Büttner, HJ; Kastrati, A; Laugwitz, KL; Massberg, S; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Schulz, S; Schuster, T; Seyfarth, M; Valina, C | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 1 |
| Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Abdel-Karim, AR; Banerjee, S; Brilakis, ES; Gandhi, NK | 1 |
| Chu, KM; Han, CL; Lin, GM | 1 |
| Bax, JJ; Boersma, EE; Chonchol, M; Flu, WJ; Hoeks, SE; Poldermans, D; Schouten, O; van Kuijk, JP; Verhagen, HJ; Voute, MT | 1 |
| Kastrati, A; Koch, W; Mehilli, J; Roosen-Runge, T; Schömig, A; Sibbing, D; Tiroch, KA | 1 |
| Aradi, D; Horváth, IG; Komócsi, A; Magyarlaki, T; Rideg, O; Serebruany, VL; Tokés-Füzesi, M; Vorobcsuk, A | 1 |
| Memtsoudis, SG; Sharrock, NE | 1 |
| Batyraliev, TA; Besnili, F; Fettser, DV; Niiazova-Karben, ZA; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Breet, NJ; Brueren, BR; Dambrink, JH; Heestermans, AA; Kelder, JC; Koolen, JJ; ten Berg, JM; van der Heyden, JA; van Werkum, JW; van't Hof, AW; Zijlstra, F; Zwart, B | 1 |
| Chua, D; Jung, J; Legal, MG; Shalansky, SJ | 1 |
| Jin, B; Li, J; Li, Y; Ni, HC; Shen, W; Shi, HM | 1 |
| Abildstrøm, SZ; Ahlehoff, O; Charlot, M; Gislason, G; Hansen, PR; Jørgensen, CH; Køber, L; Madsen, JK; Norgaard, ML; Sørensen, R; Torp-Pedersen, C | 1 |
| Brophy, JM; de Aquino Lima, JP | 1 |
| Blackburn, DF; Eurich, DT; Lamb, DA; Mcleod, MM | 1 |
| Alden, PB; Goldman, JA; Graber, JN; Rizvi, AZ; Rosenbaum, A; Sullivan, TM; Tretinyak, AS | 1 |
| Dill, T; Hamm, C; Heestermans, T; Ottervanger, JP; Slingerland, R; Smit, JJ; ten Berg, J; van 't Hof, AW; van Werkum, JW | 1 |
| Marcucci, R | 1 |
| Kostrzewa, G; Kruk, M; Kłopotowski, M; Małek, LA; Przyłuski, J; Płoski, R; Rużyłło, W; Spiewak, M; Witkowski, A | 1 |
| Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E | 1 |
| Pai, RG; Tafreshi, J; Tran, M | 1 |
| Cho, BR; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Han, KR; Hur, SH; Lee, S; Lee, SH; Lee, SY; Lim, DS; Park, HS; Park, JS; Rha, SW; Song, YB; Yoon, J | 1 |
| Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Fileti, L; Furgieri, A; Meliga, E; Russo, F; Valgimigli, M | 1 |
| Barriales, V; Fernández-Cimadevilla, OC; Lozano, I | 1 |
| Fu, Q; Ishikawa, S; Isshiki, T; Takada, K; Yokoyama, N | 1 |
| Fan, ZJ; Fang, Q; Jin, XF; Liu, ZY; Shen, ZJ; Wang, CH; Xie, HZ; Yang, J; Zhang, SY | 1 |
| Aakhus, S; Arnesen, H; Bjørnerheim, R; Forfang, K; Lunde, K; Seljeflot, I; Solheim, S | 1 |
| Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W | 1 |
| Braun, S; Byrne, RA; Kastrati, A; Mehilli, J; Ndrepepa, G; Schömig, A; Schulz, S; Tiroch, K | 1 |
| Dart, AM; Du, XJ; Gao, XM; Head, GA; Kiriazis, H; Liu, Y; Lobo, A; Shan, L | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| 't Jong, GW; Kuipers, EJ; Sturkenboom, MC; Valkhoff, VE; Van Soest, EM | 1 |
| Chow, BJ; Small, GR; So, DY | 1 |
| Chen, A; de Lemos, JA; Foody, JM; Kontos, MC; Newby, LK; Ou, FS; Roe, MT; Wiviott, SD | 1 |
| Haraguchi, Y; Hariki, H; Hirata, K; Honjo, T; Inoue, T; Ishida, T; Kawamori, H; Kozuki, A; Nishio, R; Sawada, T; Shinke, T; Shinohara, M; Shite, J; Toh, R | 1 |
| Silber, S | 1 |
| Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F | 1 |
| Menown, IB | 1 |
| Bauters, C; Delhaye, C; Fayad, G; Koussa, M; Lablanche, JM; Lemesle, G; Modine, T; Sudre, A; Vanesson, L | 1 |
| Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Chabanel, D; Cook, S; Hayoz, D; Oberhänsli, M; Ribordy, V; Stauffer, JC; Togni, M | 1 |
| Casu, G; Meloni, I; Merella, P | 1 |
| Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J | 1 |
| Akazawa, Y; Hirata, A; Kashiwase, K; Kashiyama, T; Kodama, K; Masumura, Y; Matsuo, K; Muller, JE; Nemoto, T; Nishio, M; Ueda, Y; Wada, M | 1 |
| Byron, KA; Dear, AE; Dick, RJ | 1 |
| Bae, JH; Bae, JW; Chae, IH; Cho, MC; Cho, YS; Choi, DJ; Kang, HJ; Kim, HS; Koo, BK; Kwon, TG; Lee, HY; Lee, SP; Park, KW; Rha, SW; Suh, JW; Youn, TJ | 1 |
| Ahlehoff, O; Andersson, C; Charlot, MG; Fosbøl, EL; Gislason, GH; Hansen, PR; Olesen, JB; Selmer, C; Torp-Pedersen, C; Weeke, P | 1 |
| Bataille, V; Blanchard, D; Bonello, L; Coste, P; Danchin, N; Drouet, E; Ferrières, J; Gilard, M; Hanssen, M; Lardoux, H; Lefèvre, T; Mulak, G; Simon, T; Steg, PG; Verstuyft, C | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N | 1 |
| Li, YH; Lin, GM | 1 |
| Jung, HJ; Sir, JJ | 1 |
| Chauret, D; Deyoung, JP; Eagle, KA; Edwards, J; Goodman, SG; Kornder, JM; Picard, JP; Welsh, RC; Yan, AT; Yan, RT | 1 |
| Ahn, TH; Ahn, YK; Bae, JH; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Choi, CU; Choi, DH; Chung, WS; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, CJ; Kim, EJ; Kim, HS; Kim, JW; Kim, YJ; Lim, HE; Na, JO; Oh, DJ; Park, CG; Park, JS; Park, SJ; Poddar, KL; Rha, SW; Seo, HS; Seong, IW; Seung, KB; Tahk, SJ; Yoon, JH | 1 |
| Ben-Dor, I; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kent, KM; Laynez-Carnicero, A; Lindsay, J; Mahmoudi, M; Maluenda, G; Pichard, AD; Romaguera, R; Sardi, G; Satler, LF; Suddath, WO; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z | 1 |
| Ahmed, S; Cannon, CP; Michael Gibson, C; Murphy, SA; Sabatine, MS | 1 |
| Assennato, P; Bajardi, G; Bracale, UM; Caruso, M; Hoffmann, E; Incalcaterra, E; Novo, S; Vitale, G | 1 |
| Cheng, JW; Dorsch, MP; Goldberg, T; Mohammad, RA | 1 |
| Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O | 1 |
| Abildstrøm, SZ; Andersson, C; Charlot, M; Fosbøl, EL; Gislason, GH; Hansen, PR; Hvelplund, A; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C | 1 |
| Angiolillo, DJ; Aragon, JR; Berger, PB; Bertrand, OF; Cannon, CP; Garratt, KN; Kandzari, DE; Lee, MS; Manoukian, SV; Price, MJ; Puri, S; Robbins, M; Schork, NJ; Spriggs, D; Stillablower, ME; Stillabower, ME; Stinis, CT; Tanguay, JF; Teirstein, PS; Topol, EJ | 1 |
| Fantoni, C; Inglese, L | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C | 1 |
| Albuquerque, A; Araújo, C; Fontes-Carvalho, R; Pimentel-Nunes, P; Ribeiro, VG | 1 |
| Don, CW; Fraulo, E; Li, S; Palacios, I; Pomerantsev, E; Roe, MT; Wiviott, SD | 1 |
| Boes, L; Bonz, AW; Ertl, G; Lengenfelder, B; Stoerk, S; Strotmann, J; Voelker, W | 1 |
| Bouman, HJ; Breet, NJ; Hackeng, CM; Harmsze, AM; Kelder, JC; ten Berg, JM; van Werkum, JW | 1 |
| Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Kim, S; Koh, EH; Kwak, CH; Park, JR; Park, KS; Park, Y; Yun, SE | 1 |
| Anzaha, G; Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Caron, C; Cayla, G; Chastre, T; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Montalescot, G; Pena, A; Silvain, J; Vignalou, JB | 1 |
| Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
| Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U | 1 |
| Ben-Dor, I; Bonello, L; Collins, SD; de Labriolle, A; Lemesle, G; Maluenda, G; Pichard, AD; Satler, LF; Syed, AI; Torguson, R; Waksman, R; Xue, Z | 1 |
| Crimizade, U; El Adraa, E; El Ghannudi, S; Gachet, C; Jesel, L; Morel, O; Ohlmann, P; Radulescu, B; Wiesel, ML | 1 |
| Chang, CM; Cheng, JJ; Chiu, CZ; Chua, SK; Hung, HF; Kuan, P; Lee, SH; Liao, CS; Lin, SC; Liou, JY; Lo, HM; Shyu, KG | 1 |
| Behr, T; Behr, W; Kuch, B; von Scheidt, W | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD | 1 |
| Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G | 1 |
| Andreotti, F; Bielis, L; Boinska, J; Grabczewska, Z; Kozinski, M; Kubica, A; Kubica, J; Marciniak, A; Navarese, EP; Rosc, D; Siller-Matula, JM; Stolarek, W; Wisniewska-Szmyt, J | 1 |
| Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN | 1 |
| Bauersachs, J; Flierl, U; Kobsar, A; Kössler, J; Schäfer, A; Seydelmann, N; Störk, S | 1 |
| Gąsior, M; Greif, M; Kaczmarski, J; Kuliczkowski, W; Poloński, L; Pres, D | 1 |
| Jeong, YH; Kim, IS; Park, Y | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 2 |
| El-Omar, M; Imola, F; Mamas, MA; Manzoli, A; Pappalardo, A; Prati, F; Ramazzotti, V | 1 |
| Airaksinen, KE; Biancari, F; Lip, GY | 1 |
| Cosentino, N; Crea, F; Minelli, S; Niccoli, G | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA | 1 |
| Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG | 1 |
| Byrne, RA; Hausleiter, J; Laugwitz, KL; Orban, M; Sibbing, D | 1 |
| Brunner-La Rocca, H; Burkard, T; Jeger, RV; Kaiser, CA; Osswald, S; Pfisterer, ME | 1 |
| Aïssaoui, N; Bataille, V; Blanchard, D; Carrié, D; Coste, P; Danchin, N; Dentan, G; Drouet, E; Mulak, G; Puymirat, E; Simon, T | 1 |
| Birdane, A; Nadiradze, A; Ünalır, A; Yazıcı, HU | 1 |
| Alfieri, A; Bellone, P; Berti, S; Cassese, S; De Luca, G; Marraccini, P; Montinaro, A; Piscione, F; Quaranta, G; Villari, B | 1 |
| Chu, KM; Han, CL; Li, YH; Lin, GM | 1 |
| Colic, M; Djukanovic, N; Dolijanovic, SP; Grdinic, A; Grdinic, AG; Ignjatovic, V; Ilic, V; Magic, Z; Majstorovic, I; Obradovic, S; Ostojic, M; Vojvodic, D | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, AT; Hamm, C; Heestermans, T; Koopmans, P; Mosterd, A; ten Berg, JM; van 't Hof, AW; van Houwelingen, G; van Werkum, JW; Zijlstra, F | 1 |
| Hoffman, MK; Marshall, ES; Myers, GR | 1 |
| Carpio, A; Chae, YK; Gupta, S; Khemasuwan, D; Lucca, AB; Mora, JI; Neagu, S; Valsecchi, ME; Yun, JH | 1 |
| Abhay, K; Albaladejo, P; Bosson, JL; Charbonneau, H; Collet, JP; Jaber, S; Loutrel, O; Marret, E; Piriou, V; Samama, CM; Thoret, S | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, AL; Clark, DJ; Duffy, SJ; Loane, P; Reid, CM; Yan, BP | 1 |
| Clough, JD; Cope, MW; Martin, SS | 1 |
| Nusca, A; Patti, G | 1 |
| Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L | 1 |
| Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW | 1 |
| Begg, A; Boggon, R; Emmas, C; Fox, KA; Hemingway, H; Ray, KK; Timmis, A; van Staa, TP | 1 |
| Angiolillo, DJ; Berger, PB; Cannon, CP; Lillie, E; Manoukian, SV; Price, MJ; Tanguay, JF; Teirstein, PS; Topol, EJ | 1 |
| Blackman, DJ; Blaxill, JM; Chitkara, K; Dorsch, MF; Greenwood, JP; McLenachan, JM; Shelton, RJ; Singh, R; Somers, K; Wheatcroft, SB | 1 |
| Chen, M; Huang, DJ; Liu, XJ; Wei, JF; Xu, YN | 1 |
| Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C | 1 |
| Golian, M; Hussain, F | 1 |
| Beddingfield, R; Held-Godgluck, BM; Peppard, SR | 1 |
| Chauhan, A; More, RS; Morgan, KP | 1 |
| Beijk, M; Damman, P; de Winter, RJ; Iñiguez, A; Klomp, M; Ribeiro, EE; Silber, S; Sim, KH; Suryapranata, H; Tijssen, JG; Woudstra, P | 1 |
| Becquemont, L; Danchin, N; Drouet, E; Ferrari, E; Grollier, G; Kotti, S; Schiele, F; Simon, T; Steg, PG; Verstuyft, C | 1 |
| Alber, HF; Altenberger, J; Benzer, W; Dörler, J; Edlinger, M; Grimm, G; Huber, K; Pachinger, O; Schuchlenz, H; Siostrzonek, P; Weidinger, F; Zenker, G | 1 |
| Chen, MF; Chen, WJ; Chiu, FC; Huang, CH; Lee, JK; Lin, JW; Shih, FY; Wang, TD | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Angiolillo, DJ | 1 |
| Ilic, I; Neskovic, AN; Putnikovic, B; Stankovic, I; Vlahovic-Stipac, A | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Barbato, E; Bárczi, G; Colonna, G; Di Sciascio, G; Edes, I; Mangiacapra, F; Merkely, B; Orlic, D; Ostojic, M; Pasceri, V; Patti, G; Wijns, W | 1 |
| Allanic, F; Bellemain-Appaix, A; Cayla, G; Collet, JP; Hulot, JS; Montalescot, G; Scott, SA; Silvain, J | 1 |
| Alexander, KP; Chen, AY; Ho, PM; Melloni, C; Peterson, ED; Roe, MT; Wang, TY; Wiviott, SD | 1 |
| Gornik, I; Lovric, D; Milicic, D; Narancic-Skoric, K; Sertic, J; Skoric, B | 1 |
| Snoep, JD | 1 |
| Brar, SS; Breet, NJ; Cuisset, T; Dangas, G; DiSciascio, G; Kim, HS; Marcucci, R; Patti, G; Price, MJ; ten Berg, J; Valgimigli, M | 1 |
| Colak, N; Erpolat, S; Nazli, Y; Yenidunya, S | 1 |
| Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK | 1 |
| Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S | 1 |
| Fang, MC | 1 |
| Bliden, KP; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, IS; Koh, JS; Kwak, CH; Kwon, TJ; Park, Y; Tantry, US | 1 |
| Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C | 1 |
| Baron, JA; Bøtker, HE; Jensen, LO; Johansen, MB; Kaltoft, A; Maeng, M; Robertson, DJ; Schmidt, M; Sørensen, HT; Tilsted, HH | 1 |
| Delhaye, C; Lemesle, G | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Biondi-Zoccai, G; Bramucci, E; Colombo, A; Ferlini, M; Grinfeld, L; Iadanza, A; Morice, MC; Petronio, AS; Pierli, C; Sangiorgi, GM | 1 |
| Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S | 1 |
| Coppérré, B; Hot, A; Karkowski, L; Lescampf, J; Ninet, J; Veyradier, A; Wolf, M | 1 |
| Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Chitose, T; Fujimoto, K; Hirose, T; Hokimoto, S; Kaikita, K; Maruyama, H; Miyao, Y; Mizobe, M; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Shimomura, H; Tsunoda, R; Yamamoto, K | 1 |
| Bouman, HJ; de Maat, MP; Hackeng, CM; Leebeek, FW; Rudež, G; ten Berg, JM; ten Cate, H; van Werkum, JW | 1 |
| Dwivedi, G; Felmeden, DC; Lip, GY | 1 |
| Breet, NJ; Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; ten Berg, JM; van 't Hof, AW; van Houwelingen, KG; van Werkum, JW | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Brieger, D; Collet, JP; Costagliola, D; Lancar, R; Mercadier, A; Montalescot, G; Silvain, J | 1 |
| Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Ahn, T; Chae, IH; Choi, JH; Choi, SH; Choi, YJ; Chung, WY; Gwon, HC; Hahn, JY; Han, KR; Hong, TJ; Hur, SH; Jang, Y; Jeon, DW; Jeon, HK; Jeong, MH; Kang, HJ; Kim, BO; Kim, HS; Koo, BK; Kwon, HM; Lee, NH; Lim, DS; Park, KW; Park, SH; Song, YB; Yoon, JH | 1 |
| Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
| Arntz, HR; Darius, H; Dill, T; Diller, F; Fichtlscherer, S; Huber, K; Mark, B; Schöller, R; Werner, G; Zahn, R; Zeymer, U | 1 |
| Basford, MA; Bowton, E; Cleator, JH; Crawford, DC; Delaney, JT; Denny, JC; Jahangir, E; Masys, DR; Oetjens, M; Pulley, JM; Ramirez, AH; Ritchie, MD; Roden, DM; Schildcrout, JS; Shi, Y; Xu, H; Zink, R | 1 |
| Braunwald, E | 1 |
| Alessi, MC; Cuisset, T; Morange, PE | 1 |
| Krasznai, Z; Toth, P | 1 |
| Aihara, H; Akiyama, D; Aonuma, K; Hoshi, T; Kakefuda, Y; Nishina, H; Sato, A; Takeyasu, N; Watabe, H | 1 |
| Calvi, V; Capodanno, D; Tamburino, C | 1 |
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; de Carlo, C; Fedele, F; Lucisano, L; Mancone, M; Sardella, G; Stio, R | 1 |
| Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Shuldiner, AR | 1 |
| Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S | 1 |
| Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US | 1 |
| Agnani, S; Akkus, NI; Rajpal, S | 1 |
| Angiolillo, DJ; Cattaneo, M; Rollini, F | 1 |
| Passlick, B; Wiesemann, S | 1 |
| He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH | 1 |
| Lopez, J; Luzardo, H; Molero, T; Perera, M; Suarez, A | 1 |
| Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S | 1 |
| Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G | 1 |
| Abbate, R; Antoniucci, D; Gensini, GF; Giglioli, C; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Parodi, G; Saracini, C; Valente, S | 1 |
| Asanin, M; Ignjatovic, S; Majkic-Singh, N; Marinkovic, J; Matic, D; Mrdovic, I; Ostojic, M; Savic, L; Stankovic, S; Trifunovic, D; Vasiljevic, Z | 1 |
| Chang, SA; Choe, YH; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Lee, SC; Lee, SH; Oh, JK; Song, YB | 1 |
| Grajek, S | 1 |
| Grześk, G; Koziński, M; Kubica, J | 1 |
| Borghesi, M; Campo, G; Cangiano, E; Castriota, F; Cavazza, C; Colombo, F; Ferrari, R; Frangione, A; Fucà, G; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Vranckx, P | 1 |
| Duval, S; Ghali, MG; Henry, TD; Iannone, LA; Johnson Brown, S; Larson, DM; Poulose, AK; Smith, LG; Tannenbaum, MA | 1 |
| Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M | 1 |
| Ishii, H; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Fabiszak, T; Gierach, J; Kozinski, M; Kubica, A; Kubica, J; Magielski, P; Navarese, EP; Odrowaz-Sypniewska, G; Sukiennik, A; Swiatkiewicz, I | 1 |
| Berger, PB; Bhakta, N; Bhatt, DL; Cacoub, P; Creager, MA; Eikelboom, JW; Emison, ES; Flather, MD; Fox, KA; Hacke, W; Kottke-Marchant, K; Lincoff, AM; Mak, KH; Mehta, SR; Montalescot, G; Murugesan, G; Paré, G; Simonsen, KL; Steg, PG; Steinhubl, SR; Topol, EJ | 1 |
| Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES | 1 |
| Dong, CM; Jia, XQ; Qin, J; Zhang, L | 1 |
| Ammann, P; Borovicka, J; Haile, SR; Häuptle, R; Knellwolf, C; Schneider, T; Weilenmann, D | 1 |
| Alexander, KP; Fosbol, EL; Klaskala, W; Li, S; Lopes, RD; Mills, RM; Peterson, ED; Piccini, JP; Roe, MT; Shah, B; Thomas, L; Wang, TY | 1 |
| Couffinhal, T; Lafitte, M; Latry, P; Martin-Latry, K; Peter, C | 1 |
| Assali, A; Battler, A; Codner, P; Greenberg, G; Hasdai, D; Iakobishvili, Z; Kornowski, R; Lev, EI; Rechavia, E; Vaduganathan, M | 1 |
| Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F | 1 |
| Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y | 1 |
| Gąsior, M; Greif, M; Hawranek, M; Kaczmarski, J; Kuliczkowski, W; Poloński, L; Pres, D; Serebruany, V; Szewczyk, M; Tajstra, M; Żegleń, S; Łaszewska, A | 1 |
| Doğan, A; Erdogan, D; Icli, A; Varol, E | 1 |
| Kalidoss, L; Sankardas, MA; Subban, V | 1 |
| Held, C | 1 |
| Ho, PM; Li, S; Maddox, TM; Masoudi, FA; Peng, SA; Rumsfeld, JS; Tsai, TT; Wang, TY; Wiviott, SD | 1 |
| Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
| Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC | 1 |
| Bauer, ME; Bauer, ST; Mhyre, JM; Rabbani, AB | 1 |
| Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD | 1 |
| Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J | 1 |
| Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U | 1 |
| Alexopoulos, D; Chiladakis, J; Chouchoulis, K; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M | 1 |
| Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
| Di Sciascio, G; Mangiacapra, F | 1 |
| Bernlochner, I; Kastrati, A; Massberg, S; Mehilli, J; Schömig, A; Schulz, S; Sibbing, D | 2 |
| Chung, SR; Hur, SH; Jang, JS; Jin, HY; Kim, DI; Kim, DK; Kim, DS; Kim, KH; Kim, W; Kim, YJ; Nam, CW; Park, JS; Seo, JS; Seol, SH; Yang, TH | 1 |
| Igarashi, K; Ikari, Y; Isshiki, T; Kimura, T; Kobayashi, M; Nakamura, M; Ueno, T; Yokoi, H | 1 |
| Alonso-Rodríguez, D; Bangueses, R; Cuellas, C; de Miguel, A; de Prado, AP; Diego, A; Fernandez-Vazquez, F; Martín, J; Samaniego, B; Vega, B | 1 |
| Cung, TT; Elbaz, M; Lairez, O; Mewton, N; Ovize, M; Piot, C; Ranc, S; Rioufol, G; Roubille, F; Sanchez, I | 1 |
| Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
| Andreassen, T; Bendz, B; Brosstad, F; Erikssen, G; Kunszt, G; Liestøl, K; Meen, O; Schjelderup, NM; Wettergreen, M | 1 |
| Barbato, E; D'Ambrosio, A; Di Sciascio, G; Mangiacapra, F; Orlic, D; Ostojic, M; Patti, G; Peace, AJ; Wijns, W | 1 |
| Berti, S; Della Pina, F; Dushpanova, A; Gianetti, J; Giusti, B; Marcucci, R; Parri, MS; Saracini, C | 1 |
| Angelini, GD; Aresu, G; Caputo, M; de Siena, PM; Duggan, SM; Glauber, M; Miceli, A; Romeo, F | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM | 1 |
| Crimizade, U; El Ghannudi, S; Gachet, C; Hess, S; Jesel, L; Morel, O; Ohlmann, P; Radulescu, B; Reydel, A; Wiesel, ML | 1 |
| Budaj, A; Gurbel, PA; Tantry, US | 1 |
| Douglas, IJ; Evans, SJ; Grosso, AM; Hemingway, H; Hingorani, AD; Smeeth, L; Timmis, A | 1 |
| Gurbel, PA; Jeong, YH; Tantry, US | 1 |
| Bae, EH; Choi, JS; Choi, YH; Jeong, MH; Kim, CS; Kim, SW; Lim, SY; Ma, SK; Sim, DS; Suh, SH | 1 |
| Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
| Gurbel, PA; Nolin, TD; Tantry, US | 1 |
| Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C | 1 |
| Durak, M; Gajos, G; Lech, P; Nessler, J; Rosławiecka, A; Undas, A; Zalewski, J; Zmudka, K | 1 |
| Benavente, OR; Hart, RG; Palacio, S; Pearce, LA | 1 |
| Deng, J; Geng, DF; Jin, DM; Liu, M; Wang, JF; Wu, W | 1 |
| Akhmetov, II; Arkhipova, AA; Galiavi, RA; Galiavich, AS; Minnetdinov, RSh; Valeeva, DD | 1 |
| Dong, L; Feng, Y; Hu, XY; Jiang, J; Liu, XB; Sun, Y; Wang, JA; Xiang, MX | 1 |
| Chan, KH; Chan, MY; Lee, CH; Li, Y; Low, A; Phua, QH; Richards, MA; Roe, MT; Sia, W; Sim, TB; Tai, BC; Tan, HC; Teo, SG; Yeo, TC | 1 |
| Boggi, A; Colantonio, R; Monti, F; Rotolo, F; Serdoz, R | 1 |
| Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Ahn, KT; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Kang, GH; Kim, HS; Lim, WH; Park, KW; Song, PS; Song, YB | 1 |
| Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C | 1 |
| Bates, ER; Menees, DS | 1 |
| de Caterina, R; Renda, G | 1 |
| Huber, K | 1 |
| Rao, SV; Vavalle, JP | 1 |
| Meade, T | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ | 1 |
| Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Ahn, YK; Chae, IH; Chae, SC; Cho, MC; Hong, TJ; Hur, SH; Jang, YS; Jeong, MH; Kim, JY; Kim, YJ; Moon, JH; Park, SJ; Seong, IW; Seung, KB; Yoon, JH | 1 |
| Boden, H; Guchelaar, HJ; Heijmans, BT; Jukema, JW; Putter, H; Schalij, MJ; Trompet, S; van der Hoeven, BL; Verschuren, JJ; Wessels, JA | 1 |
| Chan, MY; Li, Y | 1 |
| Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G | 1 |
| Andersson, C; Gislason, GH; Køber, L; Lyngbæk, S; Nguyen, CD; Nielsen, M; Torp-Pedersen, C | 1 |
| Bhatt, DL | 3 |
| Ament, PW; Dicola, DB; James, ME | 1 |
| Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H | 1 |
| Iversen, AZ | 1 |
| Bondor, CI; Cadiş, H; Iancu, A; Ober, C | 1 |
| Gottlieb, SS; Huang, TY; Pierce, SA; Rattinger, GB; Shenolikar, R; Simoni-Wastila, L; Stuart, B; Yin, X; Zuckerman, IH | 1 |
| Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O | 1 |
| Minematsu, K; Tanahashi, N; Uchiyama, S | 1 |
| Avorn, JL; Berman, C; Choudhry, NK; Fischer, MA; Jan, S; Lee, JL; Lii, J; Mahoney, JJ; Schneeweiss, S; Shrank, WH; Solomon, DH | 1 |
| Bednar, F; Benesova, L; Kocka, V; Minarik, M; Motovska, Z; Osmancik, P; Paulu, P; Tousek, P; Widimsky, P | 1 |
| Chen, AY; de Lemos, JA; Gharacholou, SM; Leonardi, S; Peterson, ED; Roe, MT; Saucedo, JF; Wang, TY | 1 |
| Brodie, B; Cooper, M; Garg, A; Hansen, C; Kissling, G; McAlhany, C; Milks, S; Pokharel, Y; Stuckey, T | 1 |
| Alshaikh, M; Fnais, N; Gomes, T; Juurlink, D; Mamdani, M; Yao, Z | 1 |
| Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH | 1 |
| Biscaglia, S; Campo, G; Tebaldi, M; Valgimigli, M; Vranckx, P | 1 |
| Meyer, S | 1 |
| Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
| Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E | 1 |
| Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G | 1 |
| Aharonian, V; Bavisetty, S; Beckham, G; Brar, SS; Contreras, R; Hyett, R; Leon, M; Mansukhani, P; Moore, N; Moses, J; Sachdeva, A; Shen, AY; Stone, GW | 1 |
| Gao, RL; Han, YL; Jiang, TM; Jing, QM; Li, SM; Li, WM; Li, Y; Liu, HL; Qu, P; Xu, B; Yang, LX; Zhang, L; Zhang, QY | 1 |
| Abrams, J; Berra, K; Blankenship, JC; Dallas, AP; Douglas, PS; Fihn, SD; Foody, JM; Gardin, JM; Gerber, TC; Hinderliter, AL; King, SB; Kligfield, PD; Krumholz, HM; Kwong, RY; Lim, MJ; Linderbaum, JA; Mack, MJ; Munger, MA; Prager, RL; Sabik, JF; Shaw, LJ; Sikkema, JD; Smith, CR; Smith, SC; Spertus, JA; Williams, SV | 1 |
| Argay, M; Dormaeva, I; Hankó, B; Koós, I; Meskó, A; Takács, I; Zelkó, R | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| FitzGerald, GA; Fries, S; Grant, GR; Grosser, T; Kapoor, SC; Lawson, JA | 1 |
| Amann, M; Hochholzer, W; Leggewie, S; Neumann, FJ; Nührenberg, TG; Ristau, I; Stratz, C; Trenk, D; Valina, CM | 1 |
| Dalsgaard, J; Funck-Jensen, KL; Grove, EL; Hvas, AM; Kristensen, SD | 1 |
| Hamanaka, I; Hara, K; Ishiwata, S; Itoh, T; Kawai, K; Kimura, T; Nakamura, M; Sugano, T; Ueno, T; Wakatsuki, T; Yamagishi, M | 1 |
| Cohen, MV; Cui, L; Downey, JM; Kambayashi, J; Liu, Y; Tandon, N; Yang, X; Yang, XM | 1 |
| Capuano, F; Derumeaux, G; Desplanques-Leperre, A; Gardel, C; Grenier, C; Loirat, P; Schiele, F; Thebaut, JF | 1 |
| Abbate, R; Gensini, GF; Gori, AM; Marcucci, R; Paniccia, R | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K | 1 |
| Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
| Ang, L; Ilapakurti, M; Lee, MS; Mahmud, E; Palakodeti, V; Thani, KB | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Gao, W; Han, JL; Li, HY; Li, L; Qiao, R; Yu, HY; Zeng, H; Zhang, J | 1 |
| Andrade, C | 1 |
| Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W | 1 |
| Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P | 1 |
| Choi, WG; Kim, HS; Kim, SY; Koo, BK; Kwan, J; Park, CG; Park, J; Park, JB | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N | 1 |
| Bacci, MR; Namura, JJ; Nogueira, LF; Santos, JA | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Anderson, JL; Carlquist, JF; Horne, BD; Huntinghouse, JA; Knight, S; May, H; Muhlestein, JB; Rollo, JS | 1 |
| Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M | 1 |
| Akbulut, M; Karadağ, MK; Kaya, OK; Korkmaz, H; Kurtoğlu, E; Kuzu, Z; Solmaz, H; Uysal, A; Yavuzkir, MF | 1 |
| Brar, SS; Itagaki, BK | 1 |
| Bassand, JP | 1 |
| Alonso, JJ; Arós Borau, F; Bayón Fernández, J; Bueno, H; Cequier Fillat, A; Coma Canella, I; Fernández-Ortiz, A; Lidón Corbi, RM; Loma-Osorio, A; López Bescós, L; Marrugat De La Iglesia, J; Masiá Martorell, R; Palencia Pérez, M; Tuñón Fernández, J | 1 |
| Callahan, KP; Gurbel, PA; Malinin, AI; O'Connor, CM; Serebruany, VL | 1 |
| Bhatt, DL; Hacke, W; Hirsch, AT; Marso, SP; Ringleb, PA; Topol, EJ | 1 |
| Alpert, JS; Antman, EM; Beasley, JW; Braunwald, E; Califf, RM; Cheitlin, MD; Faxon, DP; Fuster, V; Gibbons, RJ; Gregoratos, G; Hiratzka, LF; Hochman, JS; Jacobs, AK; Jones, RH; Kereiakes, D; Kupersmith, J; Levin, TN; Pepine, CJ; Schaeffer, JW; Smith, EE; Smith, SC; Steward, DE; Theroux, P | 1 |
| Boccanelli, A; Burzotta, F; Grollier, G; Hamon, M; Prati, F; Sabatier, R | 1 |
| Bottorff, MB; Nappi, JM; Spinler, SA; Talbert, RL | 1 |
| Choi, JW; Davidson, CJ | 1 |
| Valentín Segura, V | 1 |
| Howard, PA | 1 |
| Berger, PB; DeLago, A; Fry, ET; Mann, JT; Steinhubl, SR; Topol, EJ; Wilmer, C | 1 |
| Kübler, W | 1 |
| Jagroop, IA; Mikhailidis, DP | 1 |
| Dauterman, K; Topol, E | 1 |
| Zaliūnas, R | 1 |
| Armstrong, EC | 1 |
| Hughes, K | 1 |
| Blumenthal, M; Budaj, A; Commerford, PJ; Fox, KA; Gersh, BJ; Mehta, SR; Wittlinger, T; Yusuf, S; Zhao, F | 1 |
| Peterson, ED; Pollack, CV; Roe, MT | 1 |
| Behrens, P; Bernotat, J; Böhm, S; Gille, J; Löhr, JF | 1 |
| Meyer, BJ | 1 |
| Dörffler-Melly, J; Mahler, F; Schmidli, J | 1 |
| Boden, WE; Pepine, CJ | 1 |
| Mehta, SR; Yusuf, S | 1 |
| Mehta, SR | 2 |
| Bhatt, DL; Popma, J | 1 |
| Bartolozzi, JJ; Price, WF; Sauls, FC | 1 |
| Heras, M; Sionis, A | 1 |
| Hildebrandt, PR; Husted, SE; Kristensen, SD; Nielsen, HK; Rasmussen, LH; Ziegler, BK | 1 |
| Gandhi, PJ; Schroeder, WS | 1 |
| Böhm, M; Fries, R | 1 |
| Herrmann, HC; Valettas, N | 1 |
| Albirini, A; Aronow, HD; Bhatt, DL; Cura, FA; Ellis, SG; L'Allier, PL; Schneider, JP; Topol, EJ | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Gersh, BJ; Holmes, DR; Mathew, V; Prasad, A | 1 |
| Pasternak, R | 1 |
| Martín, M; Morís, C; Romero, E | 1 |
| Averkov, OV | 1 |
| Braunwald, E; Giugliano, RP | 2 |
| Boccanelli, A; Bolognese, L; Chiarella, F; Coccolini, S; De Servi, S; Di Chiara, A; Greco, C; Lucci, D; Maggioni, AP; Savonitto, S; Zonzin, P | 1 |
| Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F | 1 |
| Berger, PB; Bhatt, DL; Chan, AW; DiBattiste, PM; Moliterno, DJ; Sapp, SK; Stone, GW; Topol, EJ; Wolski, K; Yakubov, SL | 1 |
| Campbell, ME; Tcheng, JE | 1 |
| Aronow, WS | 1 |
| Tendera, M; Wojakowski, W | 1 |
| Averkov, OV; Gratsianskiĭ, NA; Slavina, NN | 2 |
| Benhameid, O; Endo, M; Shennib, H | 1 |
| Berger, PB; Bollwein, H; Dirschinger, J; Dotzer, F; Gawaz, M; Kastrati, A; Mehilli, J; Neumann, FJ; Schömig, A; Schühlen, H; ten Berg, JM; Volmer, C | 1 |
| Hillis, LD; Lange, RA | 2 |
| Teal, PA | 1 |
| Bal dit Sollier, C; Choussat, R; Collet, JP; Dalby, M; Drobinski, G; Drouet, L; Gallois, V; Montalescot, G; Soulat, T; Thomas, D; Vicaut, E | 1 |
| Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ | 2 |
| Von Scheidt, W | 1 |
| Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR | 1 |
| Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C | 1 |
| Chen, WH; Lau, CP; Lee, PY; Ng, W; Tse, HF | 1 |
| Rodgers, JE; Steinhubl, SR | 1 |
| Rozenman, Y | 1 |
| Ankri, A; Beygui, F; Choussat, R; Collet, JP; Drobinski, G; Golmard, JL; Montalescot, G; Tanguy, ML; Thomas, D; Vignolles, N | 1 |
| Abdel-Aty, H; Al-Saadi, N; Friedrich, MG; Messroghli, DR; Schulz-Menger, J; Taylor, AJ | 1 |
| Steimle, AE | 1 |
| Théroux, P; Xiao, Z | 1 |
| Dambrink, JH; de Boer, MJ; De Luca, G; Gosselink, AT; Hoorntje, JC; Ottervanger, JP; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Bennett, SK; Redberg, RF | 1 |
| Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D | 1 |
| Banas, JS | 1 |
| Gitt, AK; Gottwik, M; Heer, T; Juenger, C; Schiele, R; Senges, J; Vogel, C; Wienbergen, H | 1 |
| Herbert, JM; Savi, P | 1 |
| Besta, F; Gawaz, M; Müller, I | 1 |
| Brosstad, F; Otterstad, JE | 1 |
| Bergovec, M | 1 |
| Best, PJ; Markovic, SN; Mathew, V | 1 |
| SoRelle, R | 1 |
| Kiemeneij, F; Laarman, GJ; Riezebos, RK; Slagboom, T; van der Heijden, DJ; van der Wieken, LR; Westendorp, IC | 1 |
| Stadius, ML | 1 |
| Ankri, A; Beygui, F; Choussat, R; Collet, JP; Dumaine, R; Gallois, V; Montalescot, G; Payot, L; Tanguy, ML; Thomas, D | 1 |
| Bachinsky, W; Bass, T; DeMaio, S; Fry, E; Holmes, DR; Kuntz, RE; Leon, MB; Moses, JW; Popma, JJ; Sawhney, N; Teirstein, PS | 1 |
| Aghababian, RV | 1 |
| Boucher, M; Pharand, C; Skidmore, B | 1 |
| Brener, SJ; Lincoff, AM; Moliterno, DJ; Steinhubl, SR; Topol, EJ; Wolski, KE | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Hagymási, K | 1 |
| Akinina, SA; Petrik, ES; Sereshcheva, AKh; Shalaev, SV; Vorob'eva, NM | 1 |
| Schwaab, B | 1 |
| Dambrink, JH; de Boer, MJ; Ernst, NM; Gosselink, AT; Hoorntje, JC; Miedema, K; Ottervanger, JP; Slingerland, RJ; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Becker, RC; Ezekowitz, M; Guyatt, GH; Harrington, RA; Meade, TW; O'Connor, CM; Vorchheimer, DA | 1 |
| Cannon, CP; Goodman, SD; Harrington, RA; Hochman, JS; Menon, V; Ohman, EM; Schünemann, HJ; Wilcox, RG | 1 |
| Dalen, JE; Gutterman, D; Schünemann, HJ; Stein, PD | 1 |
| Choudhury, A; Fisher, E; Kim, MC; Kini, AS; Lee, J; Sharma, SK; Steinheimer, AM | 1 |
| Schwimmbeck, PL | 1 |
| Diehm, C; Huber, R; Lawall, H | 1 |
| Füessl, HS | 1 |
| Rupprecht, HJ | 1 |
| Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N | 1 |
| Schnell, O; Standl, E | 1 |
| Cobbe, SM; Francis, LM; Lowe, GD; Rumley, A; Woodward, M | 1 |
| Nicholls, C; Sani, M | 1 |
| Canoniero, MJ; Chirinos, JA; de Marchena, E; Ferreira, A; Garcia, S; Salerno, T | 1 |
| Steinhubl, SR; Topol, EJ | 1 |
| Bakhai, A; Chrolavicius, S; Culler, S; Gafni, A; Jönsson, B; Lamy, A; Lindgren, P; Mahoney, E; Weintraub, WS; Yusuf, S; Zhao, F | 1 |
| Berger, PB; Bollwein, H; Dirschinger, J; Dotzer, F; Kandzari, DE; Kastrati, A; Mehilli, J; Neumann, FJ; Schömig, A; Steinhubl, SR; Ten Berg, JM | 1 |
| Eagle, KA; Fang, J; Kline-Rogers, E; Mukherjee, D; Munir, K | 1 |
| Deutsch, HJ; Feldmann, C | 1 |
| Hacke, W; Schellinger, PD | 1 |
| Bhatt, DL; Rajagopal, V | 1 |
| Davis, KE; Denardo, SJ; Tcheng, JE | 1 |
| Cowper, PA; Peterson, ED; Sketch, MH; Udayakumar, K | 1 |
| Brouwer, A; Verheugt, FW; Waskowsky, WM | 1 |
| Heidenreich, PA; Schleinitz, MD | 1 |
| Agnelli, G; Dabbous, OH; Dibenedetto, D; Eagle, KA; Gore, JM; Kline-Rogers, EM; Lim, MJ; Mehta, RH; Spencer, FA | 1 |
| Berger, PB; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; ten Berg, JM; Volmer, C | 1 |
| Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA | 1 |
| Colonna, G; Di Sciascio, G; Montinaro, A; Pasceri, V; Patti, G; Pepe, LL | 1 |
| Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P | 1 |
| Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S | 1 |
| Erkoc, R; Eryonucu, B; Tuncer, M | 1 |
| Han, KH; Hong, MK; Kang, SJ; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, JH; Park, SJ; Park, SW | 1 |
| Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I | 1 |
| Buresly, K; Eisenberg, MJ; Pilote, L; Zhang, X | 1 |
| Cannon, CP; Gibson, CM; McCabe, CH; Sabatine, MS | 1 |
| Aengevaeren, WR; Dieker, H; Verheugt, FW | 1 |
| Kunz, I; Ruggieri, F; Spada, S; Sütsch, G | 1 |
| Elsässer, A; Hamm, CW; Möllmann, H; Nef, H | 1 |
| Gluckman, TJ; Rade, JJ; Schulman, SP | 1 |
| Hansen, DB | 1 |
| Babor, EM; Chua, D; Lo, C | 1 |
| Akowuah, E; Braidley, P; Cooper, G; Hopkinson, D; Jamnadas, B; Sarkar, P; Shrivastava, V; Storey, R | 1 |
| Bhatt, DL; Fathi, RB | 1 |
| Altinbas, A; Aslan, SM; Dogan, A; Gedikli, O; Ozaydin, M; Ozgul, M | 1 |
| Etemad, L; McCollam, P | 1 |
| Castelvetri, C; Cosmi, B; Milandri, M; Rubboli, A | 1 |
| Doggrell, SA | 2 |
| Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R | 1 |
| Beinart, SC; Bouin, O; Caro, J; Chen, R; Gabriel, S; Jackson, J; Kolm, P; Mahoney, EM; Steinhubl, S; Topol, E; Veledar, E; Weintraub, WS; Zhang, Z | 1 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Braunwald, E; Cannon, CP; Gibson, CM; Lewis, BS; López-Sendón, JL; McCabe, CH; Montalescot, G; Murphy, SA; Sabatine, MS; Theroux, P | 1 |
| Blatt, A; Finkelstein, A; Frimmerman, A; George, J; Herz, I; Keren, G; Krakover, R; Massachi, R; Michowitz, Y; Miller, H | 1 |
| Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A | 1 |
| Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA | 1 |
| Eriksson, P | 1 |
| Rothberg, M | 1 |
| Fayad, P; Frentzko, M; Hopkins, N; Katzen, BT; Kuntz, RE; Mishkel, G; Ouriel, K; Satler, L; Wechsler, L; Whitlow, P; Wholey, MH; Yadav, JS | 1 |
| Blann, A | 1 |
| Bijsterveld, NR; Büller, HR; Di Nisio, M; Levi, M; Meijers, JC; Peters, RJ | 1 |
| Harrington, RA; Tricoci, P; Valgimigli, M | 1 |
| Burton, PB; Palabrica, TM | 1 |
| Altman, R | 1 |
| Atmaca, Y; Erol, C; Gulec, S; Kumbasar, D; Ozdol, C; Rahimov, U | 1 |
| Kleiman, NS | 2 |
| Jönsson, B; Lindgren, P; Ringborg, A | 1 |
| Chen, YP; Chen, ZM; Collins, R; Jiang, LX; Liu, LS; Pan, HC; Peto, R; Xie, JX | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G | 1 |
| Gill, SS | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Dellborg, M; Gibson, CM; Keltai, M; Leiva-Pons, JL; McCabe, CH; Montalescot, G; Morrow, DA; Murphy, SA; Sabatine, MS | 1 |
| Chen, JL; Chen, ZJ; Gao, RL; Jing, ZC; Meng, L; Tian, Y; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Bert, A; Maslow, A; Ng, T | 1 |
| Din, JN; Fox, KA | 1 |
| Budaj, A; Fox, KA; Halon, DA; Keltai, M; Lewis, BS; Mehta, SR; Peters, RJ; Yusuf, S; Zhao, F | 1 |
| Caro, J; Chen, R; Culler, S; Gabriel, S; Jackson, J; Lamy, A; Mahoney, EM; Mehta, S; Weintraub, WS; Yuan, Y; Yusuf, S | 1 |
| Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Sangiorgi, GM; Valgimigli, M | 1 |
| Aguiar-Souto, P; Garcia-Pavia, P; Silva-Melchor, L | 1 |
| Fox, KA; Newby, DE | 1 |
| Gao, RL; Jing, ZC; Meng, L; Wang, YW; Wu, YJ; Yang, WX; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA | 1 |
| Chen, YG; Ji, QS; Li, RJ; Lü, RJ; Sun, Y; Xu, F; Zhang, Y | 1 |
| Kashyap, VS; Ouriel, K; Tulsyan, N | 1 |
| Borja, J; Donado, E; García, O; Izquierdo, I | 1 |
| Bhala, N; Taggar, J | 1 |
| Karthikeyan, G | 1 |
| Asaro, PV; Char, DM; Sheldahl, AL | 1 |
| Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA | 1 |
| Berger, PB; Bollwein, H; Dirschinger, J; Dotzer, F; Graf, I; Ibrahim, M; Kastrati, A; Mehilli, J; Neumann, FJ; Pache, J; Schömig, A; Schühlen, H; Seyfarth, M; ten Berg, J | 1 |
| Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W | 1 |
| Akbulut, T; Akgoz, H; Bilsel, T; Ciloglu, F; Dayi, SU; Ergelen, M; Sayar, N; Terzi, S; Yesilcimen, K | 1 |
| Casella, G; Di Pasquale, G; Greco, C; Maggioni, AP | 1 |
| Drexler, H; Schaefer, A; Stumme, B; Templin, C; von Depka, M | 1 |
| Bhatt, DL; Cannon, CP; Fintel, DJ; Gibler, WB; Harrington, RA; Mulgund, J; Newby, LK; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC; Tricoci, P | 1 |
| Calvet, D; Mas, JL; Touzé, E | 1 |
| Cannizzaro, S; Di Pasquale, P; Fasullo, S; Ganci, F; Giambanco, F; La Manna, N; La Rocca, G; Parrinello, G; Paterna, S; Sarullo, F; Scalzo, S; Vitale, G | 1 |
| de Boer, MJ; Hautvast, RW; Heestermans, AA; Jaarsma, W; ten Berg, JM; van Werkum, JW | 1 |
| Drozdz, J | 1 |
| Dambrink, JH; de Boer, MJ; Gosselink, M; Hoorntje, JC; Miedema, K; Ottervanger, JP; Rasoul, S; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Armstrong, PW; Buller, CE; Gallo, R; O'Neill, BJ; Pate, GE; Webb, JG; Welsh, RC | 1 |
| Armstrong, PW | 1 |
| Bach, RG; Cohen, DJ; Decker, C; Jones, PG; Kettelkamp, R; Khanal, S; Krumholz, HM; Messenger, JC; Peterson, ED; Rumsfeld, JS; Spertus, JA; Vance, C | 1 |
| Avsar, A; Celik, A; Kaya, D | 1 |
| Bode, C | 1 |
| Braunwald, E; Cannon, CP; Gibson, CM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC | 1 |
| Cannon, CP; Ferguson, TB; Gibler, WB; Mehta, RH; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC | 1 |
| Aroesty, JM; Cannon, CP; Gibson, CM; Kirtane, AJ; Murphy, SA; Sabatine, MS; Vafai, JJ | 1 |
| Aggelis, D; Bosinakou, I; Karambelas, I; Latsios, G; Stefanadis, C; Tousoulis, D; Toutouzas, K; Vavuranakis, M | 1 |
| Hamdalla, H; Moliterno, DJ | 1 |
| Giliarov, MIu; Malova, EV; Novikova, NA; Sulimov, VA; Syrkin, AL | 1 |
| Abbate, R; Antonucci, E; Gensini, GF; Giglioli, C; Gori, AM; Mannini, L; Marcucci, R; Paniccia, R; Prisco, D; Valente, S | 1 |
| Garton, M | 1 |
| Brady, WJ; Decker, WW; Diercks, DB; Fesmire, FM; Ghaemmaghami, CA; Hahn, S; Jagoda, AS; Nazarian, D | 1 |
| Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG | 1 |
| Buros, JL; Cannon, CP; Ciaglo, LN; Gibson, CM; Ly, HQ; Murphy, SA; Sabatine, MS; Southard, MC; Stein, EB | 1 |
| Beyar, R; Gruberg, L | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
| Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B | 1 |
| Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frere, C; Lambert, M; Lehmann, A; Morange, PE; Nait-Saidi, L; Quilici, J | 1 |
| Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS | 1 |
| Brindis, RG; Califf, RM; Chen, AY; Fintel, D; Fraulo, ES; Gibler, WB; Harrington, RA; Lytle, BL; Mehta, RH; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC | 1 |
| Jilma, B; Mayr, FB | 1 |
| Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U | 1 |
| Rihal, CS; Ting, HH; Yang, EH | 1 |
| Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ | 1 |
| Chrissoheris, MP; Donohue, TJ; Mruthyunjayanna, V | 1 |
| Wiviott, SD | 1 |
| Chen, WH; Cheng, X; Simon, DI | 1 |
| Alessi, MC; Bonnet, JL; Carvajal, J; Cuisset, T; Frère, C; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Saidi, LN | 1 |
| Ziegelstein, RC | 1 |
| Das, K; Karabatsou, K; Rainov, NG; Sinha, A | 1 |
| Radke, PW; Schunkert, H | 1 |
| Arntz, HR; Darius, H; Huber, K; Senges, J; Zeymer, U | 1 |
| Aslani, A; Sharifkazemi, MB; Zamirian, M | 1 |
| Arabi, A; Chen-Scarabelli, C; Desai, DM; Jabaren, M; Kareti, G; Rosman, HS | 1 |
| O'Donoghue, M; Wiviott, SD | 1 |
| Anstrom, KJ; Califf, RM; Eisenstein, EL; Harrington, RA; Kandzari, DE; Kong, DF; Kramer, JM; Mark, DB; Matchar, DB; Peterson, ED; Schulman, KA; Shaw, LK; Tuttle, RH | 1 |
| Atmaca, Y; Erol, C; Gulec, S; Ozdol, C; Rahimov, U; Turhan, S | 1 |
| Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW | 1 |
| Köster, R | 1 |
| Bhatt, DL; Cannon, CP | 1 |
| Bader, F; Brunner-La Rocca, HP; Buser, PT; Hunziker, P; Jeger, R; Kaiser, C; Mueller, C; Osswald, S; Pfisterer, M; Rickenbacher, P | 1 |
| Brennan, D; Francis, GS; Maroo, A; McErlean, E; Steinhubl, SR; Tang, WH; Topol, EJ; Van Lente, F | 1 |
| Alviar, CL; Arikan, ME; Dave, BP; DeLao, T; Granada, JF; Kleiman, NS; Lev, EI; Maresh, K; Tellez, A | 1 |
| Adala, D; Bearez, E; Boulé, S; Courteaux, C; Gongora, A; Hannebicque, G; Randriamora, M; Rifaï, A; Taghipour, K | 1 |
| Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN | 1 |
| Dickie, JS; Scott, LJ | 1 |
| Moses, JW | 1 |
| Steinhubl, SR | 1 |
| Campbell, ME; Dery, JP; Gibson, CM; Harrington, RA; Madan, M; Mathias, J; O'Shea, JC; Pieper, KS; Tcheng, JE; Tolleson, TR | 1 |
| Gurbel, PA | 1 |
| Ornato, JP | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J | 1 |
| Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A | 1 |
| Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B | 1 |
| Dániel, A; Horváth, IG; Komócsi, A; Pintér, T | 1 |
| Armstrong, PW; Buller, CE; Gordon, P; O'Neill, B; Welsh, RC; Westerhout, CM | 1 |
| Cannon, CP; Guo, W; McCabe, CH; McLean, DS; Sabatine, MS | 1 |
| Eikelboom, JW; Mehta, SR; Tran, H | 1 |
| Ayral, Y; Boltzen, U; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C; Szotowski, B; Willich, T | 1 |
| Bareiss, P; Chauvin, M; Desprez, D; Faure, A; Grunebaum, L; Jesel, L; Morel, O; Ohlmann, P; Roul, G; Viellard, C | 1 |
| Apostolović, S; Bozinović, N; Damjanović, M; Janković, R; Martinović, SS; Milenković, D; Pavlović, M; Perisić, Z; Radojković, DD; Tomasević, M | 1 |
| Emmons, KL; Taylor, NR | 1 |
| Aleil, B; Cazenave, JP; Gachet, C; Monassier, JP; Rochoux, G | 1 |
| Bobilewicz, D; Filipiak, KJ; Grabowski, M; Huczek, Z; Imiela, T; Malek, LA; Opolski, G; Spiewak, M; Szpotanska, M | 1 |
| Hoffmeister, HM; Oikonomopoulos, T; Szabo, S | 1 |
| Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT | 1 |
| Bartorelli, AL; Benassi, A; Chierchia, S; Di Mario, C; Galassi, A; Piovaccari, G; Reimers, B; Sangiorgio, P; Serdoz, R; Sheiban, I; Tamburino, C; Trabattoni, D; Zimarino, M | 1 |
| Finn, AV; Gold, HK; John, MC; Joner, M; Kolodgie, F; Nakazawa, G; Newell, J; Virmani, R | 1 |
| Gong, YJ; Hong, T; Huo, Y; Jiang, J; Liu, QZ; Liu, ZP; Meng, L; Sheng, QH; Shi, LB | 1 |
| Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S | 1 |
| Adnet, F; Catineau, J; Lapandry, C; Lapostolle, F | 1 |
| Kastrati, A; Schömig, A; Sibbing, D; von Beckerath, N; von Beckerath, O | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Quilici, J; Saidi, LN | 1 |
| Bauersachs, J; Bonz, AW; Eigenthaler, M; Schäfer, A | 1 |
| Breall, JA; Kalaria, V; Karlsson, G; Rehman, J | 1 |
| Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Hamm, CW; Hankey, GJ; Hu, T; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA | 1 |
| Brown, MT; Kikano, GE | 1 |
| Spinler, SA | 1 |
| Aubry, P; Benamer, H; Ducrocq, G; Feldman, LJ; Himbert, D; Juliard, JM; Majdoub, MA; Sauguet, A; Steg, PG; Tchetche, D | 1 |
| Antman, EM; Braunwald, E; Dalby, A; Duris, T; Gao, R; Lopez-Sendon, J; Morrow, DA; Murphy, SA; Pfisterer, M; Sabatine, MS | 1 |
| Blancas Gómez-Casero, R; Chana García, M; González Manzanares, JL; López Matamala, B; Martín Delgado, C; Martínez Díaz, C; Nevado Losada, E; Serrano Castañeda, J; Yáñez Parareda, E | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Escaned, J; Fernández, C; Fernández-Avilés, F; Gómez-Hospital, JA; Hernández-Antolín, R; Jiménez-Quevedo, P; Macaya, C; Moreno, R; Sabaté, M; SanMartín, M | 1 |
| Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E | 1 |
| Amorn, AM; Cercek, B; Dohad, S; Forrester, JS; Kapoor, N; Kar, S; Kupferwasser, LI; Lee, MS; Makkar, RR; Mirocha, J; Shah, PK | 1 |
| Chang, LT; Chua, S; Hang, CL; Lee, FY; Sheu, JJ; Wu, CJ; Yang, CH; Yeh, KH; Yip, HK; Youssef, AA | 1 |
| Chappell, LT | 1 |
| Collins, JS; Gurm, HS | 1 |
| Roe, MT; Steinhubl, S | 1 |
| Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR | 1 |
| Abdel-Wahab, M; Amin, M; Awadalla, H; Ayoub, A; El-Hammady, W; El-Shahed, G | 1 |
| Meinertz, T | 1 |
| Arora, R; Deo, D; Deshpande, NV; Hiremath, JS; Hiremath, MS; Joseph, J; Khan, A; Mardikar, HM; Mathew, R; Moliterno, DJ; Mukherjee, D | 1 |
| Baglini, R; Baldari, D; Mezzapelle, G | 1 |
| Avci, A; Boztosun, B; Kirma, C; Olcay, A | 1 |
| Stiefelhagen, P | 1 |
| Bhatt, DL; Boden, WE; Brennan, DM; Flather, MD; Fox, KA; Hacke, W; Mak, KH; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Wang, TH | 1 |
| Berg, J; Jönsson, B; Lindgren, P; Parry, D; Spiesser, J | 1 |
| Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M | 1 |
| Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H | 1 |
| Bocksch, W; Boxberger, M; Degenhardt, R; Gross, M; Horstkotte, D; Nienaber, C; Schneider, H; Unverdorben, M; Vallbracht, C; Wiemer, M | 1 |
| Bystron, M; Cervinka, P; Jakabcin, J; Kala, P; Kvasnak, M; Malý, J; Spacek, R; Veselka, J | 1 |
| Gabriel, RS; White, HD | 1 |
| Nisanci, Y; Okcular, I; Sezer, M; Umman, B; Umman, S | 1 |
| Berger, P; Kalyanasundaram, A; Kastrati, A | 1 |
| de Lemos, JA; Wiviott, SD | 1 |
| Adamopoulou, EN; Argyrakis, SK; Fakiolas, CN; Foussas, SG; Handanis, SM; Makrygiannis, SS; Olympios, CD; Patsourakos, NG; Pissimissis, EG; Prekates, AA; Zairis, MN | 1 |
| Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A | 1 |
| Diez, J; Ferguson, JJ; Wilson, JM | 1 |
| Bauer, T; Gitt, AK; Gottwik, M; Heer, T; Jünger, C; Köth, O; Senges, J; Wienbergen, H; Zahn, R; Zeymer, U | 1 |
| Richard Conti, C | 1 |
| Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M | 1 |
| Schmaier, AH; Simon, DI | 1 |
| Eagle, KA; Froehlich, J; Gurm, HS; Li, J; Moscucci, M; Motivala, AA; Rogers, EK; Saab, F; Tamhane, U | 1 |
| Bryson, CL; Fihn, SD; Ho, PM; Jesse, RL; Lowy, E; Magid, DJ; Maynard, C; Peterson, ED; Rumsfeld, JS; Wang, L | 1 |
| Becker, RC; Gurbel, PA; Mann, KG; Michelson, AD; Steinhubl, SR | 1 |
| Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG | 1 |
| Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
| Horowitz, J; Kaski, JC; McMurray, JJ; Recio-Mayoral, A; Remme, WJ; van Veldhuisen, DJ | 1 |
| Ahn, M; Choe, H; Choe, KH; Kim, JY; Lee, K; Lee, SH; Shin, M; Yoo, BS; Yoon, J | 1 |
| Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Cairns, R; Frelinger, AL; Hod, H; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Montalescot, G; Murphy, SA; Neumann, FJ; O'Donoghue, M; Trenk, D; Wiviott, SD | 1 |
| Konopka, A; Pilichowska, I; Piotrowski, W; Sitkiewicz, D; Spychalska, J; Stepińska, J; Zdebska, E | 1 |
| Aroesty, JM; Braunwald, E; Cannon, CP; Ciaglo, LN; Gibson, CM; Kirtane, AJ; Murphy, SA; Pride, YB; Sabatine, MS; Southard, MC; Stein, EB | 1 |
| Black, SA; Bolsin, SN; Conroy, M; Orford, N | 1 |
| Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J | 1 |
| Salzman, BE; Simmons, BB | 1 |
| Delate, T; Johnson, SG; Rogers, K; Witt, DM | 1 |
| Abgrall, JF; Arnaud, B; Boschat, J; Cornily, JC; Gilard, M; Lacut, K; Le Calvez, G; Le Gal, G; Mansourati, J; Mottier, D | 1 |
| De Caterina, R; Renda, G; Sacchetta, D; Zimarino, M | 1 |
| Aylward, PG; Califf, RM; Chew, DP; Ferguson, JJ; Huang, Z; Mahaffey, KW; Pieper, KS; White, H | 1 |
| Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U | 1 |
| Fares, RR; Gallati, CA; Lansing, LS; Mousa, SA | 1 |
| Danchin, N; Decalf, V; Durand, E; Lafont, A; Sabbah, L | 1 |
| Keim, SM; Rosen, P; Vadera, R; Worster, A | 1 |
| Cannon, CP; Gibson, CM; Kirtane, AJ; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS | 1 |
| Buros, JL; Cannon, CP; Gibson, CM; Josephson, ME; Lord, E; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS; Shui, A; Zimetbaum, PJ | 1 |
| Arnold, AE; de Swart, JB; Hautvast, RW; Huybregts, MA; Jessurun, GA; Peels, JO; Umans, VA; Zijlstra, F | 1 |
| Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L | 1 |
| Batyraliev, TA; Pershukov, IV | 1 |
| Atsma, DE; Bootsma, M; Dijkstra, J; Jukema, JW; Liem, SS; Oemrawsingh, PV; Putter, H; Schalij, MJ; Suraphakdee, N; van der Hoeven, BL; van der Wall, EE; Zeppenfeld, K | 1 |
| Boden, WE; Hoekstra, J; Miller, CD | 1 |
| Fineschi, M; Gori, T | 1 |
| Hegbom, K; Slette, M; Vik-Mo, H | 1 |
| FitzGerald, GA | 1 |
| Assali, A; Battler, A; Brosh, D; Fuchs, S; Kornowski, R; Lev, EI; Vaknin-Assa, H | 1 |
| Schaerlig, E | 1 |
| Iqbal, MB; Swanton, RH; Westwood, MA | 1 |
| Cannon, CP; Gibson, CM; Guo, W; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW | 1 |
| Azcona, L; Farré, J; Fernández-Ortiz, A; López-Farré, AJ; Macaya, C; Romero, J; Sacristán, D; Zamorano-León, JJ | 1 |
| Paulus, W; Riggert, J; von Lewinski, F | 1 |
| Fan, WZ; Fu, XH; Geng, W; Gu, XS; Hao, GZ; Hao, QQ; Jia, XW; Jiang, YF; Li, SQ; Wu, WL | 1 |
| Aradi, D; Komócsi, A; Paska, T; Tökés-Füzesi, M | 1 |
| Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ | 1 |
| Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD | 1 |
| Atiemo, AD; Williams, MS | 1 |
| Arques, S; Barragan, P; Bonello, L; Boyer, C; Camoin-Jau, L; Dignat-George, F; Paganelli, F; Panagides, D; Simeoni, MC; Wittenberg, O | 1 |
| Al Ali, A; Andrade, J; Saw, J; Wong, GC | 1 |
| Brandslund, I; Buck, TC; Christensen, C; Jørgensen, LG; Nielsen, AA; Veien, KT | 1 |
| Ezekowitz, M; Lee, R; Nagarakanti, R; Sodhi, S | 1 |
| Brodie, BR | 1 |
| King, SB | 1 |
| Smith, D; Srinivasan, M | 1 |
| Antman, EM; Braunwald, E; Murphy, SA; Wiviott, SD | 1 |
| Aschermann, M; Bílková, D; Holm, F; Kala, P; Kuchynka, P; Maly, M; Miklík, R; Motovská, Z; Petr, R; Poloczek, M; Pudil, R; Simek, S; Skalická, H; Widimsky, P | 1 |
| Hackeng, CM; Heestermans, AA; Schömig, E; Seesing, TH; Taubert, D; ten Berg, JM; van Werkum, JW; Verheugt, FW; von Beckerath, N | 1 |
| Al-Aqeedi, RF; Al-Nabti, AD | 1 |
| Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S | 1 |
| Bestehorn, HP; Büttner, HJ; Chialda, LE; Fromm, MF; Hochholzer, W; Neumann, FJ; Pahl, A; Schmiebusch, P; Stratz, C; Trenk, D; Valina, CM | 1 |
| Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
| Alvarez, W | 1 |
| Hirata, Y; Nakashima, M; Uematsu, T; Umemura, K | 1 |
| Violi, F | 1 |
| Bahadori, B; Toplak, H; Wascher, TC | 1 |
| Born, GV; Collins, R | 1 |
| Hankey, GJ | 1 |
| Sternon, J | 1 |
| Choussat, R; Montalescot, G | 1 |
| Ferguson, JJ; Gonzalez, ER; Kannel, WB; Olin, JW; Raps, EC | 1 |
| Pepine, CJ | 1 |
| Ellis, CJ; French, JK; White, HD | 1 |
| Dippel, DW | 1 |
| Topol, EJ | 2 |
| Creager, MA | 1 |
| Thizon-de-Gaulle, I | 1 |
| D'Sa, S; Machin, SJ | 1 |
| Bassand, JP; Cariou, R; Grollier, G; Heyndrickx, GR; Kragten, J; Wolf, JE | 1 |
| Bergman, G; Deutsch, E; Jauhar, R; Parikh, M; Sanborn, TA; Savino, S; Shaknovich, A | 1 |
| Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ | 1 |
| Fitzgerald, DJ; Quinn, MJ | 1 |
| Algra, A; Kappelle, LJ; Koudstaal, PJ; Stam, J; van Gijn, J; Vermeulen, M | 1 |
| Caro, JJ; Migliaccio-Walle, K | 1 |
| Bhatt, DL; Topol, EJ | 1 |
| Bates, SM; Weitz, JI | 1 |
| Oomen, PH; Tulleken, JE; Zijlstra, JG | 1 |
| Ferguson, JJ | 1 |
| Janzon, L | 1 |
| Hohlfeld, T | 1 |
| Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA | 1 |
| Elmi, F; Peacock, T; Schiavone, J | 1 |
| Montalescot, G | 1 |
| Mitka, M | 1 |
| Einecke, D | 1 |
| Cheng, JW; Gardner, SF; Hilleman, DE; Howard, PA; Lopez, LM; Mauro, VF; Munger, MA; Nappi, JM; Spinler, SA | 1 |
| Auer, J; Berent, R; Eber, B; Maurer, E; Mayr, H; Weber, T | 1 |
| Huber, K; Niessner, A; Niessner, H | 1 |
| Jackson, G | 1 |
| Bertrand, ME; Chrolavicius, S; Copland, I; Fox, KA; Lewis, BS; Malmberg, K; Mehta, SR; Natarajan, MK; Peters, RJ; Rupprecht, H; Yusuf, S; Zhao, F | 1 |
| Haldemann, R; Lüscher, TF; Szucs, TD | 1 |
| Bhatt, DL; Chew, DP; Ellis, SG; Mukherjee, D; Robbins, MA; Roffi, M; Schneider, JP; Topol, EJ | 1 |
| Wehrmacher, WH | 1 |
| Chesterman, CN; Fahmy, RG; Khachigian, LM; Kumar, RK; Lowe, HC | 1 |
| Valentín, V | 1 |
| Barragan, P; Botosezzy, I; Bouvier, JL; Comet, B; Commeau, P; Macaluso, G; Roquebert, PO; Teuma, X | 1 |
| Morais, J | 1 |
| Hacke, W | 1 |
| Bahit, MC; Granger, CB; Wallentin, L | 1 |
| Klinzing, P; Liesaus, K; Markert, UR; Peiker, G | 1 |
| Cerbone, AM; Di Minno, G; Tufano, A | 1 |
| Bradley, C | 1 |
| Botey, A; Cases, A; Pou, M; Vera, M | 1 |
| Brouwer, MA; Verheugt, FW | 1 |
| Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ | 1 |
| Bhatt, DL; Gerschutz, GP | 1 |
| Haberl, R | 1 |
246 review(s) available for clopidogrel and Cardiovascular Stroke
| Article | Year |
|---|---|
Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors in Patients Undergoing Elective PCI: a Network Meta-analysis.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke | 2023 |
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Receptors, Proteinase-Activated; Stroke; Treatment Outcome | 2023 |
Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Ticlopidine; Treatment Outcome | 2021 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Effects of the
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Loss of Function Mutation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Thrombosis; Treatment Outcome | 2022 |
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2023 |
Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2022 |
Newer P2Y
Topics: Clopidogrel; Female; Heart Arrest; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thrombosis; Treatment Outcome | 2022 |
P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Regression Analysis; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Treatment Outcome | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome | 2023 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Secondary Prevention; Stroke | 2019 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine | 2020 |
Meta-Analysis Comparing Ticagrelor or Prasugrel Versus Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Postoperative Care; Stroke; Thrombosis; Transcatheter Aortic Valve Replacement | 2021 |
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients.
Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Ethnicity; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Stroke; Ticlopidine | 2021 |
Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Differences in relative and absolute effectiveness of oral P2Y
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Sex Characteristics; Ticagrelor; Treatment Outcome; Young Adult | 2018 |
Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Asia; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2018 |
Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
Topics: Adenosine Monophosphate; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2018 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Biotransformation; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Humans; Myocardial Infarction; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome | 2019 |
Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stents; Stroke; Thrombosis; Warfarin | 2018 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Rivaroxaban; Stents; Stroke; Thrombophilia; Ticlopidine | 2018 |
Drug eruption due to prasugrel hydrochloride: A case report and mini-review.
Topics: Aged, 80 and over; Clopidogrel; Desensitization, Immunologic; Drug Eruptions; Drug Substitution; Female; Glucocorticoids; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Skin; Skin Tests; Ticagrelor | 2019 |
Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cigarette Smoking; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Expression; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Survival Analysis; Thrombosis | 2019 |
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis | 2019 |
Prehospital treatment of ST-segment elevated myocardial infarction patients.
Topics: Antithrombins; Clopidogrel; Electrocardiography; Emergency Medical Services; Hirudins; Humans; Myocardial Infarction; Myocardial Reperfusion; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Registries; Survival Analysis; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Models, Statistical; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Postoperative Hemorrhage; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2013 |
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Topics: Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2013 |
Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Adenosine Monophosphate; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine | 2014 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Drug-Eluting Stents; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Failure; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; Withholding Treatment | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Electrocardiography; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Tetrazoles; Thrombosis; Ticlopidine | 2015 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Transcatheter Aortic Valve Replacement | 2015 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis.
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Maintenance Chemotherapy; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Stroke; Thrombosis; Ticlopidine | 2015 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Survival Analysis; Ticlopidine; Transcatheter Aortic Valve Replacement; Treatment Outcome; Ultrasonography | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Eptifibatide; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Risk Assessment; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.
Topics: Adenosine; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Survival Analysis; Ticagrelor; Ticlopidine | 2015 |
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
Topics: Adenosine; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Heparin; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Ticlopidine | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; Lactones; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.
Topics: Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2016 |
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine; Warfarin | 2016 |
Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
Topics: Adenosine; Administration, Oral; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Management of Antiplatelet Allergy After Cardiac Stenting.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Eruptions; Drug-Eluting Stents; Female; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prednisone; Stents; Thrombosis; Ticlopidine | 2016 |
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Contemporary management of ST-segment elevation myocardial infarction.
Topics: Analgesics; Clopidogrel; Humans; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stents; Ticlopidine; Treatment Outcome | 2017 |
The year in interventional cardiology.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; United States | 2008 |
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Diabetic Angiopathies; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Reoperation; Stents; Ticlopidine; Treatment Outcome | 2008 |
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; C-Reactive Protein; Clopidogrel; Coronary Disease; Female; Humans; Immunoglobulin Fab Fragments; Male; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Ticlopidine | 2009 |
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2008 |
[Acute intervention for ST-elevation myocardial infarction].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; History, 20th Century; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Stents; Thrombolytic Therapy; Ticlopidine; Time Factors | 2008 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2009 |
Critical review of prasugrel for formulary decision makers.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Formularies, Hospital as Topic; Humans; Managed Care Programs; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Ticlopidine | 2009 |
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Sirolimus; Ticlopidine; Treatment Outcome | 2009 |
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Drug Administration Schedule; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardium; Necrosis; Patient Selection; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome; Troponin | 2009 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Resistance; Hematologic Diseases; Humans; Myocardial Infarction; Personal Health Services; Ticlopidine; Treatment Failure | 2008 |
Bedside evaluation of thienopyridine antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Hemorrhage; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombin; Ticlopidine; Treatment Outcome | 2008 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Ticlopidine; von Willebrand Factor | 2009 |
Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Ticlopidine; Treatment Outcome | 2009 |
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Platelet-directed therapies and coronary artery bypass grafting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Current controversies in the pharmacogenomics of clopidogrel.
Topics: Clopidogrel; Confidence Intervals; Coronary Artery Disease; Genotype; Humans; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2009 |
Platelet monitoring for PCI: is it really necessary?
Topics: Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Monitoring, Physiologic; Myocardial Infarction; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Precision Medicine; Ticlopidine | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
[Acute coronary syndrome in patients with carbohydrate metabolic disturbances (a review)].
Topics: Acute Coronary Syndrome; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Ticlopidine | 2010 |
Acute myocardial infarction in a patient with post-splenectomy thrombocytosis: a case report and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Radiography; Smoking; Splenectomy; Stents; Thrombocytosis; Ticlopidine; Treatment Outcome | 2010 |
Combined mechanical and pharmacological approach to a thrombus-containing lesion.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Coronary Vessels; Dilatation, Pathologic; Eptifibatide; Filtration; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Thrombectomy; Thrombolytic Therapy; Ticlopidine; Ultrasonography, Interventional | 2010 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Adding clopidogrel to standard treatment for acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Elective Surgical Procedures; Emergencies; Evidence-Based Medicine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Practice Guidelines as Topic; Risk Assessment; Stents; Ticlopidine; Time Factors | 2010 |
Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Comorbidity; Contraindications; Heparin, Low-Molecular-Weight; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Reperfusion; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Contraindications; Critical Pathways; Heparin; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombolytic Therapy; Ticlopidine | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2011 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Intention to Treat Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prognosis; Stents; Thrombosis; Ticlopidine | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Circulation; Death, Sudden, Cardiac; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Streptokinase; Stroke; Thrombosis; Ticlopidine; Time Factors | 2010 |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Myocardial Infarction; Myocardial Ischemia; Odds Ratio; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Agonists; Randomized Controlled Trials as Topic; Registries; Secondary Prevention; Ticlopidine; Time Factors; United Kingdom | 2010 |
Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
[ST-elevation myocardial infarction: reperfusion strategy based on the results from large clinical trials].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Fibrinolytic Agents; Guidelines as Topic; Heparin; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticlopidine; Time Factors | 2010 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Female; Hemorrhage; Humans; Length of Stay; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Reoperation; Research Design; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2011 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Administration Schedule; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Reoperation; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Data Interpretation, Statistical; Drug Interactions; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2012 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Humans; Models, Economic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticlopidine | 2011 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Outcome; Ventricular Dysfunction, Left | 2011 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thromboembolism; Ticlopidine; Warfarin | 2011 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Recent advances in the pharmacogenetics of clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Genotype; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet therapy beyond 2012: role of personalized medicine.
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
Topics: Clopidogrel; Costs and Cost Analysis; Drug Interactions; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2012 |
Acute ST-elevation myocardial infarction.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Hemodynamics; Humans; Hypothermia, Induced; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Heart Diseases; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Thromboembolism; Ticlopidine; Treatment Outcome | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticlopidine | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Thrombosis; Ticlopidine | 2012 |
Reducing adverse effects of proton pump inhibitors.
Topics: Anemia, Iron-Deficiency; Clopidogrel; Clostridioides difficile; Critical Care; Diarrhea; Drug Interactions; Enterocolitis, Pseudomembranous; Gastroesophageal Reflux; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pneumonia; Proton Pump Inhibitors; Recurrence; Risk Factors; Stomach Ulcer; Stress, Physiological; Ticlopidine; Ulcer | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Randomized Controlled Trials as Topic; Registries; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Early Diagnosis; Fluoxetine; Fluvoxamine; Gastrointestinal Hemorrhage; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Selective Serotonin Reuptake Inhibitors; Ticlopidine | 2012 |
Controversies in the use & implementation of drug-eluting stent technology.
Topics: Absorbable Implants; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Restenosis; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; History, 20th Century; History, 21st Century; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2012 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Patient Compliance; Peptides; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2002 |
Spontaneous multivessel coronary artery dissection in a long-distance runner successfully treated with oral antiplatelet therapy.
Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Exercise; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Ticlopidine | 2002 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Interactions; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine | 2002 |
[Treatment strategy of unstable angina and non-ST-segment elevation myocardial infarction].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ticlopidine; Time Factors | 2002 |
2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.
Topics: American Heart Association; Angina, Unstable; Anticoagulants; Cardiology; Child; Clopidogrel; Electrocardiography; Emergency Service, Hospital; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Societies, Medical; Ticlopidine; United States | 2003 |
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Survival Rate; Ticlopidine | 2002 |
Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Emergency Service, Hospital; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome | 2003 |
Clopidogrel in acute coronary syndromes (unstable angina and non-Q-wave myocardial infarction).
Topics: Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Thrombosis; Ticlopidine | 2003 |
Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Emergency Medical Services; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Ticlopidine | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
The role of platelets and platelet inhibition in acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Fibrinolytic Agents; Humans; Membrane Glycoproteins; Myocardial Infarction; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Ticlopidine; Tissue Plasminogen Activator | 2003 |
Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Echocardiography, Stress; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome; Ticlopidine | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Resistance; Drug Tolerance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
Treatment of unstable angina pectoris/non-ST-segment elevation myocardial infarction in elderly patients.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Humans; Hypolipidemic Agents; Myocardial Infarction; Oxygen Inhalation Therapy; Ticlopidine | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Risk Reduction Behavior; Stroke; Ticlopidine | 2004 |
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Stents; Ticlopidine; Treatment Outcome; Vascular Diseases | 2003 |
Acute coronary syndromes in women: is treatment different? Should it be?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Female; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stents; Syndrome; Thrombin; Ticlopidine; Women's Health | 2004 |
P2Y12, a new platelet ADP receptor, target of clopidogrel.
Topics: Adenosine Diphosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Down-Regulation; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stroke; Ticlopidine | 2003 |
Combined antithrombotic therapy for acute coronary syndrome.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2003 |
Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Comorbidity; Coronary Restenosis; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Peptide Fragments; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Stents; Thrombophilia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Ticlopidine | 2004 |
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Injections, Subcutaneous; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Thrombolytic Therapy; Ticlopidine | 2004 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Internal Mammary-Coronary Artery Anastomosis; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Assessment; Ticlopidine; Veins | 2004 |
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Insulin; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Primary Prevention; Risk; Risk Factors; Stents; Ticlopidine; Time Factors | 2004 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Endarterectomy, Carotid; Fibrinolytic Agents; Humans; Myocardial Infarction; Plasminogen Activators; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Ticlopidine; Treatment Outcome | 2005 |
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergism; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2004 |
[Antithrombotic therapy after myocardial infarction: arguments for the use of acetylsalicylic acid and coumarin derivatives].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coumarins; Death, Sudden, Cardiac; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2005 |
[Antithrombotic therapy during percutaneous coronary interventions].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Germany; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Syndrome; Ticlopidine; Treatment Outcome | 2005 |
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; Follow-Up Studies; Humans; Long-Term Care; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Treatment Outcome | 2005 |
CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Syndrome; Ticlopidine | 2005 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine; Time Factors; Vasodilator Agents | 2005 |
Clopidogrel in acute coronary heart disease.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemic Attack, Transient; Myocardial Infarction; Pentoxifylline; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine; Tissue Plasminogen Activator; Vasodilator Agents | 2006 |
[Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chest Pain; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Diagnosis, Differential; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Forecasting; Guideline Adherence; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prognosis; Risk Assessment; Syndrome; Ticlopidine | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Placebos; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2006 |
Current developments in anti-platelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2006 |
Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction.
Topics: Aged; Algorithms; Clopidogrel; Contraindications; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors | 2006 |
Clopidogrel response variability, resistance, or both?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Research Design; Ticlopidine | 2006 |
Aspirin resistance or variable response or both?
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
[Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Tyrosine | 2006 |
Evolving management of ST-segment elevation myocardial infarction: update on recent data.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Societies, Medical; Thrombolytic Therapy; Ticlopidine; United States | 2006 |
[Acute myocardial infarction: what is new?].
Topics: Acute Disease; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2005 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardial Ischemia; Patient Selection; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Risk Factors; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2006 |
Accelerating time to reperfusion in acute myocardial infarction: prehospital and emergency department strategies, systems of care, and pharmacologic interventions.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Platelets; Cardiovascular Agents; Clopidogrel; Community Health Services; Critical Pathways; Emergency Medical Services; Emergency Service, Hospital; Fibrinolytic Agents; Health Services Accessibility; Heparin; Humans; Myocardial Infarction; Patient Care Team; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Program Development; Ticlopidine; Time Factors; Treatment Outcome; Triage; United States | 2006 |
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine; Treatment Outcome | 2006 |
Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ticlopidine; Time Factors | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Health Care; Recurrence; Risk Assessment; Stroke; Syndrome; Thrombosis; Ticlopidine | 2007 |
Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Chelating Agents; Clopidogrel; Drug Implants; Edetic Acid; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2007 |
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Cost-Benefit Analysis; Guideline Adherence; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflammation; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Stroke; Thrombosis; Ticlopidine | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Ticlopidine | 2007 |
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Ticlopidine; Treatment Outcome | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resistance; Humans; Monitoring, Physiologic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Treatment Outcome | 2007 |
Facilitated PCI: rationale, current evidence, open questions, and future directions.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2008 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
[Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Hirudins; Humans; Myocardial Infarction; Myocardial Revascularization; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Recombinant Proteins; Ticlopidine; Troponin T | 2007 |
Do patients with acute myocardial infarction benefit from treatment with clopidogrel?
Topics: Adult; Clopidogrel; Emergency Medical Services; Evidence-Based Medicine; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2008 |
[Drug-eluting stent thrombosis and its pharmacological prevention].
Topics: Aspirin; Clopidogrel; Death, Sudden, Cardiac; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Incidence; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Terminology as Topic; Thrombosis; Ticlopidine; Turkey | 2007 |
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine | 2008 |
[Antithrombotic therapy after percutanous coronary intervention with stenting].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine; Time Factors; Warfarin | 2008 |
Translational therapeutics at the platelet vascular interface. Summary.
Topics: Angina, Unstable; Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Drug Evaluation, Preclinical; Education, Medical, Continuing; Humans; Mice; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sensitivity and Specificity; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Recent developments in acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithrombins; Clopidogrel; Fondaparinux; Heparin, Low-Molecular-Weight; Hirudins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Recombinant Proteins; Thrombolytic Therapy; Ticlopidine | 2008 |
Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Thrombolytic Therapy; Thrombosis; Ticlopidine; Vitamin K; Warfarin | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
[Post myocardial infarction management].
Topics: Aftercare; Anticholesteremic Agents; Antioxidants; Atorvastatin; Chromans; Clopidogrel; Diet, Fat-Restricted; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Thiazoles; Thiazolidinediones; Ticlopidine; Troglitazone | 1997 |
Beyond aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 1998 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Research Design; Ticlopidine | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome | 1998 |
Antiplatelet drugs in secondary prevention after acute myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 1998 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bone Marrow Diseases; Carbamazepine; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Disease; Drug Interactions; Hemorrhage; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Phenytoin; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Safety; Stents; Theophylline; Thrombolytic Therapy; Ticlopidine | 1999 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine; Treatment Outcome | 2000 |
Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
Topics: Angina, Unstable; Antithrombins; Clopidogrel; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thromboxane; Recombinant Proteins; Thromboxane-A Synthase; Ticlopidine | 2000 |
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Topics: Arteriosclerosis; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Tirofiban; Tyrosine | 2000 |
The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome.
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine | 2000 |
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
Topics: Adrenergic beta-Antagonists; Aged; American Heart Association; Angioplasty, Balloon, Coronary; Cardiology; Clopidogrel; Contraindications; Female; Fibrinolytic Agents; Heparin; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Societies, Medical; Stents; Thrombolytic Therapy; Ticlopidine; United States | 2001 |
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Angina, Unstable; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Terminology as Topic; Ticlopidine; Tirofiban; Tyrosine | 2001 |
[Antithrombotic treatment protocols in interventional cardiology].
Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thrombosis; Ticlopidine | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Arteriosclerosis; Intracranial Thrombosis; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Recurrence; Risk Factors; Stroke; Ticlopidine | 2002 |
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticlopidine; Time Factors; Warfarin | 2002 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pulmonary Embolism; Secondary Prevention; Stroke; Thromboembolism; Thrombolytic Therapy; Ticlopidine; Venous Thrombosis; Warfarin | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Rate; Ticlopidine | 2002 |
426 trial(s) available for clopidogrel and Cardiovascular Stroke
| Article | Year |
|---|---|
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
Topics: Clopidogrel; Humans; Internationality; Ischemia; Ischemic Stroke; Myocardial Infarction; Peripheral Arterial Disease; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2021 |
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2022 |
The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI: Observations from Prague-18 Study.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2022 |
ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2022 |
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Humans; Microcirculation; Myocardial Infarction; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thrombotic Stroke; Treatment Outcome | 2023 |
Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Factors; Treatment Outcome | 2022 |
Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel.
Topics: Clopidogrel; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Stroke Volume; Thrombolytic Therapy; Ticagrelor; Ventricular Function, Left | 2022 |
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome | 2022 |
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.
Topics: Anticholesteremic Agents; Clopidogrel; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Scattering, Small Angle; Simvastatin; Ticagrelor; X-Ray Diffraction | 2022 |
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Growth Differentiation Factor 15; Humans; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome; Troponin | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome | 2023 |
Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
Topics: Acute Coronary Syndrome; Brain Ischemia; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2023 |
Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.
Topics: Clopidogrel; Endothelial Cells; Extracellular Vesicles; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Death; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies | 2020 |
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor | 2020 |
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Clopidogrel; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Organophosphonates; Patient Safety; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyrimidines; Ticagrelor; Treatment Outcome | 2020 |
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2020 |
Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven
Topics: Angina, Stable; Clopidogrel; Coronary Angiography; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine; Treatment Outcome | 2020 |
A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Atherosclerosis; Case-Control Studies; Clopidogrel; Cysteine Endopeptidases; Cysteine Proteases; Death; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Ticagrelor; Treatment Outcome | 2020 |
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Shock, Cardiogenic; Ticagrelor | 2021 |
Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Fatty Acids, Unsaturated; Female; Humans; Lipid Metabolism; Male; Metabolomics; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug Therapy, Combination; Early Termination of Clinical Trials; Europe; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Factors; South America; Stroke; Thrombosis; Ticlopidine; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2017 |
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticlopidine; Time Factors | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2017 |
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thrombosis; Ticlopidine; Tomography, Optical Coherence | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decision Support Techniques; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Prosthesis Design; Reproducibility of Results; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Ticlopidine; Treatment Outcome | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Ticlopidine | 2017 |
Low-Dose Ticagrelor Versus Clopidogrel in Patients With Prior Myocardial Infarction.
Topics: Aged; Clopidogrel; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2017 |
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2018 |
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
Topics: Aged; Clopidogrel; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREA
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Endpoint Determination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Stroke; Survival Rate; Treatment Outcome | 2018 |
Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Stents; Ticlopidine; Time Factors | 2018 |
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
Topics: Acute Coronary Syndrome; Aged; Blood Coagulation; Clopidogrel; Double-Blind Method; Female; Fibrin; Fibrin Clot Lysis Time; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2018 |
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Ticagrelor | 2018 |
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Survival Rate; Time Factors; Treatment Outcome; United States | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Secondary Prevention; Stroke; Ticlopidine | 2018 |
The Incidence of Myocardial Injury after Loading Doses of Clopidogrel versus Prasugrel in the Candidates for Percutaneous Coronary Intervention: A Randomized Controlled Trial.
Topics: Adult; Angina, Stable; C-Reactive Protein; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Troponin I | 2018 |
Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Neointima; Prospective Studies; Prostheses and Implants; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Blood Platelets; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Single-Blind Method; Stroke | 2018 |
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Topics: Aged; Ankle Brachial Index; Clopidogrel; Coronary Artery Bypass; Death; Extremities; Female; Hospitalization; Humans; Incidence; Ischemia; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2019 |
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
Topics: Aged; Clopidogrel; Cost Sharing; Drug Costs; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticagrelor | 2019 |
Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Single-Blind Method; Survival Rate; Time Factors | 2019 |
Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I).
Topics: Adult; Aged; Brain Ischemia; Clopidogrel; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke | 2019 |
The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Disease-Free Survival; Female; Humans; Male; Myocardial Infarction; Registries; Risk Factors; Stroke; Survival Rate; Ticagrelor | 2019 |
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor | 2019 |
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk Assessment; Stroke; Treatment Outcome | 2019 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; France; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Research Design; Stroke; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Severity of Illness Index; Ticlopidine | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heart Failure; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Time-to-Treatment; Tissue Plasminogen Activator | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Ticlopidine | 2013 |
[Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Tirofiban; Tyrosine; Warfarin | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Platelet Activation; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticlopidine | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Topics: Aged; Aspirin; China; Clopidogrel; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Comparison of pre-hospital 600 mg or 900 mg vs. peri-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Topics: Adult; Aged; Alleles; Angina, Stable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Restenosis; Female; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Stroke; Ticlopidine | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine | 2013 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Hyperplasia; Italy; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Myocardial Infarction; Neointima; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Factors; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatine Kinase, MB Form; Electrocardiography; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Sex Factors; Ticlopidine | 2014 |
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Retrospective Studies; Ticlopidine; von Willebrand Factor | 2013 |
Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Preoperative Care; Propensity Score; Registries; Retrospective Studies; Serbia; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
Topics: Antithrombins; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
Topics: Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Fibrinogen; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Preoperative Period; Retrospective Studies; Risk Factors; Ticlopidine | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2014 |
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Early Termination of Clinical Trials; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Resistance; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiography; Female; Follow-Up Studies; Genetic Techniques; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2015 |
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Topics: Aged; Angina, Unstable; Clopidogrel; Endpoint Determination; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
Prehospital ticagrelor in ST-segment elevation myocardial infarction.
Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time-to-Treatment | 2014 |
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hirudins; Humans; Internationality; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Recombinant Proteins; Ticlopidine; Treatment Outcome | 2015 |
Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Risk Factors; Thrombelastography; Ticlopidine | 2014 |
Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Prospective Studies; Therapeutic Equivalency; Ticlopidine | 2014 |
Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Epinephrine; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2014 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Risk Assessment; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2014 |
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Switzerland; Ticlopidine; Treatment Outcome | 2016 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Stroke; Ticlopidine; Treatment Outcome | 2015 |
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno
Topics: Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Vessels; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2015 |
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Prospective Studies; Ticagrelor; Ticlopidine | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Stents; Stroke; Ticlopidine; Tunica Intima | 2015 |
Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drugs, Generic; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Testing; Genotype; Heterozygote; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine | 2016 |
[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
Topics: Adenosine; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Agonists; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre tri
Topics: Adolescent; Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Research Design; Ticlopidine; Young Adult | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acu
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome | 2016 |
Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).
Topics: Antithrombins; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Recombinant Proteins; Reproducibility of Results; Sensitivity and Specificity; Thrombelastography; Ticlopidine; Treatment Outcome | 2016 |
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thiophenes; Ticlopidine | 2016 |
P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cross-Sectional Studies; Female; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2016 |
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2015 |
Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
Topics: Adenosine; Biomarkers; Blood Platelets; Clopidogrel; Electrocardiography; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.
Topics: Aged; Clopidogrel; Comparative Effectiveness Research; Electrocardiography; Enoxaparin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for
Topics: Adenosine; Biomarkers; C-Reactive Protein; CD40 Ligand; Clinical Protocols; Clopidogrel; Endothelium, Vascular; Humans; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sample Size; Ticagrelor; Ticlopidine | 2016 |
Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study.
Topics: Aged; Aspirin; Cardiomyopathy, Dilated; Clopidogrel; Cohort Studies; Female; Heart Diseases; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Surgical Procedures, Operative; Ticlopidine; Treatment Outcome; Troponin I | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Hyperplasia; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima | 2016 |
Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspepsia; Female; Gastrointestinal Hemorrhage; Humans; Intestinal Obstruction; Intestinal Perforation; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Omeprazole; Pain; Peptic Ulcer; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stroke; Ticlopidine | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Drug Compounding; Drugs, Generic; Female; Greece; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Secondary Prevention; Stroke; Therapeutic Equivalency; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; China; Cilostazol; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Hemorrhage; Humans; Intention to Treat Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
[The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2015 |
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Ticlopidine | 2015 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Alcohols; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Stroke; Ticlopidine | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Disease Management; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Assessment; Risk Factors; Sex Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Risk Factors; Sirolimus; Ticlopidine; Time Factors | 2017 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, Combination; Embolism; Factor Xa Inhibitors; Heart Valve Diseases; Humans; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Pulmonary Embolism; Rivaroxaban; Stroke; Thrombosis; Ticlopidine; Transcatheter Aortic Valve Replacement; Venous Thrombosis | 2017 |
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Treatment Outcome; United States | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Resistance; Europe; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Research Design; Ticlopidine; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2008 |
Long-term cost-effectiveness of clopidogrel in STEMI patients.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudins; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Premedication; Recombinant Proteins; Recurrence; Risk; Stents; Thrombosis; Ticlopidine | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk; Secondary Prevention; Stroke; Telmisartan; Ticlopidine; Vascular Diseases | 2008 |
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Su
Topics: Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Electrocardiography; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Ticlopidine; Treatment Outcome | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Necrosis; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2008 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Topics: Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Endpoint Determination; Female; Follow-Up Studies; Genotype; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proportional Hazards Models; Risk Factors; Secondary Prevention; Stents; Ticlopidine | 2009 |
Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Feasibility Studies; Female; Humans; Iron; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Stainless Steel; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Coagulation; Blood Platelets; Clopidogrel; Collagen; Drug Therapy, Combination; Eptifibatide; Female; Hemorheology; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thrombin; Recombinant Proteins; Stents; Thrombelastography; Ticlopidine | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials.
Topics: Aged; Brain Infarction; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Japan; Liver; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticlopidine; Treatment Outcome | 2009 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; Female; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Stroke; Stroke Volume; Ticlopidine; Warfarin | 2009 |
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Cardiac Catheterization; Child; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Radionuclide Imaging; Radiopharmaceuticals; Stents; Technetium Tc 99m Sestamibi; Ticlopidine | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Vascular Diseases; Vitamin K | 2009 |
Interaction between cigarette smoking and clinical benefit of clopidogrel.
Topics: Aged; Clopidogrel; Electrocardiography; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Smoking; Ticlopidine; Treatment Outcome | 2009 |
Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction.
Topics: Aspirin; C-Reactive Protein; Clopidogrel; Coronary Circulation; Creatine Kinase, MB Form; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2009 |
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Immunosuppressive Agents; Incidence; Male; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Ticlopidine; Tubulin Modulators | 2009 |
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T | 2009 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Young Adult | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Eptifibatide; Female; Heart Diseases; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Necrosis; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
The FDA prasugrel review: adjudication of myocardial infarction controversy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Resistance; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2009 |
A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study.
Topics: Anterior Wall Myocardial Infarction; Anti-Inflammatory Agents; C-Reactive Protein; Cell Adhesion Molecules; Clopidogrel; Humans; Microfilament Proteins; Myocardial Infarction; Phosphoproteins; Platelet Aggregation; Ticlopidine | 2010 |
Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
Topics: Angina Pectoris; Clopidogrel; Drug-Eluting Stents; Endpoint Determination; Humans; Myocardial Infarction; Pilot Projects; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Risk Factors; Stroke Volume; Tachycardia, Ventricular; Thrombolytic Therapy; Ticlopidine; Ventricular Fibrillation | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Proportional Hazards Models; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Heparin; Hirudins; Humans; Incidence; Ischemia; Length of Stay; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Sex Factors; Stents; Thrombosis; Ticlopidine | 2009 |
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Clopidogrel; Confidence Intervals; Female; Hirudins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recombinant Proteins; Ticlopidine; Treatment Outcome | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Follow-Up Studies; Hematoma; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Premedication; Retreatment; Sex Factors; Stents; Ticlopidine; Troponin T; Whole Blood Coagulation Time | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Sirolimus; Ticlopidine | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Ontario; Peptides; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aprotinin; Blood Transfusion; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemostatics; Humans; Intraoperative Care; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Fibrinolysis; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Probability; Risk Assessment; Severity of Illness Index; Survival Analysis; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2010 |
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Drug Resistance; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2010 |
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patie
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Vessel Prosthesis Implantation; Cells, Cultured; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tetrazoles; Ticlopidine | 2010 |
Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiotonic Agents; Chemotherapy, Adjuvant; Clopidogrel; Disease Progression; Electrocardiography; Female; Heart Function Tests; Heparin; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Survival Analysis; Ticlopidine | 2010 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Ontario; Platelet Aggregation Inhibitors; Recurrence; Stroke; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Warfarin | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Predictive Value of Tests; Prospective Studies; Stents; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Antibodies, Monoclonal; Arm; Aspirin; Clopidogrel; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Hospitalization; Humans; Immunoglobulin Fab Fragments; Ischemic Preconditioning, Myocardial; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Platelet Aggregation Inhibitors; Prospective Studies; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Ticlopidine; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Troponin T | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retreatment; Stroke; Thrombosis; Ticlopidine | 2010 |
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Korea; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Recurrence; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Coronary Aneurysm; Double-Blind Method; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2010 |
Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; Vascular Patency | 2010 |
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug-Eluting Stents; Embolism; Female; Humans; Incidence; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Saphenous Vein; Survival Rate; Ticlopidine; United States | 2010 |
Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.
Topics: Adult; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Smoking; Ticlopidine | 2010 |
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genetic Variation; Genotype; Humans; Middle Aged; Myocardial Infarction; Pharmacogenetics; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New Zealand; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemorrhage; Humans; Ischemia; Leg; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Troponin | 2010 |
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
Topics: Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Immunoassay; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Survival Rate; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome; Troponin | 2010 |
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Stroke; Ticlopidine; Treatment Outcome | 2010 |
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study.
Topics: Aged; Aspirin; Cardiac Catheterization; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Prospective Studies; Survival Rate; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage
Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Global Health; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Minnesota; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Survival Rate; Ticlopidine; Treatment Outcome | 2010 |
Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.
Topics: Ambulances; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Circulation; Creatine Kinase; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; France; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Secondary Prevention; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2010 |
Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) ra
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Republic of Korea; Research Design; Stroke; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Clopidogrel; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticlopidine; Treatment Outcome | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Stroke; Ticlopidine | 2010 |
The efficacy and safety of clopidogrel in vascular surgery patients with immediate postoperative asymptomatic troponin T release for the prevention of late cardiac events: Rationale and design of the Dutch Echocardiographic Cardiac Risk Evaluation Applyin
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Echocardiography, Stress; Humans; Myocardial Infarction; Myocardial Ischemia; Netherlands; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Research Design; Ticlopidine; Troponin T; Vascular Surgical Procedures | 2010 |
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) tr
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With Th
Topics: Aged; Aged, 80 and over; Antithrombins; Biomarkers; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prognosis; Registries; Retrospective Studies; Risk Factors; Ticlopidine; Troponin; United States | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Tetrazoles; Ticlopidine; Treatment Outcome | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stents; Stroke; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2011 |
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Angiography; Female; Fibrinolysis; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2011 |
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk; Thrombosis; Ticlopidine | 2011 |
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2011 |
Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Troponin; Tyrosine | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Stents; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heparin; Hirudins; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Recombinant Proteins; Risk Factors; Ticlopidine; Treatment Outcome; Tubulin Modulators | 2011 |
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Korea; Liver; Male; Middle Aged; Myocardial Infarction; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Regression Analysis; Risk Assessment; Risk Factors; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Topics: Adenosine Diphosphate; Adult; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Bypass; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Resistance; Female; France; Gene Dosage; Heterozygote; Homozygote; Humans; Male; Middle Aged; Myocardial Infarction; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; United States | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2011 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2011 |
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2012 |
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay.
Topics: Aged; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Fibrinolytic Agents; Health Services Accessibility; Heparin; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Netherlands; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prosthesis Failure; Receptors, Purinergic P2Y12; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2011 |
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Tetrazoles; Ticlopidine | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Death; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Registries; Risk Factors; Stents; Thrombosis; Ticlopidine | 2011 |
Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Biomarkers, Pharmacological; Clopidogrel; Cohort Studies; Cross-Over Studies; Cytochrome P-450 CYP2C19; DNA Mutational Analysis; Female; Genotype; Humans; Male; Mutation; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Survival Analysis; Ticlopidine; Treatment Outcome | 2011 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Sensitivity and Specificity; Stroke; Ticlopidine; Vitamin K | 2011 |
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot Genous trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Severity of Illness Index; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I | 2012 |
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Severity of Illness Index; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 2012 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2012 |
Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Emergency Medical Services; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2012 |
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prevalence; Retrospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Italy; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Heterozygote; Humans; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stroke; Thrombosis; Ticlopidine | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activating Factor; Prospective Studies; Ticlopidine; Tissue Plasminogen Activator; von Willebrand Factor | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2012 |
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Heart Diseases; Hemorrhage; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Sulfonamides; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2012 |
Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pantoprazole; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action fo
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Clopidogrel; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Recombinant Proteins; Signal Processing, Computer-Assisted; Stents; Survival Analysis; Ticlopidine | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome; Young Adult | 2012 |
P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYo
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Internationality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pantoprazole; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Ticlopidine | 2013 |
Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Survival Rate; Tetrazoles; Ticlopidine | 2012 |
The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Smoking; Stents; Ticlopidine; Treatment Outcome | 2012 |
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Singapore; Thiophenes; Ticlopidine | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antagonism; Famotidine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine | 2012 |
Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
Topics: Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Renal Insufficiency, Chronic; Republic of Korea; Retrospective Studies; Risk Factors; Stents; Survival Rate; Ticlopidine | 2012 |
Microvascular effect of intracoronary eptifibatide in acute myocardial infarction.
Topics: Adolescent; Adult; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Eptifibatide; Female; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Ticlopidine; Treatment Outcome; Young Adult | 2012 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prospective Studies; Stroke; Survival Rate; Ticlopidine | 2013 |
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine | 2013 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine | 2012 |
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Topics: Administration, Oral; Adolescent; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Stroke; Tablets, Enteric-Coated; Ticlopidine; Treatment Outcome; Young Adult | 2013 |
Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine | 2013 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Graft Occlusion, Vascular; Humans; Hyperplasia; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Sirolimus; Stents; Stroke; Ticlopidine; Tunica Intima | 2013 |
Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninfe
Topics: Aged; Blood Platelets; Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Republic of Korea; Therapeutic Equivalency; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoint Determination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Predictive Value of Tests; Risk Factors; Ticlopidine; Treatment Outcome | 2002 |
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massachusetts; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2002 |
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2002 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kinetics; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk Assessment; Secondary Prevention; Stroke; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Stroke; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Louisiana; Male; Middle Aged; Minnesota; Myocardial Infarction; New York City; Ohio; Pennsylvania; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Premedication; Severity of Illness Index; Stents; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Angina, Unstable; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine; Time Factors; Treatment Outcome; von Willebrand Factor | 2003 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Ticlopidine | 2004 |
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
Topics: Aged; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinogen; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Predictive Value of Tests; Prognosis; Prospective Studies; Recurrence; Risk Factors; Stroke; Ticlopidine | 2004 |
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; CD40 Ligand; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2004 |
Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting.
Topics: Aged; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Perioperative Care; Platelet Aggregation Inhibitors; Prosthesis Implantation; Risk Factors; Stents; Survival Analysis; Ticlopidine; Treatment Outcome | 2004 |
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiography; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Female; Follow-Up Studies; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticlopidine; Treatment Outcome; Troponin I | 2004 |
Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Cohort Studies; Combined Modality Therapy; Creatine Kinase; Creatine Kinase, MB Form; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Survival Analysis; Ticlopidine; Treatment Outcome; Troponin I | 2004 |
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Double-Blind Method; Drug Implants; Female; Humans; Life Tables; Male; Middle Aged; Myocardial Infarction; Premedication; Sirolimus; Stents; Survival Analysis; Ticlopidine; Treatment Outcome; Ultrasonography | 2004 |
[First experience of clopidogrel application in the treatment of acute myocardial infarction with ST-elevation].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Streptokinase; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Complications; Elective Surgical Procedures; Endpoint Determination; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Stents; Ticlopidine | 2004 |
A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation Factors; Blood Viscosity; C-Reactive Protein; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Thrombosis; Ticlopidine | 2004 |
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study.
Topics: Angina, Unstable; Canada; Clopidogrel; Cost-Benefit Analysis; Europe; Health Care Costs; Hospitalization; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; United States | 2004 |
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Treatment Outcome | 2004 |
Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.
Topics: Aged; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prospective Studies; Survival Analysis; Ticlopidine; Treatment Outcome | 2005 |
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Death, Sudden, Cardiac; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2005 |
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Eptifibatide; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Risk Factors; Stents; Ticlopidine | 2005 |
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Myoglobin; Platelet Aggregation Inhibitors; Premedication; Ticlopidine; Troponin I | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Thrombolytic Therapy; Ticlopidine; Vascular Patency | 2005 |
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Female; Follow-Up Studies; Humans; Length of Stay; Life Expectancy; Male; Medicare; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Sensitivity and Specificity; Syndrome; Ticlopidine; Time; Treatment Outcome; United States | 2005 |
Comparison of cilostazol and clopidogrel after successful coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tetrazoles; Thrombosis; Ticlopidine; Treatment Outcome | 2005 |
Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.
Topics: Aged; Angina, Unstable; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Hemostatics; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Regional Blood Flow; Ticlopidine | 2005 |
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radionuclide Imaging; Recurrence; Stents; Survival Analysis; Ticlopidine; Treatment Failure | 2005 |
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) tria
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2005 |
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2005 |
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Necrosis; Prospective Studies; Syndrome; Ticlopidine; Time Factors; Tirofiban; Troponin I; Tyrosine | 2005 |
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Female; Humans; Ischemia; Leg; Male; Middle Aged; Myocardial Infarction; Risk Factors; Ticlopidine | 2005 |
Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Antithrombin III; Clopidogrel; Heparin; Humans; Myocardial Infarction; Peptide Fragments; Peptide Hydrolases; Platelet Aggregation Inhibitors; Prothrombin; Syndrome; Thrombophilia; Ticlopidine | 2005 |
Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?
Topics: Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eptifibatide; Flow Cytometry; Follow-Up Studies; Humans; Myocardial Infarction; Myocardial Revascularization; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Secondary Prevention; Stents; Ticlopidine; Treatment Outcome | 2005 |
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2005 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Secondary Prevention; Ticlopidine; Treatment Outcome; Vascular Patency | 2005 |
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Recurrence; Survival Analysis; Ticlopidine; Treatment Outcome | 2005 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Agents; Hemostasis; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Syndrome; Thrombin; Ticlopidine; Time Factors | 2005 |
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Adult; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Ticlopidine; Tumor Necrosis Factor-alpha | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Thrombosis; Ticlopidine | 2006 |
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Topics: Abciximab; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk; Survival Analysis; Ticlopidine; Troponin T | 2006 |
Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
Topics: Aged; Aspirin; Clopidogrel; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Probability; Severity of Illness Index; Survival Rate; Ticlopidine; Treatment Outcome | 2006 |
Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors; Tissue Plasminogen Activator | 2006 |
A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Drug Combinations; Enzymes; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Enoxaparin; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator | 2006 |
[Therapy of acute mayocardial infarction: COMMIT (Clopidogrel and Metoprolol Infarction Trial)].
Topics: Administration, Oral; Antihypertensive Agents; China; Clopidogrel; Drug Combinations; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Ticlopidine; Treatment Outcome | 2006 |
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.
Topics: Aged; Clopidogrel; Coronary Circulation; Double-Blind Method; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Rate; Thrombolytic Therapy; Ticlopidine | 2006 |
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Blind Method; Drug Combinations; Fibrinolytic Agents; Humans; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Ticlopidine | 2006 |
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; C-Reactive Protein; CD40 Ligand; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Single-Blind Method; Syndrome; Ticlopidine | 2006 |
[Effectiveness and safety of clopidogrel bisulfate in complex therapy of patients with acute coronary syndrome with ST segment elevation].
Topics: Acute Disease; Angina Pectoris, Variant; Clopidogrel; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine; Treatment Outcome | 2006 |
Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients.
Topics: Aged; Angina, Unstable; Aspirin; Bleeding Time; Blood Viscosity; Clopidogrel; Drug Resistance; Erythrocyte Deformability; Female; Hemorheology; Humans; Leukocyte Count; Leukocytes; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2006 |
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Platelet Aggregation; Platelet Aggregation Inhibitors; Single-Blind Method; Ticlopidine; Troponin I | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Ticlopidine; Treatment Outcome | 2006 |
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Stents; Ticlopidine; Treatment Outcome | 2006 |
Efficacy and safety of clopidogrel 600 mg administered pre-hospitally to improve primary percutaneous coronary intervention in patients with acute myocardial infarction (CIPAMI): study rationale and design.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Administration Schedule; Enoxaparin; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Research Design; Ticlopidine; Treatment Outcome | 2007 |
Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Clopidogrel; Creatine Kinase, MB Form; Drug Combinations; Female; Follow-Up Studies; Humans; Inflammation; Intraoperative Period; Male; Middle Aged; Myocardial Infarction; Naproxen; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome; Troponin I | 2007 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Medical Services; Female; Fibrinolysis; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Delivery Systems; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine | 2006 |
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Jeffrey W Moses.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Retrospective Studies; Risk Assessment; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Function Tests; Prevalence; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2007 |
A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Canada; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome; Urban Population | 2007 |
Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Perioperative Care; Premedication; Risk Assessment; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
[Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation].
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Vascular Patency | 2007 |
Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Drug Resistance; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine | 2007 |
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Registries; Retrospective Studies; Sirolimus; Stents; Survival Rate; Ticlopidine; Treatment Outcome | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Drug Combinations; Equipment Design; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Reoperation; Stents; Ticlopidine; Treatment Outcome | 2007 |
[The effect of different loading doses of clopidogrel on platelet aggregation].
Topics: Adult; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Ticlopidine | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Research Design; Risk Factors; Severity of Illness Index; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2007 |
Platelet function in clopidogrel-treated patients with acute coronary syndrome.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2007 |
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2007 |
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
[Absence of benefit with triple antiaggregation in acute non persistent ST segment elevation myocardial infarction in patients not subjected to early interventionism].
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Tyrosine | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, Sudden, Cardiac; Diabetic Angiopathies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Failure; Reoperation; Sirolimus; Ticlopidine; Treatment Outcome | 2007 |
Association of interleukin-10 level with increased 30-day mortality in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention.
Topics: Aged; Angioplasty, Balloon; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Interleukin-10; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Registries; Ticlopidine; Tirofiban; Tyrosine | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Epidemiologic Methods; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2007 |
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Survival Rate; Thrombosis; Ticlopidine; Tubulin Modulators | 2007 |
ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
Topics: Adult; Age Factors; Aged; Clopidogrel; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Heart Conduction System; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Risk Factors; Survival Analysis; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; CD40 Antigens; Cilostazol; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Treatment Outcome | 2007 |
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Electrocardiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Probability; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind Method; Epidemiologic Methods; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2008 |
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Double-Blind Method; Drug Antagonism; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Omeprazole; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stents; Ticlopidine | 2008 |
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study).
Topics: Blood Glucose; Clopidogrel; Coronary Angiography; Female; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tachycardia, Ventricular; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Ventricular Fibrillation | 2008 |
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.
Topics: Clopidogrel; Coronary Angiography; Epidemiologic Methods; Female; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Neutrophils; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
Topics: Aged; alpha 1-Antitrypsin; Clopidogrel; Drug Administration Schedule; Female; Humans; Inflammation; Infusions, Intravenous; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2008 |
Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine; Vasodilation | 2008 |
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stents; Ticlopidine; Treatment Outcome | 2008 |
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Male; Microfilament Proteins; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Vasodilation | 2008 |
Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Chronic Disease; Clopidogrel; Coronary Angiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Premedication; Risk Factors; Ticlopidine; Troponin | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome | 1998 |
Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recombinant Proteins; Recurrence; Ticlopidine; Tissue Plasminogen Activator | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointestinal Diseases; Hemorrhage; Humans; Myocardial Infarction; Neutropenia; Platelet Aggregation Inhibitors; Stroke; Thrombocytopenia; Ticlopidine; Time Factors; Treatment Outcome | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Female; Hemorrhage; Hospitalization; Humans; Incidence; Ischemia; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Secondary Prevention; Survival Analysis; Ticlopidine | 2000 |
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Humans; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Prospective Studies; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Tetraspanin 30; Ticlopidine | 2000 |
Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborativ
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Ticlopidine | 2000 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Preoperative Care; Proportional Hazards Models; Prospective Studies; Risk; Survival Analysis; Ticlopidine; Treatment Outcome | 2001 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Arteriosclerosis; Intracranial Thrombosis; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Analysis; Ticlopidine; Treatment Outcome | 2002 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2002 |
985 other study(ies) available for clopidogrel and Cardiovascular Stroke
| Article | Year |
|---|---|
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2022 |
European NSTEMI guidelines-return of clopidogrel?
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Receptors, Purinergic P2Y12; Retrospective Studies | 2022 |
Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thrombosis | 2022 |
Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study.
Topics: Clopidogrel; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2021 |
Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Comparative Effectiveness Research; Computer Simulation; Female; Hospitalization; Humans; Intention to Treat Analysis; Latent Class Analysis; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Selection Bias; Stroke; Ticagrelor; Treatment Outcome; Treatment Switching | 2022 |
Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Humans; Kidney Failure, Chronic; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Renal Dialysis; Ticagrelor; Treatment Outcome | 2021 |
Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk.
Topics: Acute Disease; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Risk; Ticagrelor; Treatment Outcome | 2021 |
Clopidogrel versus ticagrelor for antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular Surgery Vascular Quality Initiative.
Topics: Clopidogrel; Endovascular Procedures; Femoral Artery; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2022 |
The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction.
Topics: Clopidogrel; Hemorrhage; Hospitals; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2022 |
Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Ticagrelor; Treatment Outcome | 2022 |
Predictors of In-Hospital De-Escalation of P2Y12 Inhibitors to Clopidogrel in Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hospitals; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
DAPT de-escalation from ticagrelor to clopidogrel 1 mo after PCI for acute MI reduced net clinical events at 1 y.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Cost Utility of Prasugrel in Postangioplasty Diabetic Patients.
Topics: Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality of Life; Ticlopidine | 2022 |
Short- and Long-term Myocardial Infarction Survival Rate According to the Type of Drugs Prescribed at the Time of Discharge: A Study Using Iran National Registry Data.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Calcium; Clopidogrel; Diuretics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Myocardial Infarction; Nitrates; Patient Discharge; Registries; Retrospective Studies; Survival Rate | 2022 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Practice of antiplatelet therapy in acute myocardial infarction
Topics: Clopidogrel; Humans; Hungary; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Treatment Outcome | 2022 |
Cangrelor Use Patterns and Transition to Oral P2Y
Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome | 2022 |
A young patient with recurrent myocardial infarction within a half month.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombophilia; Treatment Outcome | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Effectiveness and Safety of Clopidogrel vs Aspirin in Elderly Patients With Ischemic Stroke.
Topics: Aged; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Stroke; Treatment Outcome | 2022 |
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Topics: Anticoagulants; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials.
Topics: Clopidogrel; Cytochrome P-450 CYP2C9; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention | 2023 |
Topics: Clopidogrel; Humans; Myocardial Infarction | 2023 |
Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Geriatric Pharmacotherapy Case Series: Potential Drug Interactions With Antiplatelet Medications and Cannabidiol-A Focus on P2Y12 Inhibitors.
Topics: Activities of Daily Living; Aged; Cannabidiol; Clopidogrel; Humans; Hypertension; Male; Myocardial Infarction; Pain; Platelet Aggregation Inhibitors; Stroke | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Factors; Stroke; Ticlopidine; Treatment Outcome; Warfarin | 2023 |
Prognostic value of a decrease in mean platelet volume, platelet distribution width, and platelet-large cell ratio for major adverse cardiovascular events after myocardial infarction without ST-segment elevation: An observational study.
Topics: Clopidogrel; Humans; Mean Platelet Volume; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prognosis; Prospective Studies | 2023 |
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk.
Topics: Clopidogrel; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagic Stroke; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Stroke; Treatment Outcome | 2023 |
Differential Impact of Clinical Factors for Predicting High Platelet Reactivity on Clinical Outcomes in Acute Myocardial Infarction Patients Treated With Clopidogrel and Prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Clinical outcomes of generic versus brand-name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study.
Topics: Clopidogrel; Cohort Studies; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2023 |
Determinants of Left Ventricular Systolic Function One Year after Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction in a Middle-Income Country.
Topics: Aged; Clopidogrel; Creatinine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2023 |
Nitroglycerin plus clopidogrel for acute myocardial infarction and the effect on cardiac function indices.
Topics: Clopidogrel; Humans; Myocardial Infarction; Myocardium; Nitroglycerin; Quality of Life | 2023 |
Thrombus architecture is influenced by the antiplatelet loading treatment in patients with acute myocardial infarction.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; RNA; ST Elevation Myocardial Infarction; Thrombosis; Treatment Outcome | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2023 |
A Rare Case of Acute Myocardial Infarction in Pregnancy: Successful Treatment Strategies.
Topics: Cesarean Section; Chest Pain; Clopidogrel; Electrocardiography; Female; Humans; Hypothyroidism; Myocardial Infarction; Pregnancy; Young Adult | 2023 |
Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cause of Death; Clopidogrel; Cohort Studies; Comorbidity; Coronary Angiography; Female; Healthcare Disparities; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Income; Indigenous Peoples; Male; Manitoba; Middle Aged; Mortality; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proportional Hazards Models; Retrospective Studies; Stroke | 2019 |
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study.
Topics: Aged; Aspirin; Cardiologists; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2019 |
Efficacy and Safety of Different Antiplatelet Strategies in Survivors of Myocardial Infarction With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Survivors; Ticagrelor; Treatment Outcome | 2019 |
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Topics: Aged; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Techniques; Europe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome | 2020 |
Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cardiovascular System; Clopidogrel; Female; Humans; Longitudinal Studies; Male; Middle Aged; Middle East; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Tailoring P2Y
Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Proportional Hazards Models; Randomized Controlled Trials as Topic; Single-Blind Method; Stroke | 2019 |
Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction.
Topics: Aged; Alleles; Aspirin; CD40 Ligand; Clopidogrel; Cyclooxygenase 1; Cytochrome P-450 Enzyme System; Dual Anti-Platelet Therapy; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Thromboxane B2 | 2019 |
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Topics: Acute Coronary Syndrome; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Adjustment; Therapeutic Equivalency; Ticagrelor | 2020 |
Safe and Effective Management of Antiplatelet Therapy in a Clopidogrel-Naive Patient Undergoing "Ad Hoc" Complex Coronary Intervention: A Case Report.
Topics: Aged; Clopidogrel; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Resistance; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2020 |
Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Transfusion; Preoperative Care; Retrospective Studies | 2019 |
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Republic of Korea; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Recurrence; Thrombosis; Young Adult | 2020 |
Clopidogrel or prasugrel reduces mortality and lessens cardiovascular damage from acute myocardial infarction in hypercholesterolemic male rats.
Topics: Animals; Cardiovascular System; Clopidogrel; Creatine Kinase, MB Form; Endothelin-1; Gene Expression Regulation; Hypercholesterolemia; Male; Models, Animal; Mortality; Myocardial Infarction; Nitric Oxide Synthase Type III; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Signal Transduction; Treatment Outcome | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Recurrence; Risk Factors; Sex Factors; Stroke; Treatment Outcome | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
Topics: Age Factors; Aged; Body Mass Index; Clinical Decision Rules; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Databases, Factual; Diabetes Mellitus; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Obesity; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Reproducibility of Results; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Stroke | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Gastrointestinal Hemorrhage; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prevalence; Renal Insufficiency; Risk; Risk Assessment; Stents; Thrombosis | 2020 |
Influences of Smoking Status on Effectiveness of Cytochrome P450 Enzyme System Metabolized Medications in Reducing In-Hospital Death in 14 658 Patients With Acute Myocardial Infarction: Data From CPACS-3 Study.
Topics: Aged; Biotransformation; Calcium Channel Blockers; China; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Hospital Mortality; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Non-Smokers; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Risk Factors; Smokers; Smoking; Time Factors; Treatment Outcome | 2020 |
Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2022 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Endarterectomy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
Topics: Aged; Aged, 80 and over; Alleles; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hemorrhage; Humans; Japan; Loss of Function Mutation; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stroke; Treatment Outcome | 2020 |
Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
Topics: Aged; Asian People; Clopidogrel; Cohort Studies; Data Management; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Stroke; Taiwan; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction: When the Choice Makes the Difference.
Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; Cause of Death; Clopidogrel; Databases, Factual; Dyspnea; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Propensity Score; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Retrospective Studies; Stroke; Ticagrelor; United States | 2020 |
Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhagic Stroke; Humans; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual Anti-Platelet Therapy; Duration of Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Proportional Hazards Models; Registries; Risk Assessment; Stroke | 2021 |
Comparison of therapeutic effects of ticagrelor and clopidogrel on patients with acute myocardial infarction and influence of lncRNA BANCR.
Topics: Acute Disease; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; RNA, Long Noncoding; Ticagrelor | 2020 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Humans; Integrin alpha2; Mutation; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stents; Thrombectomy; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2021 |
The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Young Adult | 2021 |
CARDIOVASCULAR EVENT ASSESSMENT IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE UNDERGOING DUAL ANTIPLATELET TREATMENT.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Databases, Factual; Endpoint Determination; Female; Genome-Wide Association Study; Homozygote; Humans; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Postoperative Care; Propensity Score; Stroke | 2021 |
Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Sweden; Ticagrelor; Treatment Outcome | 2021 |
Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR).
Topics: Aftercare; Clopidogrel; Humans; Japan; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries | 2021 |
Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Stroke; Thrombosis; Treatment Outcome | 2021 |
Comparison of Clinical Outcomes of Acute Myocardial Infarction Between Prasugrel and Clopidogrel.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Treatment Outcome | 2021 |
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Retrospective Studies; Ticagrelor | 2021 |
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
Topics: Clopidogrel; Cohort Studies; Coronary Disease; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2022 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabetes Mellitus; Hospitalization; Humans; Insurance, Health; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
Expression of NLR and IL-1β and their predictive efficacy value in acute myocardial infarction patients treated with aspirin combined with clopidogrel.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Resistance; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Ticagrelor Versus Clopidogrel on Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention.
Topics: Clopidogrel; Dose-Response Relationship, Drug; Humans; Magnetic Resonance Imaging, Cine; Myocardial Infarction; Myocardium; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Period; Severity of Illness Index; Ticagrelor | 2017 |
Association of measured platelet reactivity with changes in P2Y
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prevalence; Proportional Hazards Models; Republic of Korea; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2017 |
Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.
Topics: Adolescent; Adult; Aged; Clopidogrel; Databases, Factual; Female; Humans; Male; Medicare; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; United States; Young Adult | 2017 |
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
APpropriateness Assessment in Antiplatelet THerapY (APATHY) registry: Insight from current clinical practice.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Ticlopidine | 2017 |
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
Topics: Aged; Asian People; Calcium Channel Blockers; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2018 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Middle Aged; Models, Economic; Monte Carlo Method; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Databases, Factual; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover.
Topics: Adenosine; Brain Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polycythemia Vera; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thrombocytosis; Ticagrelor; Ticlopidine | 2017 |
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2018 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Humans; Long-Term Care; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors | 2017 |
Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
Topics: Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Ischemia; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Taiwan; Ticagrelor; Treatment Outcome | 2018 |
Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Retrospective Studies; Treatment Outcome; Vitamin K | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Coronary Vasospasm; Female; Follow-Up Studies; Humans; Incidence; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Propensity Score; Proportional Hazards Models; Recurrence; Retrospective Studies; Ticlopidine | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Postoperative Hemorrhage; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Assessment of Early Clopidogrel Therapy Use among Acute Myocardial Infarction Patients in Central-rural China in 2006 and 2011.
Topics: Acute Disease; China; Clopidogrel; Hospitalization; Humans; Logistic Models; Myocardial Infarction; Retrospective Studies; Rural Population | 2017 |
Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Aryldialkylphosphatase; Aspirin; California; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Group III Phospholipases A2; Humans; Limb Salvage; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2018 |
Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Registries; Reoperation; Risk Assessment; Risk Factors | 2018 |
Dyspnea or Cheyne-Stokes respiration associated with Ticagrelor?
Topics: Aged; Cheyne-Stokes Respiration; Clopidogrel; Dyspnea; Humans; Male; Myocardial Infarction; Polysomnography; Ticagrelor | 2018 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatients; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Factors; Secondary Prevention; Sex Factors; Ticagrelor | 2018 |
Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Clopidogrel; Drug Interactions; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Medicaid; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Ticlopidine; United States; Young Adult | 2018 |
Dual antiplatelet therapy in the 'real world'.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function.
Topics: Aged; Clopidogrel; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Sweden; Ticagrelor | 2018 |
Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Clopidogrel; Cyclooxygenase 2; Gastric Mucosa; Male; Myocardial Infarction; Myocardium; Panax; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Saponins; Thromboxane B2; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A | 2018 |
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Taiwan; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Thrombosis; Ticlopidine; Treatment Failure | 2018 |
Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Diffusion Magnetic Resonance Imaging; Female; Fibrinogen; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis | 2018 |
Comparison of Platelet Function Guided Versus Unguided Treatment With P2Y12 Inhibitors in Patients With Acute Myocardial Infarction (from the Hungarian Myocardial Infarction Registry).
Topics: Aged; Cause of Death; Clopidogrel; Drug Substitution; Female; Humans; Hungary; Male; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Function Tests; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Registries; Treatment Outcome | 2018 |
Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting.
Topics: Aged; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Republic of Korea; Risk Assessment; Ticagrelor | 2018 |
Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk; Stroke; Ticlopidine | 2018 |
Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction.
Topics: Adult; Aged; Blood Platelets; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time Factors; Treatment Outcome | 2019 |
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
Topics: Aged; Clopidogrel; Denmark; Drug Resistance; Female; Humans; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervent
Topics: Adenosine; Adult; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Female; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prognosis; Proteoglycans; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Platelet Function Tests | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Review Literature as Topic; Stroke; Ticlopidine | 2018 |
Extended Clopidogrel Therapy Beyond 12 Months and Long-Term Outcomes in Patients With Diabetes Mellitus Receiving Coronary Arterial Second-Generation Drug-Eluting Stents.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Treatment Outcome | 2018 |
P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs.
Topics: AMP-Activated Protein Kinases; Animals; Clopidogrel; Disease Models, Animal; Echocardiography; Fibrosis; Heart Ventricles; Magnetic Resonance Imaging, Cine; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Signal Transduction; Stroke Volume; Sus scrofa; Ticagrelor; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Massive stent thrombosis during active ulcerative colitis: the tricky balance between manifest hemorrhagic and concealed thrombotic risk.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Colitis, Ulcerative; Coronary Thrombosis; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor | 2018 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Stents; Stroke; Sweden | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2018 |
Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses.
Topics: Adult; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Clopidogrel; Female; Follow-Up Studies; Heart Valve Prosthesis; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Puerto Rico; Stroke; Young Adult | 2017 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronary Artery Disease; Denmark; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Stroke; Warfarin | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Comorbidity; Comparative Effectiveness Research; Diabetes Mellitus; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor; Treatment Outcome; United States | 2018 |
Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
.
Topics: Clopidogrel; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2019 |
Patients Prescribed Direct-Acting Oral Anticoagulants Have Low Risk of Postpolypectomy Complications.
Topics: Aged; Anticoagulants; Case-Control Studies; Clopidogrel; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Stroke; Warfarin | 2019 |
Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Stroke; Ticagrelor | 2019 |
Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Galactosyltransferases; Gene Frequency; Genotype; Hispanic or Latino; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Thrombosis | 2019 |
Increased Use of Ticagrelor After Myocardial Infarction Is Not Associated With Intracranial Hemorrhage.
Topics: Age Factors; Aged; Clopidogrel; Cohort Studies; Female; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proportional Hazards Models; Secondary Prevention; Sweden; Ticagrelor | 2018 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study.
Topics: Aged; Case-Control Studies; Cerebral Hemorrhage; Clopidogrel; Dipyridamole; Disease-Free Survival; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Proportional Hazards Models; Secondary Prevention; Stroke; Survival Rate | 2019 |
Open Repair of a Ruptured Abdominal Aortic Aneurysm on a Patient Under Rivaroxaban and Clopidogrel.
Topics: Aortic Aneurysm, Abdominal; Aortic Rupture; Aortography; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Clopidogrel; Computed Tomography Angiography; Drug Administration Schedule; Emergencies; Factor Xa Inhibitors; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Rivaroxaban; Treatment Outcome | 2019 |
Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2019 |
One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
Topics: Aged; Cause of Death; Clopidogrel; Combined Modality Therapy; Drug Substitution; Female; Hemorrhage; Humans; Incidence; Insurance, Health; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction.
Topics: Aged; Brain Ischemia; Clopidogrel; Comorbidity; Humans; Incidence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Stroke; Sweden; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Period; Prasugrel Hydrochloride; Republic of Korea; Thromboembolism; Ticagrelor | 2019 |
Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Aged; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2019 |
Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Retrospective Studies; Stroke; Ticagrelor | 2019 |
Antithrombotic Activity of a Novel Diazepino[1,2-α] Benzimidazole Derivative on Arterial Thrombosis Model in Rats without Concomitant Pathology and in Rats with Experimental Myocardial Infarction.
Topics: Animals; Animals, Outbred Strains; Aspirin; Azepines; Benzimidazoles; Blood Coagulation Tests; Chlorides; Clopidogrel; Disease Models, Animal; Ferric Compounds; Fibrinolytic Agents; Male; Myocardial Infarction; Platelet Aggregation; Rats; Thrombosis | 2019 |
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis.
Topics: Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Primary Prevention; Renal Dialysis; Secondary Prevention; Stroke; Surveys and Questionnaires; Ticlopidine | 2019 |
Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Stroke | 2020 |
Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Prescriptions; Drug Utilization; Dual Anti-Platelet Therapy; Female; Healthcare Disparities; Hospitalization; Humans; Male; Massachusetts; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Adherence to Antiplatelet Therapy after Coronary Intervention among Patients with Myocardial Infarction Attending Vietnam National Heart Institute.
Topics: Adult; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Heart; Humans; Income; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Regression Analysis; Surveys and Questionnaires; Ticlopidine; Vietnam | 2019 |
Tailored P2Y
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Thrombosis | 2019 |
Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction - Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).
Topics: Aged; Aged, 80 and over; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Recurrence; Registries; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2019 |
Safety and Effectiveness of Contemporary P2Y
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Asian People; Cardiovascular Diseases; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prognosis; Proportional Hazards Models; ST Elevation Myocardial Infarction; Stroke | 2019 |
Long-term outcome after angiographically proven coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Female; Follow-Up Studies; Germany; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Prosthesis Failure; Registries; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Cardiac magnetic resonance detection of left ventricular thrombus in acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Echocardiography; Female; Humans; Incidence; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stroke Volume; Thrombosis; Ticlopidine; Ventricular Dysfunction, Left; Warfarin | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; General Practice; Humans; Male; Middle Aged; Myocardial Infarction; Pantoprazole; Platelet Aggregation Inhibitors; Prevalence; Ticlopidine; Treatment Outcome | 2013 |
Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Clopidogrel; Female; Humans; Incidence; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2013 |
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Postoperative Hemorrhage; Stents; Survival Analysis; Thrombosis; Ticlopidine | 2013 |
Questions and answers on treating acute myocardial infarction.
Topics: Cardiac Catheterization; Clopidogrel; Decision Making; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recombinant Proteins; Thrombolytic Therapy; Ticlopidine; Time-to-Treatment; Tissue Plasminogen Activator | 2004 |
Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Out-of-Hospital Cardiac Arrest; Paclitaxel; Thrombocytosis; Ticlopidine; Withholding Treatment | 2013 |
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2013 |
Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
Topics: Arteries; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Preoperative Care; Prevalence; Prospective Studies; Ticlopidine; Vascular Patency | 2013 |
Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285.
Topics: Adult; Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Calcium Channel Blockers; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Synergism; Female; Humans; Male; Middle Aged; Myocardial Infarction; Ticlopidine | 2013 |
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Should alcohol be considered a minor protective factor for unprovoked venous thromboembolism?
Topics: Arteries; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2013 |
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Registries; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; Cardiac Catheterization; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Stroke; Survival Analysis; Ticlopidine | 2014 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ischemia; China; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Receptors, Purinergic P2Y12; Risk Factors; ROC Curve; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: risk of coronary events and peptic ulcer bleeding.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Vessels; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticlopidine; United Kingdom | 2013 |
Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel.
Topics: Age Factors; Aged; Anastomosis, Surgical; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Heparin; Humans; Intraoperative Complications; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Perioperative Period; Platelet Aggregation Inhibitors; Premedication; Reference Values; Retrospective Studies; Sex Factors; Ticlopidine; Whole Blood Coagulation Time | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Genetic Linkage; Genetic Variation; Genotype; Hemorrhage; Humans; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2013 |
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching.
Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Recombinant Proteins; Retrospective Studies; Thiophenes; Thrombosis; Ticlopidine | 2013 |
TRILOGY ACS: prasugrel of benefit only after angiography?
Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve; Blood Platelets; Blood Vessel Prosthesis; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Activation; Ticlopidine | 2013 |
Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy').
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Adult; Aspirin; Bisoprolol; Chest Pain; Clopidogrel; Female; Humans; Infant, Newborn; Male; Myocardial Infarction; N-Methyl-3,4-methylenedioxyamphetamine; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Ticlopidine | 2013 |
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2014 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency, Chronic; Taiwan; Ticlopidine; Treatment Outcome | 2013 |
Stratified reporting of high sensitivity troponin I assay is associated with suboptimal management of patients with acute coronary syndrome and intermediate troponin elevation.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Clopidogrel; Cohort Studies; Coronary Angiography; Female; Humans; Male; Myocardial Infarction; Retrospective Studies; Risk; Ticlopidine; Troponin I; Withholding Treatment | 2013 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Prognosis; Registries; Stroke; Taiwan; Ticlopidine; Treatment Outcome | 2014 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2013 |
[Primary angioplasty in a patient with acute inferior myocardial infarction: the unexpected trap].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortography; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Electrocardiography; Female; Humans; Lysine; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radial Artery; Stents; Ticlopidine; Tomography, X-Ray Computed | 2013 |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Discontinuation of secondary prevention medication after myocardial infarction - the role of general practitioners and patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Female; General Practice; Guideline Adherence; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Surveys and Questionnaires; Ticlopidine | 2013 |
Monitoring persistent platelet reactivity in patients with unprotected left main stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine | 2013 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Therapy, Combination; Drug-Eluting Stents; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Drug Administration Schedule; Female; Flow Cytometry; Humans; Leukocytes; Lipid Peroxidation; Male; Middle Aged; Myocardial Infarction; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Reactive Oxygen Species; Ticlopidine | 2013 |
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
Topics: Adenosine Monophosphate; Blood Platelets; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
A patient with HIV and tuberculosis with diminished clopidogrel response.
Topics: Antitubercular Agents; Clopidogrel; Drug Interactions; Drug Resistance; HIV Infections; HIV Protease Inhibitors; Humans; Isoniazid; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ritonavir; Ticlopidine; Tuberculosis | 2014 |
High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine | 2014 |
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Treatment Outcome | 2014 |
Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel.
Topics: Acute Disease; Age Factors; Aged; Anticoagulants; Chronic Disease; Clopidogrel; Female; Gastrointestinal Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Liver Diseases; Male; Middle Aged; Myocardial Infarction; Ohio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Veterans; Warfarin | 2014 |
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Peripheral Arterial Disease; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, PAR-1; Recurrence; Stents; Stroke; Thrombin; Ticlopidine | 2014 |
Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
Topics: Aged; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Drug Combinations; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk; Stents; Survival Analysis; Ticlopidine | 2014 |
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Clopidogrel; Computer Simulation; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Heparin; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ticlopidine | 2014 |
Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
Topics: Adult; Aged; Clopidogrel; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine | 2014 |
Immune thrombocytopenic purpura and myocardial infarction: a dilemma of management.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Disease Management; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Mechanical Thrombolysis; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Purpura, Thrombocytopenic, Idiopathic; Stents; Ticlopidine; Treatment Outcome | 2013 |
Temporary adjunctive cilostazol vs clopidogrel loading for ST-segment elevation acute myocardial infarction.
Topics: Acute Disease; Aged; Cilostazol; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Tetrazoles; Ticlopidine | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine; Vitamin K; Warfarin | 2014 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Risk Factors; Ticlopidine; Treatment Outcome | 2014 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Female; Fibrin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Thrombelastography; Ticlopidine | 2014 |
Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction.
Topics: Aged; Cardiac Catheterization; Clopidogrel; Female; Humans; Magnetic Resonance Angiography; Male; Microvessels; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Ticlopidine; Time-to-Treatment; Treatment Outcome | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Cilostazol in acute myocardial infarction: new tricks for an old drug?
Topics: Cilostazol; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2014 |
Estimating the effects of time-varying exposures in observational studies using Cox models with stabilized weights adjustment.
Topics: Clopidogrel; Confounding Factors, Epidemiologic; Drug-Eluting Stents; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Observational Studies as Topic; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticlopidine; Time Factors | 2014 |
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2013 |
Point-of-care testing of clopidogrel-mediated platelet inhibition and risk for cardiovascular events after coronary angiography with or without percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; ROC Curve; Stents; Survival Analysis; Thrombosis; Ticlopidine | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Retrospective Studies; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2015 |
We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization.
Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.
Topics: Aged; Angina, Unstable; Clopidogrel; Cohort Studies; Disease Management; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2014 |
A cautionary tale on the use of antiplatelet treatment following TURP.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Thrombosis; Ticlopidine; Transurethral Resection of Prostate; Urinary Bladder; Urinary Bladder Diseases | 2014 |
Controversies in acute cardiovascular care.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.
Topics: Adult; Aged; Black People; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Prospective Studies; Ticlopidine; White People | 2014 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Registries; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Smoking; Stents; Thrombosis; Ticlopidine | 2015 |
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Thrombosis; Electrocardiography; HIV; HIV Infections; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.
Topics: Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Genotyping Techniques; Humans; Multiplex Polymerase Chain Reaction; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Purinergic P2Y12; Republic of Korea; Sequence Analysis, DNA; Ticlopidine | 2014 |
Delay in filling first clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial infarction.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Improving outcomes with bivalirudin in primary percutaneous coronary intervention.
Topics: Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; ROC Curve; Ticlopidine | 2014 |
The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Early Medical Intervention; Female; Guideline Adherence; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Patient Transfer; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Pyridines; Recombinant Proteins; Retrospective Studies; Ticlopidine; Time-to-Treatment | 2014 |
Cholesterol embolization syndrome with an atypical proximal presentation simulating calciphylaxis.
Topics: Aspirin; Back; Buttocks; Calciphylaxis; Cardiac Catheterization; Clopidogrel; Diagnosis, Differential; Embolism, Cholesterol; Erythema; Female; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Skin Ulcer; Thigh; Ticlopidine | 2014 |
Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups.
Topics: Age Distribution; Age Factors; Aged; Aspirin; Cause of Death; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Propensity Score; Registries; Retrospective Studies; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2014 |
Early ambulance initiation versus in-hospital initiation of high dose clopidogrel in ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Cohort Studies; Electrocardiography; Emergency Medical Services; Emergency Service, Hospital; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Survival Analysis; Ticlopidine; Treatment Outcome; Vascular Patency | 2014 |
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data.
Topics: Aged; Aspirin; China; Clopidogrel; Female; Fibrinolytic Agents; Healthcare Disparities; Hospital Mortality; Hospitals, Rural; Hospitals, Urban; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Patient Admission; Percutaneous Coronary Intervention; Quality of Health Care; Retrospective Studies; Ticlopidine; Treatment Outcome | 2015 |
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
Topics: Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Factors; Ticlopidine; Time Factors | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2014 |
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Postoperative Complications; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 2014 |
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.
Topics: Aged; Clopidogrel; Coronary Thrombosis; Denmark; Drug Administration Schedule; Drug Prescriptions; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Residual platelet reactivity after clopidogrel loading in ST-elevation myocardial infarction patients undergoing a delayed catheterization. Impact on long term clinical events.
Topics: Aged; Blood Platelets; Cardiac Catheterization; Clopidogrel; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2014 |
Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Stents; Ticlopidine | 2014 |
Reanalysis or redefinition of the hypothesis?
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2015 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; Data Collection; Denmark; Female; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ticlopidine; Treatment Outcome | 2014 |
Effects of new regional cooperative rescue model on patients with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2014 |
Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program.
Topics: Adult; Aged; Clopidogrel; Female; Hospitals, Veterans; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Percutaneous Coronary Intervention; Pharmacy Service, Hospital; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; United States; United States Department of Veterans Affairs | 2014 |
Validation of acute myocardial infarction cases in the national health insurance research database in taiwan.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Coding; Clopidogrel; Cross-Sectional Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Myocardial Infarction; National Health Programs; Platelet Aggregation Inhibitors; Reproducibility of Results; Taiwan; Ticlopidine | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2014 |
Changes in thrombus composition and profilin-1 release in acute myocardial infarction.
Topics: Analysis of Variance; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Fibrinogen; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Profilins; Thrombectomy; Thrombin; Ticlopidine; Time-to-Treatment | 2015 |
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Carboxylic Ester Hydrolases; Clopidogrel; Drug Interactions; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2014 |
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Drug Synergism; Drug Therapy, Combination; Hypercholesterolemia; Isoproterenol; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Rats; Serum Amyloid P-Component; Ticlopidine; Transforming Growth Factor beta1; Triglycerides | 2014 |
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?
Topics: Aged; Blood Platelets; Clopidogrel; Elective Surgical Procedures; Female; Follow-Up Studies; Hematocrit; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Stents; Ticlopidine; Treatment Outcome | 2014 |
Spontaneous coronary artery dissection: a complete resolution with medical treatment.
Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Vascular Diseases | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Erythrocyte Indices; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Myocardial Infarction; Neutrophils; Percutaneous Coronary Intervention; Prognosis; Retrospective Studies; ROC Curve; Salvage Therapy; Sensitivity and Specificity; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Treatment Failure | 2015 |
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.
Topics: Aged; Angina, Stable; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2014 |
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Web Exclusives. The consult guys--balancing the medication portfolio 5 years after a heart attack.
Topics: Adrenergic beta-1 Receptor Antagonists; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metoprolol; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2014 |
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2015 |
Acute coronary syndromes and coronary intervention.
Topics: Angina, Unstable; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2015 |
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Serial changes of mean platelet volume in relation to Killip Class in patients with acute myocardial infarction and primary percutaneous coronary intervention.
Topics: Acute Disease; Clopidogrel; Echocardiography; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine | 2015 |
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebral Hemorrhage; Clopidogrel; Embolic Protection Devices; Female; Humans; Immunoglobulin Fab Fragments; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Suction; Thrombosis; Ticlopidine | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Erythrocytes; Female; Fibrin; Fibrinolysis; Humans; Male; Microscopy, Electron, Scanning; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Permeability; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Porosity; Suction; Thrombectomy; Ticlopidine; Time Factors | 2015 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2015 |
Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
Topics: Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticlopidine; Time Factors | 2015 |
Delayed clopidogrel transit during myocardial infarction evident on angiography.
Topics: Administration, Oral; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2015 |
The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry.
Topics: Acute Disease; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Shock, Cardiogenic; Ticlopidine; Treatment Outcome | 2015 |
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Clopidogrel; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; Lisinopril; Male; Myocardial Infarction; Perindopril; Platelet Aggregation Inhibitors; Ramipril; Recurrence; Ticlopidine; Treatment Outcome | 2015 |
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiography; Electrocardiography; Enoxaparin; Female; Humans; Myocardial Infarction; Takotsubo Cardiomyopathy; Ticlopidine | 2015 |
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Metals; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Severity of Illness Index; Stents; Ticlopidine; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Enoxaparin; Europe; Female; Fibrinolytic Agents; Health Care Surveys; Heparin; Hospital Mortality; Humans; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Propensity Score; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Registries; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Injections, Intraperitoneal; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Signal Transduction; Ticagrelor; Ticlopidine; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.
Topics: Adult; Clopidogrel; Humans; Middle Aged; Myocardial Infarction; Prospective Studies; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Young Adult | 2015 |
Assessing the Quality of Care for Patients With Acute Myocardial Infarction in China.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; China; Clopidogrel; Coronary Angiography; Female; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Quality Indicators, Health Care; Ticlopidine | 2015 |
Interaction of Panax quinquefolius Saponin and Dual Antiplatelets on Vascular Endothelial Function in Rats with Acute Myocardial Infarction.
Topics: Animals; Aspirin; Clopidogrel; Coronary Vessels; Endothelial Cells; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Rats; Saponins; Ticlopidine; Ventricular Remodeling | 2015 |
Clinical outcomes of multiple chronic total occlusions in coronary arteries according to three therapeutic strategies: Bypass surgery, percutaneous intervention and medication.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Occlusion; Coronary Vessels; Death; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prodrugs; Prognosis; Prospective Studies; Recurrence; Stents; Ticlopidine; Treatment Outcome | 2015 |
National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study.
Topics: Aged; Asian People; China; Clopidogrel; Drug Administration Schedule; Female; Healthcare Disparities; Humans; Male; Middle Aged; Myocardial Infarction; National Health Programs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Quality Improvement; Quality Indicators, Health Care; Residence Characteristics; Retrospective Studies; Risk Factors; Rural Health Services; Ticlopidine; Time Factors; Treatment Outcome; Urban Health Services | 2015 |
Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metals; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stroke; Ticlopidine; United States; United States Department of Veterans Affairs | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Echocardiography; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Plasminogen Activator Inhibitor 1; Postoperative Complications; Prospective Studies; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome; von Willebrand Factor | 2015 |
Does clopidogrel affect the efficacy of myocardial perfusion imaging?
Topics: Clopidogrel; Humans; Myocardial Infarction; Myocardial Perfusion Imaging; Ticlopidine; Treatment Outcome | 2016 |
Age- and Gender-related Disparities in Primary Percutaneous Coronary Interventions for Acute ST-segment elevation Myocardial Infarction.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Geriatrics; Hospitals; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Sex Characteristics; Switzerland; Ticlopidine; Treatment Outcome | 2015 |
Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Ticlopidine; Treatment Outcome | 2015 |
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Chromatography, Liquid; Clopidogrel; Electrodes; Female; Flow Cytometry; Humans; Luminescence; Male; Mass Spectrometry; Middle Aged; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Tandem Mass Spectrometry; Ticlopidine | 2015 |
Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).
Topics: Aged; Antithrombins; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2016 |
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery Bypass; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Stents; Stroke; Surveys and Questionnaires; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
A tablet of clopidogrel remaining in the lower esophagus after primary percutaneous coronary intervention for acute myocardial infarction.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Esophagus; Female; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tablets; Ticlopidine | 2015 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
[A case review: About a STEMI in the very elderly].
Topics: Aged, 80 and over; Aging; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Topics: Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine | 2016 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotyping Techniques; Heterozygote; Humans; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prospective Studies; Stroke; Ticlopidine | 2016 |
Determinants of pre-hospital pharmacological intervention and its association with outcome in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Analgesics, Opioid; Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Female; Humans; Male; Morphine; Myocardial Infarction; Nitroglycerin; Oxygen; Platelet Aggregation Inhibitors; Sweden; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Proportional Hazards Models; Recurrence; Registries; Republic of Korea; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism.
Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; Humans; Myocardial Bridging; Myocardial Infarction; Perindopril; Ticlopidine; Treatment Outcome; Vascular Diseases | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; Female; France; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Outpatients; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Registries; Stroke; Ticlopidine | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hospitalization; Humans; Male; Markov Chains; Monte Carlo Method; Myocardial Infarction; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pyridines; Registries; Stroke; Ticlopidine; Warfarin | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stents; Thrombosis; Ticlopidine; Ultrasonography, Interventional | 2016 |
Likelihood ratio meta-analysis: New motivation and approach for an old method.
Topics: Aspirin; Bayes Theorem; Clopidogrel; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Meta-Analysis as Topic; Models, Statistical; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; In Vitro Techniques; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prevalence; Risk Factors; Saudi Arabia; Ticlopidine; Treatment Failure | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Insurance, Health; Korea; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Succinates; Tetrazoles; Ticlopidine; Treatment Outcome | 2016 |
Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Medicare; Myocardial Infarction; Myocardial Revascularization; Patient Discharge; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Pharmacogenetics of Clopidogrel: An Unresolved Issue.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Electrocardiography; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Tandem Mass Spectrometry; Ticlopidine | 2016 |
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Propensity Score; Registries; Republic of Korea; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Male; Myocardial Infarction; Postoperative Hemorrhage; Pyridines; Survival Analysis; Ticlopidine; Treatment Outcome | 2016 |
Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Emergency Medical Services; Europe; Female; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System.
Topics: Aftercare; Aged; Cardiology; Cause of Death; Clopidogrel; Coronary Artery Disease; Deprescriptions; Drug-Eluting Stents; Female; Hospitals; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Ticlopidine; Time Factors; United States; United States Department of Veterans Affairs | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2016 |
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; Integrin beta3; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Recurrence; Stroke; Ticlopidine | 2017 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Retrospective Studies; Secondary Prevention; Stroke; Ticlopidine | 2016 |
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Metoprolol; Middle Aged; Morphine; Myocardial Infarction; Nitroglycerin; Ovarian Neoplasms; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Retreatment; Ticlopidine; Treatment Outcome; Vasodilator Agents | 2016 |
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Topics: Aged; Aged, 80 and over; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Disability Evaluation; Drug Interactions; Drug Resistance; Female; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Polypharmacy; Prospective Studies; Proton Pump Inhibitors; Recurrence; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; China; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Receptors, Purinergic P2Y12; Thrombelastography; Ticlopidine | 2016 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Electrocardiography; Female; Flow Cytometry; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Retrospective Studies; Ticlopidine | 2016 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Proton Pump Inhibitors; Registries; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Czech Republic; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Survival Analysis | 2017 |
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health Expenditures; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
Topics: Adenosine; Animals; Blood Platelets; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Myocardial Infarction; Platelet Aggregation Inhibitors; Random Allocation; Swine; Ticagrelor; Ticlopidine | 2016 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Endarterectomy; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2017 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiveness Research; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitals, Veterans; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy.
Topics: Adenosine; Aged; Canada; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infarction; Protein C; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results; Sepsis; Statistics as Topic; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2017 |
Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors.
Topics: Aged; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19 Inhibitors; Databases, Factual; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Ticlopidine | 2017 |
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after
Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug Therapy, Combination; Drug Utilization; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Stroke; Survival Rate; Ticlopidine | 2017 |
Effect of Clopidogrel by Smoking Status on Secondary Stroke Prevention.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Datasets as Topic; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Secondary Prevention; Smoking; Stroke; Ticlopidine | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Smoking; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Propensity Score; Renal Dialysis; Retrospective Studies; Stroke; Survival Rate; Taiwan; Ticlopidine | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Propensity Score; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Sex Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyridines; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.
Topics: Angioplasty, Balloon, Coronary; Cardiology; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Societies, Medical; Ticlopidine; United States | 2008 |
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Confidence Intervals; Elective Surgical Procedures; Female; Follow-Up Studies; Humans; Incidence; Male; Myocardial Infarction; Myocardial Revascularization; Odds Ratio; Platelet Aggregation Inhibitors; Point-of-Care Systems; Preoperative Care; Prospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Outcome; Troponin T | 2008 |
2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
Topics: American Heart Association; Angina, Unstable; Anticoagulants; Clopidogrel; Drug-Eluting Stents; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Practice Guidelines as Topic; Recombinant Proteins; Ticlopidine; United States | 2008 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
Hydrolysis of adenine nucleotides in platelets from patients with acute myocardial infarction.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Hydrolysis; Male; Middle Aged; Myocardial Infarction; Ticlopidine | 2008 |
Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
Topics: Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Fibrinogen; Flow Cytometry; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2008 |
Acute arthritis associated with loading dose of clopidogrel.
Topics: Aged; Arthritis; Clopidogrel; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Clopidogrel treatment and the MEND-CABG II trial.
Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Purinergic Antagonists; Pyridoxal Phosphate; Risk; Ticlopidine | 2008 |
Survival benefit with concomitant oral platelet therapy after coronary angiography and before ad hoc percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.
Topics: Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2008 |
Recurrent myocardial infarction in a young football player with antithrombin III deficiency.
Topics: Angioplasty, Balloon, Coronary; Antithrombin III Deficiency; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Football; Humans; Male; Myocardial Infarction; Myocardial Perfusion Imaging; Physical Fitness; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine; Young Adult | 2008 |
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Creatine Kinase; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Denmark; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Platelet Aggregation Inhibitors; Prescriptions; Proportional Hazards Models; Registries; Sex Factors; Ticlopidine | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Feasibility Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Sirolimus; Ticlopidine | 2008 |
Treatment of patients with cardiogenic shock in the setting of acute myocardial infarction. Case reports.
Topics: Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carbazoles; Carvedilol; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propanolamines; Shock, Cardiogenic; Stents; Ticlopidine; Vasodilator Agents | 2008 |
Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Drug-Eluting Stents; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Registries; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome; Victoria | 2008 |
Optimizing clopidogrel therapy before stent implantation: should clinical setting be taken into account?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Severity of Illness Index; Stents; Ticlopidine; Treatment Outcome | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Stroke; Thrombolytic Therapy; Ticlopidine | 2009 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Health Policy; Hemorrhage; Humans; Insurance Benefits; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Male; Myocardial Infarction; National Health Programs; Ontario; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Recurrence; Stents; Ticlopidine | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Stents; Ticlopidine; Time Factors; Troponin | 2008 |
Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Ticlopidine | 2008 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2008 |
Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Circadian Rhythm; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Mortality; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Stroke; Ticlopidine | 2008 |
A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Follow-Up Studies; Humans; Markov Chains; Middle Aged; Models, Econometric; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Survival Analysis; Ticlopidine; United Kingdom | 2010 |
Genetic determinants of response to clopidogrel and cardiovascular events.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Follow-Up Studies; Genotype; Humans; Integrin beta3; Male; Middle Aged; Mortality; Mutation; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Registries; Stroke; Ticlopidine | 2009 |
Clopidogrel, genetics, and drug responsiveness.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Mutation; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Clopidogrel use in ST-elevation myocardial infarction (STEMI).
Topics: Catheter Ablation; Clopidogrel; Electrocardiography; Emergency Service, Hospital; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2010 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Cohort Studies; Confidence Intervals; Continuity of Patient Care; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Discharge; Patient Readmission; Proton Pump Inhibitors; Recurrence; Risk Assessment; Sex Distribution; Survival Rate; Ticlopidine | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrinolytic Agents; Heparin; Humans; Hydroxyurea; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombocythemia, Essential; Ticlopidine; Tirofiban; Tissue Plasminogen Activator; Tyrosine | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Focus on adjunctive pharmacotherapy to improve outcomes of percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adjuvant; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Therapy; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Treatment Outcome | 2009 |
Successful clopidogrel desensitization after drug-eluting stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Desensitization, Immunologic; Drug-Eluting Stents; Electrocardiography; Exanthema; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Pruritus; Ticlopidine | 2009 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Hypertension; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Stroke; Ticlopidine | 2009 |
Novel antiplatelet strategies in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inhibitors; Diabetic Angiopathies; Diclofenac; Drug Interactions; Drug-Eluting Stents; Endothelium, Vascular; Humans; Intervertebral Disc Displacement; Male; Meloxicam; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Thiazines; Thiazoles; Ticlopidine; Time Factors | 2009 |
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Heterozygote; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prodrugs; Prognosis; Research Design; Ticlopidine; Treatment Outcome | 2009 |
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Follow-Up Studies; Heterozygote; Humans; Medication Adherence; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Ticlopidine; Treatment Outcome | 2009 |
Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Liver; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Safety; Ticlopidine; Treatment Outcome | 2009 |
Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Ticlopidine; Treatment Failure | 2009 |
Antithrombotic therapy for the prevention of reinfarction after reperfusion therapy: the price of success.
Topics: China; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Reperfusion; Secondary Prevention; Thrombolytic Therapy; Ticlopidine | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Clopidogrel. More on proton pump inhibitors.
Topics: Clopidogrel; Drug Combinations; Humans; Myocardial Infarction; Proton Pump Inhibitors; Recurrence; Risk Factors; Ticlopidine | 2009 |
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Metals; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Impact of combining proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Secondary Prevention; Ticlopidine | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Clopidogrel; Data Interpretation, Statistical; Drug Administration Schedule; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine | 2009 |
Risks of proton-pump inhibitors: what every doctor should know. Comment.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Secondary Prevention; Ticlopidine | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atherectomy; Catheter Ablation; Clopidogrel; Coronary Artery Bypass; Diabetes Mellitus; Drug Therapy, Combination; Female; Health Care Costs; Hospital Costs; Humans; Male; Medical Record Linkage; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Proportional Hazards Models; Registries; Risk Factors; Simvastatin; Sweden; Ticlopidine; Treatment Outcome | 2010 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Odds Ratio; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Assessment; Secondary Prevention; Ticlopidine | 2009 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Myocardial Infarction; Odds Ratio; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine | 2009 |
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Ticlopidine | 2010 |
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Registries; Retrospective Studies; Tetrazoles; Ticlopidine | 2009 |
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
Topics: Antihypertensive Agents; Aspirin; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Electrocardiography; Exercise Therapy; Humans; Hypolipidemic Agents; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Secondary Prevention; Smoking Cessation; Ticlopidine | 2009 |
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2009 |
Aspirin for heart attack, stroke prevention. When benefits outweigh risks: four new studies help clarify who should--and who shouldn't--take the drug.
Topics: Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2009 |
[Clopidogrel plus proton pump inhibitor: is infarct risk increased? (interview by Dr. Thomas Meissner)].
Topics: Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
Topics: Aged; Blood Vessel Prosthesis; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2009 |
A caution on Plavix and PPIs.
Topics: Clopidogrel; Drug Interactions; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2009 |
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease; Delivery of Health Care, Integrated; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Withholding Treatment | 2009 |
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.
Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease; Female; Hospitalization; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Population; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; United States; Withholding Treatment | 2009 |
Letter by Ryding et al regarding article, "Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review".
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Meta-Analysis as Topic; Myocardial Infarction; Ticlopidine; Treatment Outcome; Vascular Patency | 2009 |
Right ventricular function in ST elevation myocardial infarction: effect of reperfusion.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Female; Heptanoic Acids; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Pyrroles; Streptokinase; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Ventricular Function, Right | 2009 |
New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
Topics: Aged; Argentina; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Equipment Design; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2009 |
Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stents; Ticlopidine | 2009 |
Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Premedication; Ticlopidine; Treatment Outcome | 2009 |
Acute myocardial infarction associated with pregnancy successfully treated with percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Cesarean Section; Clopidogrel; Female; Humans; Infant, Newborn; Myocardial Infarction; Pregnancy; Pregnancy Complications, Cardiovascular; Ticlopidine; Treatment Outcome | 2009 |
Percutaneous coronary intervention in a patient with factor XI deficiency.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Factor XI Deficiency; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2009 |
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome | 2010 |
Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Stents; Ticlopidine | 2010 |
Headache as the sole presenting symptom of acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headache; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Inhalation Therapy; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Vascular Diseases | 2009 |
Desensitization to clopidogrel: a growing need.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Desensitization, Immunologic; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2010 |
Hunting for the "sweet spot" in P2Y12 receptor blockade.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2009 |
Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Germany; Guideline Adherence; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Odds Ratio; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Registries; Ticlopidine; Treatment Outcome | 2009 |
Routine early angioplasty after fibrinolysis.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Infarction; Patient Transfer; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Time Factors | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Case-Control Studies; Catecholamines; Cell Adhesion Molecules; Clopidogrel; Down-Regulation; Drug Monitoring; Female; Hemodynamics; Humans; International Normalized Ratio; Liver Circulation; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Respiration, Artificial; Shock, Cardiogenic; Splanchnic Circulation; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; Female; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Stroke; Stroke Volume; Ticlopidine; Warfarin | 2009 |
Therapeutic innovations, diminishing returns, and control rate preservation.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Agents; Clopidogrel; Diagnosis, Differential; Electrocardiography; Evidence-Based Medicine; Humans; International Cooperation; Metoprolol; Myocardial Infarction; Randomized Controlled Trials as Topic; Streptokinase; Therapeutics; Ticlopidine; Treatment Outcome; Troponin | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections; Length of Stay; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Radial Artery; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction.
Topics: Alleles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cimetidine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Taiwan; Ticlopidine | 2009 |
Stent thrombosis: a poor man's disease?
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort Studies; Coronary Disease; Data Interpretation, Statistical; Diabetes Complications; Drug-Eluting Stents; Female; Follow-Up Studies; Housing; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polytetrafluoroethylene; Residential Facilities; Risk Factors; Smoking; Socioeconomic Factors; Stents; Thrombosis; Ticlopidine; Time Factors | 2009 |
A regional system for delivery of primary percutaneous coronary intervention in ST-elevation myocardial infarction: STEMI-St. Cloud.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Delivery of Health Care; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Minnesota; Myocardial Infarction; Patient Transfer; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Admission; Proportional Hazards Models; Recurrence; Registries; Retrospective Studies; Risk Factors; Ticlopidine; Vitamin K | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Risk; Stents; Stroke; Thromboembolism; Thrombosis; Ticlopidine; Warfarin | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2008 |
Clopidogrel for the hot patient.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Humans; Inflammation; Inflammation Mediators; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pregnancy-Associated Plasma Protein-A; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2009 |
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Inflammation Mediators; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pregnancy-Associated Plasma Protein-A; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States; Up-Regulation | 2009 |
Improved clinical outcome after acute myocardial infarction in hospitals participating in a Swedish quality improvement initiative.
Topics: Aged; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Hemorrhage; Hospital Mortality; Hospitals; Humans; Incidence; Male; Myocardial Infarction; Outcome Assessment, Health Care; Patient Readmission; Prevalence; Quality Assurance, Health Care; Quality of Health Care; Sweden; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
[Antiplatelet therapy and urgent surgical procedures. Acute appendicitis two days after stent implantation--a case report].
Topics: Appendicitis; Clopidogrel; Coronary Thrombosis; Dobutamine; Humans; Intraoperative Complications; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Reoperation; Stents; Ticlopidine | 2009 |
Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Female; Humans; Male; Models, Theoretical; Multicenter Studies as Topic; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Failure | 2010 |
Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression.
Topics: Adenosine Diphosphate; Aged; Angina, Unstable; Anxiety Disorders; Aspirin; Clopidogrel; Cross-Sectional Studies; Depressive Disorder; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Serotonin; Ticlopidine | 2010 |
Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Incidence; Male; Medical Records; Middle Aged; Myocardial Infarction; New York City; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Rate; Ticlopidine | 2010 |
Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Denmark; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Registries; Retrospective Studies; Risk Factors; Secondary Prevention; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
HORIZONS-AMI.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Stents; Ticlopidine; Treatment Outcome | 2010 |
Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.
Topics: Aged; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Severity of Illness Index; Stents; Ticlopidine; Treatment Outcome | 2010 |
VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
Topics: Adult; Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Sensitivity and Specificity; Thrombosis; Ticlopidine | 2010 |
Antiplatelet therapy with clopidogrel or ticlopidine reduces intimal hyperplasia in an animal model of experimental arterial injury.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Arteries; Cell Division; Clopidogrel; Coronary Artery Bypass; Disease Models, Animal; Humans; Muscle, Smooth, Vascular; Myocardial Infarction; Platelet Aggregation Inhibitors; Rabbits; Ticlopidine | 2010 |
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Greece; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Omeprazole; Patient Readmission; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Tetrazoles; Thrombosis; Ticlopidine; Time Factors | 2010 |
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chemotherapy, Adjuvant; Cilostazol; Clinical Trials as Topic; Clopidogrel; Contraindications; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases.
Topics: Anti-Ulcer Agents; Clopidogrel; Confidentiality; Databases, Factual; Female; Humans; Male; Meta-Analysis as Topic; Multivariate Analysis; Myocardial Infarction; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Privacy; Product Surveillance, Postmarketing; Propensity Score; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome; Utilization Review | 2010 |
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Creatinine; Diabetes Mellitus; Drug-Eluting Stents; Follow-Up Studies; Humans; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Sirolimus; Stroke Volume; Ticlopidine | 2010 |
Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Vessels; Death, Sudden, Cardiac; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Preoperative Care; Prospective Studies; Risk Factors; Stents; Thrombosis; Ticlopidine; Time Factors | 2010 |
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Drug Administration Schedule; Drug-Eluting Stents; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Retrospective Studies; Ticlopidine | 2010 |
Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Clopidogrel; Cost-Benefit Analysis; Diagnosis-Related Groups; Female; Hospital Costs; Humans; Male; Medicare; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Ticlopidine; Time Factors | 2011 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidogrel; Confidence Intervals; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pantoprazole; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Failure | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Administration, Oral; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Infusions, Intravenous; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2010 |
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Troponin I | 2010 |
Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Survival Analysis; Ticlopidine | 2010 |
Clopidogrel and heart failure survival: missed opportunity or wrong turn?
Topics: Clopidogrel; Denmark; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography; Dyspnea; Factor VIII; Fatal Outcome; Hemophilia A; Heparin, Low-Molecular-Weight; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Renal Insufficiency; Ticlopidine | 2010 |
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Delivery of Health Care, Integrated; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Analysis; Ticlopidine; United States; Withholding Treatment | 2010 |
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications?
Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Attitudes, Practice; Heartburn; Humans; Myocardial Infarction; Omeprazole; Patient Education as Topic; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2010 |
Non-invasive coronary flow reserve after successful primary angioplasty for acute anterior myocardial infarction is an independent predictor of left ventricular adverse remodelling.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Echocardiography; Female; Fractional Flow Reserve, Myocardial; Heart Ventricles; Hemodynamics; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; ROC Curve; Sensitivity and Specificity; Statistics as Topic; Stroke Volume; Ticlopidine; Ventricular Function, Left | 2010 |
Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.
Topics: Cardiovascular Diseases; Chemotherapy, Adjuvant; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Medication Therapy Management; Myocardial Infarction; Patient Compliance; Patient Discharge; Platelet Aggregation Inhibitors; Postoperative Complications; Prescriptions; Prosthesis Implantation; Retrospective Studies; Risk Factors; Survival Analysis; Ticlopidine; United States | 2010 |
Relationship between chronic obstructive pulmonary disease and in-hospital management and outcomes in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Female; Health Services Accessibility; Hospital Mortality; Humans; Male; Myocardial Infarction; Poland; Pulmonary Disease, Chronic Obstructive; Risk Management; Ticlopidine; Treatment Outcome | 2010 |
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Readmission; Probability; Proportional Hazards Models; Proton Pump Inhibitors; Reference Values; Retrospective Studies; Risk Assessment; Sex Factors; Survival Rate; Ticlopidine | 2010 |
Thrombus too big for pharmacology alone?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Thrombectomy; Thrombolytic Therapy; Ticlopidine | 2010 |
Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent).
Topics: Aged; Clopidogrel; Comorbidity; Drug-Eluting Stents; Female; Follow-Up Studies; Health Maintenance Organizations; Humans; Male; Middle Aged; Myocardial Infarction; Postoperative Hemorrhage; Prosthesis Implantation; Registries; Risk Factors; Ticlopidine | 2010 |
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors | 2010 |
Clinician-patient discord: exploring differences in perspectives for discontinuing clopidogrel.
Topics: Aged; Attitude of Health Personnel; Attitude to Health; Clopidogrel; Communication; Comorbidity; Drug-Eluting Stents; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patients; Physician-Patient Relations; Physicians; Platelet Aggregation Inhibitors; Qualitative Research; Thrombosis; Ticlopidine | 2011 |
[Experience of treatment of patients with myocardial infarction without raise of ST segment on ECG of high risk of cardiocomplications by method of coronary angioplasty].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2010 |
[Interview with Prof. Uwe Zeymer, Ludwgshaven Clinic. Infarct register reveals high "loss ratios" in treatment (interview by Sonja Bohm)].
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Germany; Guideline Adherence; Humans; Long-Term Care; Medication Adherence; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Survival Rate; Ticlopidine | 2010 |
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Topics: Aged; Aspirin; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Sweden; Ticlopidine | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine | 2010 |
[The problems of antiaggregant therapy of patients with acute myocardial infarction. Experience with the use of clopidogrel].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drugs, Generic; Electrocardiography; Health Care Costs; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; Treatment Outcome | 2010 |
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Female; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2010 |
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Laser-Doppler Flowmetry; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Tissue Plasminogen Activator | 2010 |
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Utilization; Electronic Health Records; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Perioperative Period; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Ticlopidine; United States | 2010 |
Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Stenosis; Diabetes Complications; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2010 |
[Registries of myocardial infarction in Germany. Consequences for drug therapy of patients with acute ST elevation myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Electrocardiography; Evidence-Based Medicine; Germany; Guideline Adherence; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Registries; Secondary Prevention; Survival Analysis; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Epinephrine; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Norepinephrine; Platelet Aggregation Inhibitors; Postoperative Care; Statistics, Nonparametric; Stents; Ticlopidine; Treatment Outcome | 2010 |
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
General thoracic surgery is safe in patients taking clopidogrel (Plavix).
Topics: Adult; Aged; Aged, 80 and over; Alabama; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Case-Control Studies; Chi-Square Distribution; Clopidogrel; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Propensity Score; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thoracic Surgical Procedures; Ticlopidine; Treatment Outcome | 2010 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clopidogrel; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2010 |
Frequency and risk of noncardiac surgery after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Risk Assessment; Risk Factors; Surgical Procedures, Operative; Texas; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Stents; Tetrazoles; Thrombosis; Ticlopidine; Time Factors | 2010 |
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Coronary Restenosis; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Recurrence; Reoperation; Stents; Stroke; Ticlopidine | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2010 |
Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction.
Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Ticlopidine | 2010 |
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Topics: Adult; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Recurrence; Regression Analysis; Risk Factors; Ticlopidine; Time Factors | 2010 |
Conflicting evidence: what's a clinician to do?
Topics: Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2010 |
Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.
Topics: Adult; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Confounding Factors, Epidemiologic; Drug Therapy, Combination; Epidemiologic Studies; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Research Design; Risk Factors; Ticlopidine; Time Factors | 2010 |
Outcomes related to antiplatelet or anticoagulation use in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Endarterectomy, Carotid; Female; Hematoma; Humans; Male; Middle Aged; Minnesota; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; Warfarin | 2011 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Odds Ratio; Peptic Ulcer; Platelet Aggregation Inhibitors; Prognosis; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Ticlopidine; Time Factors | 2010 |
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Heterozygote; Homozygote; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prevalence; Risk Factors; Stents; Survival Analysis; Thrombosis; Ticlopidine | 2010 |
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Humans; Infarction; Kidney; Male; Methenolone; Myocardial Infarction; Oxymetholone; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Tomography, X-Ray Computed; Ultrasonography; Weight Lifting | 2010 |
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Stenosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Republic of Korea; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)".
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Humans; Myocardial Infarction; Postoperative Hemorrhage; Prosthesis Implantation; Risk Factors; Survival Analysis; Ticlopidine; Withholding Treatment | 2010 |
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogrel; Diabetic Angiopathies; Female; Humans; Japan; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Tetrazoles; Ticlopidine | 2010 |
[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Creatine Kinase; Echocardiography; Female; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prevalence; Statistics, Nonparametric; Stents; Ticlopidine; Tomography, Emission-Computed, Single-Photon | 2010 |
Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Survival Rate; Ticlopidine; Treatment Outcome | 2010 |
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Radiopharmaceuticals; Registries; Technetium Tc 99m Sestamibi; Ticlopidine; Tomography, Emission-Computed, Single-Photon; Troponin T | 2010 |
Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; Disease Models, Animal; Hemodynamics; Inflammation; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Myocardial Infarction; Platelet Aggregation Inhibitors; Telemetry; Thrombosis; Ticlopidine; Time Factors; Ventricular Septal Rupture | 2011 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Confounding Factors, Epidemiologic; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Regression Analysis; Risk Factors; Ticlopidine; Young Adult | 2011 |
Coprescription of clopidogrel and proton pump inhibitors.
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Secondary Prevention; Ticlopidine | 2010 |
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Cardiovascular Agents; Chi-Square Distribution; Cineangiography; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Japan; Logistic Models; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prosthesis Design; Risk Assessment; Risk Factors; Sirolimus; Thrombosis; Ticlopidine; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2011 |
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
Topics: Aftercare; Anticoagulants; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Contraindications; Electrocardiography; Emergency Medical Services; Emergency Service, Hospital; Europe; Evidence-Based Medicine; Humans; Life Style; Myocardial Infarction; Myocardial Reperfusion; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors | 2010 |
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drug-Eluting Stents; Feasibility Studies; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Tetrazoles; Ticlopidine; Time Factors | 2011 |
[Acute myocardial infarction: importance of the networking in the initial management].
Topics: Clopidogrel; Humans; Information Services; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Switzerland; Thrombectomy; Ticlopidine | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Interactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Registries; Retrospective Studies; Stroke; Ticlopidine | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Ticlopidine | 2011 |
What you need to know about Clopidogrel. This drug helps to prevent the blood clots that can cause heart attacks and stroke.
Topics: Clopidogrel; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2009 |
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Stenosis; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genotype; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Thrombosis; Ticlopidine | 2011 |
Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study.
Topics: Aged; Calcium Channel Blockers; Cause of Death; Clopidogrel; Cohort Studies; Confidence Intervals; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Registries; Retrospective Studies; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocard
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; France; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Ticlopidine; Treatment Outcome | 2011 |
Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Heart Conduction System; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance.
Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; Drug-Eluting Stents; Electrocardiography; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; Treatment Outcome | 2011 |
Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Canada; Clopidogrel; Female; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Retrospective Studies; Ticlopidine | 2011 |
Standard versus high loading doses of clopidogrel in Asian ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Republic of Korea; Retrospective Studies; Ticlopidine | 2011 |
Impact of smoking on acute phase outcomes of myocardial infarction.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Smoking; Ticlopidine; Treatment Outcome | 2011 |
Total occlusion of aortic arch in a 62-year-old man presenting with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aorta, Thoracic; Aortic Diseases; Clopidogrel; Coronary Angiography; Enoxaparin; Humans; Male; Middle Aged; Myocardial Infarction; Stents; Ticlopidine; Tomography, X-Ray Computed | 2011 |
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2011 |
Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Comorbidity; Coronary Artery Bypass; Denmark; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Period; Propensity Score; Proportional Hazards Models; Registries; Secondary Prevention; Ticlopidine | 2011 |
An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Randomized Controlled Trials as Topic; Risk; Thrombosis; Ticlopidine | 2011 |
Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Registries; Retrospective Studies; Ticlopidine; Treatment Outcome | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Care Units; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Stents; Sweden; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; District of Columbia; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Wound Healing | 2011 |
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Resistance; Female; Flow Cytometry; France; Heart Diseases; Humans; Kaplan-Meier Estimate; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Female; Gastrointestinal Hemorrhage; Heparin; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Taiwan; Ticlopidine; Treatment Outcome | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
The impact of noncardiac surgery on selection of a revascularization strategy.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Risk Factors; Surgical Procedures, Operative; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Diurnal variation in platelet inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Circadian Rhythm; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; Hemorrhage; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Premedication; Recombinant Proteins; Thrombosis; Ticlopidine | 2011 |
Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction.
Topics: Aged; Clopidogrel; Disease Progression; Drug Resistance; Early Diagnosis; Female; Flow Cytometry; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Function Tests; Predictive Value of Tests; Prognosis; Receptors, Purinergic P2Y12; Reference Values; Ticlopidine; Treatment Outcome | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complications; Electrocardiography; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Reproducibility of Results; Risk; Ticlopidine | 2011 |
Standard- vs high-dose clopidogrel after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Reproducibility of Results; Risk; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction.
Topics: Aged; Angioplasty; Bundle-Branch Block; Clopidogrel; Confidence Intervals; Coronary Artery Disease; Coronary Vessels; Emergency Medical Services; Female; Health Status Indicators; Hemodynamics; Hospital Mortality; Humans; Italy; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Shock, Cardiogenic; Ticlopidine; Treatment Outcome | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Humans; Lasers, Excimer; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Shock, Cardiogenic; Stents; Ticlopidine; Treatment Outcome | 2011 |
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Interactions; Electrocardiography; Female; Heart Arrest; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stents; Thiophenes; Ticlopidine; Time Factors | 2011 |
Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Transfusion; Clopidogrel; Female; France; Hemorrhage; Hospital Mortality; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Registries; Risk Factors; Survival Rate; Ticlopidine; Treatment Outcome | 2011 |
Late bare-metal stent thrombosis in a patient with Crohn's disease.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Crohn Disease; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2011 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hospitals, High-Volume; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Tacrolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Standard versus high loading doses of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: insights from the Korea Acute Myocardial Infarction Registry.
Topics: Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Republic of Korea; Ticlopidine; Treatment Outcome | 2011 |
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Thrombosis; Ticlopidine | 2011 |
Clopidogrel use throughout pregnancy in a patient with a drug-eluting coronary stent.
Topics: Adult; Cesarean Section; Clopidogrel; Cocaine; Drug-Eluting Stents; Female; Humans; Infant, Newborn; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Ticlopidine; Treatment Outcome | 2011 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Embolism; Retrospective Studies; Risk Reduction Behavior; Ticlopidine; Venous Thromboembolism | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Risk Assessment; Risk Factors; Stents; Surgical Procedures, Operative; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorbidity; Coronary Occlusion; Coronary Restenosis; Coronary Thrombosis; Diabetes Mellitus; Drug Utilization; Drug-Eluting Stents; Emergencies; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency; Shock, Cardiogenic; Ticlopidine | 2011 |
Sensitive troponin I assay in patients with suspected acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Creatinine; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Reproducibility of Results; Risk Factors; Ticlopidine; Troponin I | 2011 |
Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Death, Sudden, Cardiac; Female; General Practice; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Registries; Ticlopidine | 2011 |
Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI).
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confidence Intervals; Drug-Eluting Stents; Female; Heparin; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom | 2011 |
Desperate times, desperate measures: rotablating dissections in acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Atherectomy, Coronary; Clopidogrel; Female; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Use of prasugrel in a patient with clopidogrel hypersensitivity.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines.
Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Female; Follow-Up Studies; Genotype; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Prospective Studies; Registries; Ticlopidine; Treatment Outcome | 2011 |
Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Austria; Clopidogrel; Female; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Patient Transfer; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Prospective Studies; Registries; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Retrospective Studies; Stroke; Survival Rate; Taiwan; Ticlopidine; Time Factors | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Risk; Stents; Stroke; Thrombosis; Ticlopidine | 2011 |
Applying platelet function testing in clinical practice: what are the unmet needs?
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Death; Humans; Myocardial Infarction; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Standard of Care; Stents; Thrombosis; Ticlopidine | 2011 |
Aborted myocardial infarction in a patient with rapid progression of Wellens syndrome.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Early Diagnosis; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine | 2012 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction.
Topics: Administration, Cutaneous; Aged; Angioplasty; Clopidogrel; Coronary Vessels; Electrocardiography; Female; Fibrinolysis; Humans; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Reperfusion; Survival Analysis; Ticlopidine | 2011 |
Platelet response to standard aspirin and clopidogrel treatment correlates with long-term outcome in patients with acute ST-elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Leucocytoclastic vasculitis associated with clopidogrel.
Topics: Clopidogrel; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Vasculitis, Leukocytoclastic, Cutaneous | 2012 |
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency Treatment; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Patient Transfer; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Rural Health; Tenecteplase; Ticlopidine; Tissue Plasminogen Activator; Treatment Outcome | 2012 |
Selecting the optimal stroke prevention therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asia, Eastern; Asian People; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Treatment Outcome | 2011 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatible; Disease-Free Survival; Drug Therapy, Combination; Female; Hospital Mortality; Hospitals, High-Volume; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Recurrence; Registries; Risk Factors; Severity of Illness Index; Shock, Cardiogenic; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Catheter Ablation; Clopidogrel; Cohort Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Stents; Ticlopidine | 2012 |
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine | 2012 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain Ischemia; Clopidogrel; Diastole; Dipyridamole; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Reference Values; Risk; Stroke; Systole; Telmisartan; Ticlopidine; Vascular Diseases | 2011 |
[Clopidogrel induced thrombotic thrombocytopenic purpura].
Topics: Clopidogrel; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Ticlopidine | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronary Disease; Female; Follow-Up Studies; Heartburn; Hematemesis; Humans; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Registries; Retrospective Studies; Stents; Stroke; Ticlopidine; Treatment Outcome | 2012 |
The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Genetic Variation; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Software; Stents; Ticlopidine | 2012 |
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhage; Hospital Mortality; Humans; Immunoglobulin Fab Fragments; Incidence; Internet; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Paris; Platelet Aggregation Inhibitors; Proportional Hazards Models; Radial Artery; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Predicting clopidogrel response using DNA samples linked to an electronic health record.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Nucleic Acid; Electronic Health Records; Female; Genotype; Humans; Male; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contraceptives, Oral; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pregnancy; Pyrroles; Smoking; Ticlopidine | 2012 |
Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Off-Label Use; Platelet Aggregation Inhibitors; Registries; Retreatment; Retrospective Studies; Ticlopidine | 2012 |
CYP2C19 and clopidogrel response: more than validation in the real world.
Topics: Clopidogrel; Databases, Nucleic Acid; Electronic Health Records; Female; Humans; Male; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2012 |
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Disease; Drug-Eluting Stents; Female; Health Behavior; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; Ticlopidine; Time Factors | 2012 |
Toward a therapeutic window for antiplatelet therapy in the elderly.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Intra-Aortic Balloon Pumping; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Shock, Cardiogenic; Spinal Fusion; Stents; Thrombosis; Ticlopidine | 2012 |
[The GRAVITAS study].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Care; Randomized Controlled Trials as Topic; Research Design; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Data Collection; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Germany; Humans; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Stents; Surveys and Questionnaires; Thoracic Surgical Procedures; Ticlopidine | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Immunization, Passive; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Remission, Spontaneous; Rituximab; Stents; Thrombopoiesis; Thrombopoietin; Ticlopidine | 2012 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techniques; Ketanserin; Light; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Serotonin; Serotonin Antagonists; Stents; Ticlopidine; Treatment Outcome | 2012 |
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Heparin; Heterozygote; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk; Survival Rate; Ticlopidine | 2012 |
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Chemical Analysis; Clopidogrel; Coronary Angiography; Female; Heart Failure; Hospital Mortality; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peroxidase; Predictive Value of Tests; Prospective Studies; ROC Curve; Ticlopidine; Time Factors; Troponin I | 2012 |
A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2012 |
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Are the results of a regional ST-elevation myocardial infarction system reproducible?
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Databases, Factual; Female; Fibrinolytic Agents; Heparin; Hospital Mortality; Humans; Iowa; Male; Middle Aged; Minnesota; Myocardial Infarction; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prospective Studies; Regional Medical Programs; Tenecteplase; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Transportation of Patients | 2012 |
Comparison of early outcomes after primary stenting in Japanese patients with acute myocardial infarction between clopidogrel and ticlopidine in concomitant use with proton-pump inhibitor.
Topics: Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2012 |
Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Aspirin; Biomarkers; C-Reactive Protein; Clopidogrel; Female; Heparin; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Perindopril; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Ventricular Dysfunction, Left | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptic Ulcer; Platelet Aggregation Inhibitors; Precision Medicine; Proton Pump Inhibitors; Ticlopidine | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Medicare; Myocardial Infarction; Patient Readmission; Proportional Hazards Models; Registries; Ticlopidine; Treatment Outcome; United States; Warfarin | 2012 |
Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; France; Humans; Insurance, Health, Reimbursement; Male; Myocardial Infarction; Patient Compliance; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2012 |
Clopidogrel response up to six months after acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors | 2012 |
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Animals; Clinical Protocols; Clopidogrel; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Risk Factors; Ticlopidine | 2012 |
Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Clopidogrel; Diabetic Cardiomyopathies; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2012 |
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Topics: Adolescent; Anticoagulants; Aspirin; Cholesterol Ester Transfer Proteins; Clopidogrel; Coronary Angiography; Electrocardiography; Fibrinogen; Genetic Predisposition to Disease; Heparin; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Thrombosis; Ticlopidine | 2012 |
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2012 |
Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Utilization; Female; Guideline Adherence; Hospitals; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quality Indicators, Health Care; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2012 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogrel; Confidence Intervals; Drug Therapy, Combination; Electrocardiography; Female; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Registries; Switzerland; Ticlopidine; Time Factors; Young Adult | 2012 |
Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction.
Topics: Adult; Analgesia, Obstetrical; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Eptifibatide; Female; Humans; Metals; Myocardial Infarction; Nerve Block; Peptides; Peripartum Period; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications; Stents; Ticlopidine | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Pyridines; Registries; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Logistic Models; Male; Metals; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Clopidogrel; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Recombinant Proteins; Stents; Ticlopidine | 2012 |
High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Stents; Ticlopidine; Treatment Outcome | 2013 |
Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis.
Topics: Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Ticlopidine | 2012 |
Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Reproducibility of Results; Ticlopidine | 2012 |
Combined clopidogrel and aspirin treatment up to surgery increases the risk of postoperative myocardial infarction, blood loss and reoperation for bleeding in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Reoperation; Retrospective Studies; Statistics, Nonparametric; Ticlopidine; United Kingdom | 2013 |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interactions; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prospective Studies; Stroke; Ticlopidine | 2012 |
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Flow Cytometry; Glycated Hemoglobin; Humans; Inflammation; Leukocyte Count; Leukocytes; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphorylation; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Research Design; Ticlopidine; Vascular Diseases | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Clopidogrel efficacy and cigarette smoking status.
Topics: Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP1A2; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk; Smoking; Stroke; Ticlopidine; Treatment Failure | 2012 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Failure; Recurrence; Stents; Thrombosis; Ticlopidine; Withholding Treatment | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Comorbidity; Coronary Angiography; Electrocardiography; Female; Humans; Magnetic Field Therapy; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Vascular System Injuries | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
[CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Angiography; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stents; Ticlopidine; Treatment Outcome | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography, Interventional; Retrospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Simultaneous thromboses of two coronary arteries in a heavy smoker woman: a singular case of acute myocardial infarction.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Smoking; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ticlopidine; Treatment Outcome | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Denmark; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stroke; Ticlopidine; Vitamin K | 2012 |
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Thrombosis; Cyclooxygenase 1; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Population Surveillance; Stents; Ticlopidine | 2013 |
Failure of high-dose clopidogrel in recurrent stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Data Collection; Denmark; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Registries; Risk; Ticlopidine | 2012 |
Antiplatelet therapy following myocardial infarction in patients with diabetes.
Topics: Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; Blood Platelets; Chi-Square Distribution; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stents; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Intracoronary GP IIb/IIIa inhibitors: could eptifibatide be the new kid on the block?
Topics: Clopidogrel; Eptifibatide; Female; Humans; Male; Myocardial Infarction; Myocardial Reperfusion; Peptides; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2012 |
Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chemoprevention; Clopidogrel; Evidence-Based Practice; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Secondary Prevention; Ticlopidine; Treatment Outcome | 2012 |
Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recovery of Function; Ticlopidine; Treatment Outcome | 2012 |
The impact of reducing cardiovascular medication copayments on health spending and resource utilization.
Topics: Aged; Cardiology; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cost Sharing; Drug Therapy; Evidence-Based Medicine; Female; Health Care Costs; Health Care Reform; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine; Treatment Outcome | 2012 |
Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogrel; Comorbidity; Contraindications; Critical Pathways; Female; Guideline Adherence; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Registries; Ticlopidine; United States | 2012 |
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Health Status Indicators; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; United States | 2012 |
Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidepressive Agents; Case-Control Studies; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Serotonin Plasma Membrane Transport Proteins; Ticlopidine | 2012 |
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Ischemic Attack, Transient; Italy; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clopidogrel; Coronary Artery Bypass; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Risk Factors; Thrombosis; Ticlopidine | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention.
Topics: Aged; California; Cause of Death; Clopidogrel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Refusal to Treat; Retrospective Studies; Risk Factors; Saphenous Vein; Survival Rate; Ticlopidine | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Disease-Free Survival; Drug Therapy, Combination; Drug-Eluting Stents; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Registries; Risk Assessment; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight; Cholesterol, LDL; Clopidogrel; Comorbidity; Cost of Illness; Depression; Diabetes Complications; Disease Management; Electrocardiography; Exercise; Exercise Test; Glycated Hemoglobin; Health Behavior; Humans; Hypertension; Life Style; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Physical Examination; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Risk Factors; Risk Reduction Behavior; Smoking Cessation; Ticlopidine | 2012 |
Pharmaceutical care for patients with acute myocardial infarction in Hungary.
Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Hungary; Incidence; Male; Middle Aged; Muscle Hypotonia; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk; Secondary Prevention; Ticlopidine; Treatment Outcome; Young Adult | 2013 |
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Care; Prospective Studies; Registries; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2013 |
Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
Topics: Adenosine Monophosphate; Animals; Cardiotonic Agents; Clopidogrel; Coronary Vessels; Female; Heart; In Vitro Techniques; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Purinergic P2Y Receptor Antagonists; Rabbits; Receptors, Purinergic P2Y12; Signal Transduction; Ticlopidine | 2013 |
Hospital case volume and appropriate prescriptions at hospital discharge after acute myocardial infarction: a nationwide assessment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; France; Hospitals, High-Volume; Hospitals, Low-Volume; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Patient Discharge; Prescriptions; Quality Assurance, Health Care; Quality Indicators, Health Care; Retrospective Studies; Ticlopidine | 2013 |
Bioequivalence in the real world is a complex challenge: the case of clopidogrel.
Topics: Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Therapeutic Equivalency; Ticlopidine | 2013 |
Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Topics: Aged; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Fibrinogen; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Predictive Value of Tests; Premedication; Prospective Studies; ROC Curve; Sensitivity and Specificity; Ticlopidine; Troponin | 2013 |
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Recurrence; Ticlopidine | 2012 |
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Acute myocardial infarction and heart block: a challenge to emergency physicians.
Topics: Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2013 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effects of high loading dose of clopidogrel in ST elevated myocardial infarction treated with fibrinolytic agent.
Topics: Aged; C-Reactive Protein; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Ticlopidine | 2013 |
[Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2002 |
[2002 Update of the Guidelines of the Spanish Society of Cardiology for Unstable Angina/Without ST-Segment Elevation Myocardial Infarction].
Topics: Angina, Unstable; Chest Pain; Clopidogrel; Electrocardiography; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine | 2002 |
[New US guidelines. Myocardial infarct is now treated more aggressively].
Topics: Angina, Unstable; Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine; United States | 2002 |
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.
Topics: Blood Platelets; Cell Adhesion; Clopidogrel; Humans; Leukocytes; Myocardial Infarction; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine | 2002 |
Evidence-based risk stratification to target therapies in acute coronary syndromes.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Coronary Disease; Electrocardiography; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Myocardial Infarction; Risk Assessment; Risk Factors; Severity of Illness Index; Ticlopidine; Troponin | 2002 |
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidel
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clopidogrel; Disease Management; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Female; Health Behavior; Hemorrhage; Humans; Hypolipidemic Agents; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2002 |
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Drug Therapy, Combination; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2002 |
[Indications of treatment with clopidogrel in the guidelines of the Spanish Society of Cardiology for unstable angina/non-ST-segment elevation acute myocardial infarction].
Topics: Angina, Unstable; Clopidogrel; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2002 |
New treatment guidelines for unstable angina/non-ST-segment elevation myocardial infartion.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Ticlopidine | 2002 |
[New guidelines in acute coronary syndrome. Clopidogrel for nine months is recommended].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Survival Rate; Ticlopidine | 2002 |
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.
Topics: Blood Platelets; Cell Size; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2003 |
[In acute coronary syndrome. Seize platelets with pliers].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Syndrome; Ticlopidine; Time Factors | 2002 |
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myocardial Reperfusion; Nitroprusside; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombolytic Therapy; Ticlopidine | 2002 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Drug Costs; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2003 |
Pharmacological treatment of acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Ticlopidine | 2003 |
Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Hemarthrosis; Humans; Male; Myocardial Infarction; Osteoarthritis, Knee; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Risk Factors; Ticlopidine | 2003 |
Antiplatelet drug works better if used longer.
Topics: Angioplasty; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thromboembolism; Ticlopidine | 2003 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Confidence Intervals; Dipyridamole; Drug Therapy, Combination; Embolectomy; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Iloprost; Intermittent Claudication; Leg; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thrombectomy; Ticlopidine; Time Factors; Vitamin K | 2003 |
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Coronary Thrombosis; Electrocardiography; Eptifibatide; Humans; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Ticlopidine | 2003 |
Case presentations and discussions.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Chest Pain; Clopidogrel; Critical Care; Electrocardiography; Emergency Service, Hospital; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Obesity, Morbid; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Risk Assessment; Sampling Studies; Severity of Illness Index; Ticlopidine; Troponin | 2003 |
Acute coronary syndrome associated with coronary aneurysm: a case report.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Aneurysm; Coronary Disease; Diagnosis, Differential; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine | 2003 |
[Acute coronary syndrome. The second platelet inhibitor is self-paid].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2003 |
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Premedication; Product Surveillance, Postmarketing; Retrospective Studies; Stents; Survival Analysis; Ticlopidine; Treatment Outcome | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk; Stroke; Ticlopidine | 2003 |
Ask the doctor. Almost every day I read how important it is for people with heart disease to take an aspirin. Unfortunately, I am allergic to aspirin. There must be others with the same problem. Are there viable alternatives to aspirin? It's discouraging
Topics: Aspirin; Clopidogrel; Drug Hypersensitivity; Fatty Acids, Omega-3; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
[Acute myocardial infarction during pregnancy. Treatment with clopidogrel].
Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Ticlopidine; Treatment Outcome | 2003 |
Improving antithrombotic treatment in patients after myocardial infarction.
Topics: Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome; Warfarin | 2003 |
Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Care Units; Emergency Medical Services; Female; Fibrinolytic Agents; Follow-Up Studies; Guideline Adherence; Heparin; Hospitalization; Humans; Italy; Length of Stay; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Thrombolytic Therapy; Ticlopidine; Time Factors | 2003 |
Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stents; Stroke; Syndrome; Thrombosis; Ticlopidine | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Stroke; Ticlopidine; Venous Thrombosis | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2004 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitalization; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Secondary Prevention; Stroke; Survival Rate; Ticlopidine; Treatment Outcome | 2004 |
[Interaction of statins with clopidogrel].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biotransformation; Cause of Death; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Prodrugs; Rhabdomyolysis; Risk Factors; Stents; Stroke; Survival Analysis; Ticlopidine | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Warfarin | 2004 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase; Creatine Kinase, MB Form; Drug Resistance; Female; Humans; Incidence; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Period; Sex Factors; Ticlopidine; Troponin I | 2004 |
For how long should treatment with clopidogrel be continued after coronary stent implantation?
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine; Time Factors | 2004 |
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Topics: Analysis of Variance; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cardiac Catheterization; Clopidogrel; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Injections, Subcutaneous; Logistic Models; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Retrospective Studies; Risk Factors; Ticlopidine | 2004 |
2 drugs team up for protection. Old standby joins relative newcomer to battle heart disease.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
"Super aspirin" cuts risks after multiple cardiac events.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticlopidine | 2004 |
Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Circulation; Female; Heart Ventricles; Heparin; Humans; Immunoglobulin Fab Fragments; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Prospective Studies; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Function, Left | 2004 |
Antiplatelet therapy for ischemic heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Epinephrine; Eptifibatide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Prospective Studies; Purinergic P2 Receptor Antagonists; Recurrence; Risk; Smoking; Stents; Ticlopidine; Treatment Outcome | 2004 |
Long-term management of patients with unstable angina and non-ST-elevation MI.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine; Treatment Outcome | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Disease; Coronary Vessels; Drug Utilization; Electrocardiography; Female; Germany; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Recurrence; Registries; Stroke Volume; Ticlopidine; Ventricular Dysfunction, Left | 2004 |
[Antithrombotic treatment of acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2004 |
Clopidogrel-associated autoimmune thrombocytopenic purpura.
Topics: Clopidogrel; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Stents; Ticlopidine | 2004 |
Clopidogrel resistance marks recurrent risks.
Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance; Estrogen Receptor alpha; Female; Folic Acid; Genetic Predisposition to Disease; Heart Diseases; Humans; Male; Mass Screening; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Platelet Aggregation Inhibitors; Predictive Value of Tests; Recurrence; Risk; Stents; Ticlopidine; Vitamin B 12; Vitamin B 6 | 2004 |
Diminishing returns...and too many choices...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticlopidine; Troponin I | 2004 |
Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2004 |
A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
[Cost effectiveness of clopidogrel in acute coronary syndromes without ST-elevation (unstable angina, non-Q AMI)].
Topics: Acute Disease; Angina, Unstable; Canada; Cardiology; Clopidogrel; Congresses as Topic; Cost-Benefit Analysis; France; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Societies, Medical; Sweden; Ticlopidine; United Kingdom; United States | 2004 |
[Guidelines: acute coronary syndrome (ACS)].
Topics: Acute Disease; Angina, Unstable; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Electrocardiography; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Syndrome; Ticlopidine | 2004 |
Simultaneous kissing stents (SKS) technique for treating bifurcation lesions in medium-to-large size coronary arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; Coated Materials, Biocompatible; Combined Modality Therapy; Coronary Angiography; Coronary Stenosis; Coronary Vessels; Creatine Kinase; Creatine Kinase, MB Form; Disease-Free Survival; Equipment Design; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Isoenzymes; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; New York; Platelet Aggregation Inhibitors; Postoperative Complications; Severity of Illness Index; Stents; Ticlopidine; Treatment Outcome; Troponin I | 2004 |
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Ticlopidine | 2004 |
[Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!].
Topics: Arterial Occlusive Diseases; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Embolism, Cholesterol; Humans; Intracranial Embolism; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2004 |
[Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prognosis; Risk Factors; Stroke; Ticlopidine | 2004 |
[Combination is standard. Dual thrombocyte function inhibition in acute coronary syndrome].
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Ticlopidine | 2004 |
[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Syndrome; Ticlopidine | 2004 |
Antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Interactions; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine | 2004 |
Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Artery Bypass; Heart Failure; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Retrospective Studies; ROC Curve; Ticlopidine | 2004 |
Risk reduction with long-term clopidogrel following percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Ticlopidine | 2004 |
I've been taking aspirin daily for 25 years, and clopidogrel fro several years. In spite of this, I've had a number of heart attacks. You reported recently on people who can't benefit from aspirin, and I think I may be one of them. What should I do?
Topics: Aspirin; Blood Coagulation Disorders; Clopidogrel; Drug Resistance; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
[Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Splenectomy; Splenic Rupture; Stents; Ticlopidine; Tirofiban; Tomography, X-Ray Computed; Tyrosine | 2005 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Stents; Ticlopidine | 2005 |
Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticlopidine | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Electrocardiography; Hemorrhage; Humans; Markov Chains; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Recurrence; Risk Factors; Sensitivity and Specificity; Stroke; Ticlopidine | 2005 |
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry.
Topics: Adolescent; Adult; Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2005 |
Concurrent antiplatelet and fibrinolytic therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2005 |
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Administration Schedule; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2004 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardial Infarction; Norway; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Stroke; Ticlopidine | 2004 |
Who needs Plavix? This super aspirin is meant mainly for people at high risk of having a heart attack or stroke.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Ticlopidine | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Warfarin | 2005 |
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.
Topics: Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Thrombolytic Therapy; Ticlopidine | 2005 |
Cost-effectiveness of clopidogrel.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Embolism, Cholesterol; Humans; Myocardial Infarction; Ticlopidine | 2004 |
[Exercise-induced left arm pain and thrombocytosis].
Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Stenosis; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Risk Factors; Smoking; Stents; Thrombocythemia, Essential; Ticlopidine | 2005 |
The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Postoperative Complications; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2005 |
The (variable) definition of benefit in the case of clopidogrel vs aspirin.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Treatment Outcome; Vascular Diseases | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; Vascular Patency | 2005 |
Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling.
Topics: Aspirin; Clopidogrel; Coronary Circulation; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Streptokinase; Thrombolytic Therapy; Ticlopidine | 2005 |
Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Clopidogrel; Female; Health Care Costs; Health Services Needs and Demand; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Prospective Studies; Ticlopidine; Time Factors; United States | 2005 |
Plavix reduces death risk following a heart attack.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine | 2005 |
Hospitals improve heart attack care. As compliance with guidelines improves, in-hospital deaths fall.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Electrocardiography; Guideline Adherence; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Ticlopidine | 2004 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2005 |
Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Feasibility Studies; Female; Graft Occlusion, Vascular; Humans; Intracranial Embolism; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Stents; Stroke; Survival Rate; Ticlopidine; Treatment Outcome | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2006 |
ST-elevation myocardial infarction: New Zealand management guidelines.
Topics: Aged; Aspirin; Biomarkers; Cardiology; Clopidogrel; Contraindications; Creatine Kinase; Drug Monitoring; Echocardiography; Electrocardiography; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial Revascularization; New Zealand; Platelet Aggregation Inhibitors; Risk Assessment; Thrombolytic Therapy; Ticlopidine; Troponin | 2005 |
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reductio
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reductio
Topics: Clopidogrel; Coronary Artery Bypass; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Ticlopidine | 2005 |
Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Probability; Prognosis; Registries; Risk Assessment; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome | 2005 |
Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Creatine Kinase, MB Form; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardium; Necrosis; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine; Troponin T | 2005 |
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Markov Chains; Middle Aged; Models, Econometric; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Sweden; Thrombosis; Ticlopidine | 2005 |
Something old, something new: beta blockers and clopidogrel in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; China; Clopidogrel; Drug Therapy, Combination; Humans; Metoprolol; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Warfarin | 2005 |
[Effects of anti-platelet drugs on myocardial no-reflow after acute myocardial infarction and reperfusion: experiment with mini-swine model].
Topics: Animals; Clopidogrel; Coronary Circulation; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Random Allocation; Swine; Swine, Miniature; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Case 6-2005 thoracotomy after myocardial infarction and intracoronary stenting: a balance between myocardial recovery and procedural risk.
Topics: Clopidogrel; Coronary Disease; Exercise Test; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Myocardial Infarction; Oxygen Consumption; Platelet Aggregation Inhibitors; Risk; Stents; Thoracotomy; Ticlopidine | 2005 |
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Syndrome; Ticlopidine; Time Factors | 2006 |
Drawbacks of nonrandomized trials in acute coronary syndromes.
Topics: Angina, Unstable; Cardiac Catheterization; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stents; Syndrome; Ticlopidine; Time Factors | 2006 |
Management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2005 |
Management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Follow-Up Studies; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Selection Bias; Ticlopidine | 2005 |
Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion.
Topics: Animals; Aspirin; Clopidogrel; Coronary Circulation; Drug Therapy, Combination; Myocardial Infarction; Myocardial Reperfusion; Nitric Oxide; Nitric Oxide Synthase; Platelet Aggregation Inhibitors; Random Allocation; Swine; Swine, Miniature; Ticlopidine; Tirofiban; Tyrosine | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Recurrence; Regression Analysis; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Severity of Illness Index; Ticlopidine | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
Clopidogrel and metoprolol in myocardial infarction.
Topics: Adrenergic beta-Antagonists; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Ticlopidine | 2006 |
Embedded guideline information without patient specificity in a commercial emergency department computerized order-entry system.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Clopidogrel; Decision Support Systems, Clinical; Emergency Service, Hospital; Fibrinolytic Agents; Guideline Adherence; Heparin; Humans; Medical Order Entry Systems; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Risk Adjustment; Ticlopidine | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Disease; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Implants; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Internet; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Registries; Risk Factors; Sirolimus; Stents; Thrombosis; Ticlopidine; United States | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Ticlopidine; Treatment Failure | 2006 |
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Syndrome; Ticlopidine | 2006 |
Clopidogrel (Plavix) revisited.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2006 |
[More modest use in secondary prevention, risky in primary prevention].
Topics: Arteriosclerosis; Aspirin; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Intracranial Embolism; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Secondary Prevention; Survival Rate; Ticlopidine | 2006 |
[Thrombosis of a coronary stent after discontinuing treatment with clopidogrel].
Topics: Adult; Aged; Angina Pectoris; Aspirin; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2006 |
[Optimisation of the myocardial infarction pharmacotherapy--important insights from the COMMIT Trial].
Topics: Antihypertensive Agents; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiac Catheterization; Clopidogrel; Enoxaparin; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2006 |
Comment: mortality benefit of no-load clopidogrel in COMMIT: not a surprise.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cause of Death; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Administration Schedule; Drug Implants; Female; Follow-Up Studies; Hospitalization; Humans; Life Tables; Male; Middle Aged; Mortality; Myocardial Infarction; Patient Education as Topic; Platelet Aggregation Inhibitors; Prevalence; Proportional Hazards Models; Prospective Studies; Pyridines; Registries; Sirolimus; Stents; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome; Treatment Refusal | 2006 |
Spontaneous or clopidogrel related recanalisation of a coronary artery.
Topics: Clopidogrel; Coronary Angiography; Coronary Stenosis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2006 |
Plavix isn't for everyone. Adding Plavix to aspirin doesn't help people without heart disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2006 |
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Obesity; Odds Ratio; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Health Care; Risk Assessment; Risk Factors; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome; United States | 2006 |
Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery.
Topics: Aged; Angina, Unstable; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Guideline Adherence; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Syndrome; Ticlopidine; Time Factors; Treatment Outcome | 2006 |
COMMIT/CCS-2 studies.
Topics: Adrenergic beta-Antagonists; Clopidogrel; Humans; Metoprolol; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes.
Topics: Adult; Angina Pectoris; Biomarkers; Cardiology; Clopidogrel; Electrocardiography; Emergency Service, Hospital; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2006 |
[Physicians and insurance may collaborate on therapy].
Topics: Aspirin; Clopidogrel; Contract Services; Cooperative Behavior; Cost-Benefit Analysis; Drug Costs; Family Practice; Germany; Humans; Interprofessional Relations; Myocardial Infarction; National Health Programs; Physician's Role; Stroke; Ticlopidine | 2006 |
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).
Topics: Aged; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Randomized Controlled Trials as Topic; Recurrence; Ticlopidine | 2006 |
End-stage renal disease and drug-eluting stents: one small step forward.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; Infusion Pumps, Implantable; Kidney Failure, Chronic; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prevalence; Renal Dialysis; Stents; Ticlopidine; Treatment Outcome | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Thrombolytic Therapy; Ticlopidine | 2006 |
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Bypass; Counseling; Drug Utilization; Female; Guideline Adherence; Heparin; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Quality Assurance, Health Care; Smoking Cessation; Ticlopidine; United States | 2006 |
Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice.
Topics: Aged; Clopidogrel; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticlopidine | 2006 |
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Cross-Sectional Studies; Drug Therapy, Combination; Endpoint Determination; Female; Heart Conduction System; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Registries; Ticlopidine; Treatment Outcome; United States | 2006 |
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Radiography; Stents; Thrombosis; Ticlopidine; Time Factors; Ultrasonography | 2006 |
[Beneficial effect of a loading dose of 600 mg of clopidogrel on platelet parameters in patients admitted for acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Syndrome; Ticlopidine | 2006 |
Clopidogrel in patients with acute coronary syndromes: learning from clinical practice.
Topics: Aged; Angina, Unstable; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Syndrome; Ticlopidine | 2006 |
Nontraumatic spinal epidural hematoma associated with clopidogrel.
Topics: Aged; Back Pain; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Hypertension; Magnetic Resonance Imaging; Myocardial Infarction; Paraplegia; Platelet Aggregation Inhibitors; Spine; Stroke; Ticlopidine; Urinary Incontinence | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sirolimus; Ticlopidine; Time Factors | 2007 |
Effect of clopidogrel plus aspirin on ST segments in patients with ST-elevation acute myocardial infarction.
Topics: Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke Volume; Ticlopidine | 2006 |
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Ticlopidine; Treatment Outcome | 2006 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Treatment Outcome | 2007 |
[Acute coronary syndrome: when an indication for clopidogrel?].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Premedication; Stents; Ticlopidine | 2006 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Enoxaparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Societies, Medical; Stents; Thrombolytic Therapy; Ticlopidine; United States | 2006 |
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Stroke Volume; Survival Analysis; Ticlopidine | 2007 |
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2007 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Electrocardiography; Female; Germany; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; Ticlopidine | 2007 |
Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Steven R Steinhubl.
Topics: Aged; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
Clopidogrel bisulfate in st-segment elevation myocardial infarction: a viewpoint by Deepak L Bhatt.
Topics: Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2006 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; France; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prognosis; Prospective Studies; Research Design; Risk Factors; Stents; Syndrome; Ticlopidine; Time Factors; Troponin I | 2007 |
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prosthesis Failure; Retrospective Studies; Stents; Ticlopidine; Warfarin | 2007 |
Variability in response to clopidogrel: where is the threshold for 'low response'?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine; Treatment Failure | 2007 |
Acute coronary syndromes, response to clopidogrel, and worsened cardiovascular outcomes: the hen and the egg dilemma.
Topics: Clopidogrel; Death, Sudden, Cardiac; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine | 2007 |
Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease.
Topics: Adult; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Solubility; Thromboplastin; Ticlopidine; Treatment Outcome | 2007 |
[Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Follow-Up Studies; Humans; Male; Microfilament Proteins; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Ticlopidine | 2007 |
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases.
Topics: Aged; Angina, Unstable; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2007 |
Primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Platelet Aggregation Inhibitors; Spironolactone; Ticlopidine | 2007 |
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Death, Sudden, Cardiac; Drug Implants; Drug Utilization; Endothelium, Vascular; Equipment Design; Equipment Failure; Female; Follow-Up Studies; Humans; Hyperplasia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Paclitaxel; Platelet Aggregation Inhibitors; Sirolimus; Stents; Ticlopidine; Tunica Intima; Wound Healing | 2007 |
Endpoints in studies on myocardial infarction.
Topics: Clopidogrel; Coronary Disease; Endpoint Determination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 2007 |
[Acute stent thrombosis due to resistance to clopidogrel ? A case report].
Topics: Aged; Clopidogrel; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2007 |
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?
Topics: Aged; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diabetic Angiopathies; Drug Resistance; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Follow-Up Studies; Hospitals, Urban; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States | 2007 |
Managing acute coronary syndrome: evidence-based approaches.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Protocols; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recombinant Proteins; Ticlopidine | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Equipment Design; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Stents; Surface Properties; Ticlopidine; Treatment Outcome | 2007 |
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Diabetes Mellitus; Drug Implants; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency; Risk Factors; Sirolimus; Stents; Ticlopidine; Treatment Outcome | 2007 |
Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Feasibility Studies; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Metals; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Secondary Prevention; Sirolimus; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
Relationship between systolic pulsed wave tissue Doppler parameters and both invasive and noninvasive reperfusion criteria in patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography, Doppler, Pulsed; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors | 2008 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Intracranial Embolism; Irbesartan; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Thromboembolism; Ticlopidine | 2007 |
Spontaneous coronary hematoma during systemic thrombolysis for acute myocardial infarction: intracoronary ultrasound findings, percutaneous coronary intervention and complications.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Aneurysm; Drug Therapy, Combination; Female; Hematoma; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2007 |
Treatment of acute myocardial infarction in pregnancy with coronary artery balloon angioplasty and stenting: use of tirofiban and clopidogrel.
Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Myocardial Infarction; Pregnancy; Pregnancy Complications, Cardiovascular; Ticlopidine; Tirofiban; Tyrosine | 2008 |
[After coronary intervention. Which platelet inhibitor for whom?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cost Control; Drug Costs; Drug Therapy, Combination; Germany; Humans; Myocardial Infarction; National Health Programs; Platelet Aggregation Inhibitors; Secondary Prevention; Stents; Ticlopidine | 2007 |
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Topics: Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Drug Utilization Review; Female; France; Germany; Humans; Male; Markov Chains; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Sweden; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report].
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug-Eluting Stents; Electrocardiography; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Autopsy; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Endothelial Cells; Fatal Outcome; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Design; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Relationship between microvascular resistance and perfusion in patients with reperfused acute myocardial infarction.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Coronary Stenosis; Coronary Vessels; Female; Health Status Indicators; Humans; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Perfusion; Prospective Studies; Severity of Illness Index; Ticlopidine | 2007 |
Effects of glycoprotein IIb/IIIa blockers.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Clopidogrel; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2007 |
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Therapy, Combination; Drug Tolerance; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Secondary Prevention; Stents; Ticlopidine | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Recurrence; Syndrome; Ticlopidine; Treatment Outcome | 2007 |
Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prognosis; Secondary Prevention; Stroke; Ticlopidine | 2008 |
Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Electrocardiography; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine; Time Factors | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Prospective Studies; Renal Insufficiency; ROC Curve; Sensitivity and Specificity; Stroke; Ticlopidine | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Stroke; Ticlopidine | 2007 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2007 |
Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Postoperative Care; Retrospective Studies; Secondary Prevention; Stents; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Europe; Fumarates; Heart Diseases; Heart Failure; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Probucol; Recombinant Proteins; Ticlopidine; Tolvaptan | 2007 |
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis; Cost-Benefit Analysis; Germany; Humans; Models, Econometric; Myocardial Infarction; Platelet Aggregation Inhibitors; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Integrin beta3; Male; Middle Aged; Myocardial Infarction; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Membrane Glycoprotein IIb; Ticlopidine | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Clopidogrel; Contraindications; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coronary Stenosis; Drug-Eluting Stents; Electrocardiography; Evidence-Based Medicine; Exercise Test; Humans; Kidney Diseases; Myocardial Infarction; Nomograms; Patient Selection; Platelet Aggregation Inhibitors; Prognosis; Radionuclide Ventriculography; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Stents; Stroke Volume; Thrombolytic Therapy; Ticlopidine | 2008 |
Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Intraoperative Complications; Male; Medical Audit; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine | 2007 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2008 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Thromboembolism; Ticlopidine; Treatment Outcome; Warfarin | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Female; Heart Diseases; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Percutaneous coronary intervention without on site surgical back-up; two-years registry of a large Dutch community hospital.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Feasibility Studies; Female; Hospitals, Community; Humans; Male; Middle Aged; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; Registries; Risk Factors; Safety; Ticlopidine; Treatment Outcome | 2009 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster Analysis; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Poisson Distribution; Proportional Hazards Models; Retrospective Studies; Risk; Ticlopidine; Time Factors; Withholding Treatment | 2008 |
Very late thrombosis in a bare metal stent: an under-recognized problem.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Thrombectomy; Ticlopidine | 2008 |
Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Premedication; Prospective Studies; Recurrence; Registries; Retreatment; Stents; Thrombosis; Ticlopidine | 2008 |
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Randomized Controlled Trials as Topic; Ticlopidine; Troponin | 2009 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Monitoring the efficacy of antiplatelet therapy: all methods are equal, but some methods are more equal than others?
Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Stents; Ticlopidine | 2008 |
Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?
Topics: Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Humans; Microfilament Proteins; Myocardial Infarction; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticlopidine; Vasodilation | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Giant Cell Arteritis; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prednisone; Stents; Ticlopidine | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Vascular Diseases | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; Brain Infarction; Brain Ischemia; Clopidogrel; Diabetes Mellitus; Dipyridamole; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Patient Selection; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Research Design; Stents; Thrombin; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
Commentary for "Comparison of drug eluting stents with bare metal stents in unselected patients with acute myocardial infarction".
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Metals; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prosthesis Design; Research Design; Secondary Prevention; Stents; Ticlopidine; Treatment Outcome | 2008 |
Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance.
Topics: Abciximab; Aged; Antibiotics, Antitubercular; Antibodies, Monoclonal; Clopidogrel; Drug Interactions; Drug Resistance; Graft Occlusion, Vascular; Humans; Immunoglobulin Fab Fragments; Male; Mycobacterium avium-intracellulare Infection; Myocardial Infarction; Opportunistic Infections; Platelet Aggregation Inhibitors; Recurrence; Stents; Ticlopidine | 2008 |
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).
Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.
Topics: Adult; Aged; Biological Availability; Clopidogrel; Electrocardiography; Female; Humans; Intestinal Absorption; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Pregnancy Complications, Cardiovascular; Prosthesis Implantation; Ticlopidine; Treatment Outcome | 2008 |
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Treatment Outcome | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
An experimental myocardial infarction model in the rat and its properties.
Topics: Animals; Biphenyl Compounds; Clopidogrel; Coronary Vessels; Disease Models, Animal; Electrocardiography; Heptanoic Acids; Ketanserin; Male; Myocardial Infarction; Oxygen; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thrombosis; Ticlopidine | 1995 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Ticlopidine; Treatment Outcome | 1997 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Ticlopidine; Treatment Outcome | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 1997 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Ticlopidine | 1997 |
Blocking platelets more: are we skating on thin ice?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 1998 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine; United States; Vascular Diseases | 1998 |
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Ticlopidine | 1998 |
New antiplatelet agents.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticlopidine | 1998 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Vascular Diseases | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Ticlopidine; Treatment Outcome | 1999 |
[Creative mathematics with clopidogrel; exaggeration of the preventive effect by manufacturer].
Topics: Advertising; Clopidogrel; Data Interpretation, Statistical; Drug Industry; Humans; Myocardial Infarction; Netherlands; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Cohort Studies; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk; Saskatchewan; Ticlopidine; Treatment Outcome | 1999 |
Hemolytic uremic syndrome in a patient treated with clopidogrel.
Topics: Aged; Clopidogrel; Hemolytic-Uremic Syndrome; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
What have We learned from ESPRIT? What will we learn from TARGET?
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Cohort Studies; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Tirofiban; Tyrosine | 2000 |
[ASA or clopidogrel?].
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Costs; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
[Clopidogrel].
Topics: Arteriosclerosis; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2000 |
Isolated profound thrombocytopenia associated with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Follow-Up Studies; Humans; Hypersensitivity, Delayed; Immunoglobulins, Intravenous; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombocytopenia; Ticlopidine | 2000 |
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine | 2001 |
Results of CURE trial for acute coronary syndrome.
Topics: Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine | 2001 |
[Acute heart attacks. Prognosis can be further improved].
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Survival Rate; Ticlopidine | 2001 |
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors | 2001 |
CURE--clopidogrel's major advance.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2001 |
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Switzerland; Ticlopidine | 2001 |
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; C-Reactive Protein; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Ohio; Platelet Aggregation Inhibitors; Premedication; Registries; Stents; Survival Analysis; Ticlopidine; Treatment Outcome | 2001 |
Acute myocardial infarction 2000 treatment.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Heparin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Primary Health Care; Thrombolytic Therapy; Ticlopidine; United States | 2001 |
Coronary stent thrombosis: insights from the porcine coronary stent model.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Heparin; Humans; Models, Animal; Myocardial Infarction; Stents; Swine; Ticlopidine | 2001 |
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial].
Topics: Angina, Unstable; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Ticlopidine; Treatment Outcome | 2001 |
Case report: successful pregnancy and delivery after myocardial infarction and essential thrombocythemia treated with clopidrogel.
Topics: Adult; Clopidogrel; Coronary Artery Bypass; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Thrombocytosis; Ticlopidine | 2001 |
Clopidogrel--a myocardial infarction CURE?
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2001 |
[Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].
Topics: Anticholesteremic Agents; Anuria; Clopidogrel; Coronary Artery Bypass; Humans; Hypercholesterolemia; Intracranial Thrombosis; Male; Middle Aged; Muscle Weakness; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Pyridines; Rhabdomyolysis; Ticlopidine | 2001 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Humans; International Normalized Ratio; Male; Middle Aged; Myocardial Infarction; Patient Care Planning; Risk Factors; Stroke; Thrombosis; Ticlopidine; Warfarin | 2002 |
The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation.
Topics: Angina Pectoris; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Syndrome; Ticlopidine | 2002 |
[Risk improves effectiveness. Proper administration of platelet aggregation inhibitors].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Ticlopidine; Treatment Outcome | 2002 |